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Abstract
ALCOHOL AND MEDICATION USE IN COMMUNITY-DWELLING OLDER ADULTS:
UNDERSTANDING THE EFFECT OF ALCOHOL AND CENTRAL NERVOUS SYSTEMACTING MEDICATIONS ON THE RISK FOR FALLS
By Maitreyee Mohanty, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Advisor: Dr. Patricia Slattum, Professor and Director of Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University, 2013.

Introduction: Aging, comorbid conditions, and use of medications render older adults more
susceptible to alcohol-disease or alcohol-drug interactions that may lead to harmful outcomes. In
this dissertation project the risk profile of alcohol and medications use among older adults was
investigated. Considering the rise in CNS-acting medication use and the adverse effect profile
linked to CNS-acting medications, it was also of interest to find if older adults were at risk of
falling due to interactions between alcohol and CNS-acting medication.
Objectives: The objectives were as follows: 1) to determine the prevalence, pattern and factors
associated with at-risk drinking, 2) to determine the prevalence and pattern of potential
concurrent use of CNS-acting medication and alcohol, and to identify factors associated with
alcohol use among CNS-acting medication users, 3) to assess the effects of potential concurrent
use of CNS-acting medications and alcohol on the risk for falls in older adults.
Methods: The study population comprised a nationally representative sample of communitydwelling older adults aged 65 years or older. The 2009 Medicare Current Beneficiary Survey
(MCBS) data (n=7163) were employed to determine at-risk drinking based on the Comorbidity
xii

Alcohol Risk Evaluation Tool (CARET) and to assess the effects of potential concurrent use of
CNS-acting medication and alcohol on the risk for falls. The National Health and Nutrition
Examination Survey (NHANES) 2005-2010 data (n=3220) were employed to determine
potential concurrent use of alcohol and CNS-acting medications. The effect of combined use of
alcohol and CNS-acting medications on risk of falls was assessed using logistic regression
modeling and adjusting for confounders. Alcohol consumption was measured by the quantityfrequency method.
Results: In the MCBS study, 5.6% of the older adults were identified as at-risk drinkers. Adults
aged between 65-74 years, being male, non-married, former or current smoker, and having no
comorbid conditions were factors associated with at-risk drinking. In the NHANES study, 8.9%
reported potential concurrent use of alcohol and CNS-acting medication. Use of at least one
CNS-acting medication and drinking excessive alcohol, or binge drinking, was significantly
associated with odds of falling.
Conclusion: Hazardous alcohol use is common among older adults. A substantial proportion of
older adults may concomitantly consume alcohol and CNS-acting medications. Odds of falling
are greater in the presence of high alcohol intake and CNS-acting medication use. It is important
for health care professionals to warn patients against excessive alcohol consumption. Increasing
awareness of this issue among older adults and caregivers may help prevent falls. Contributions
from healthcare professionals in the form of screening for potentially harmful alcohol use,
prescription monitoring, and initiating counseling may help to reduce older adults’ risk for falls
or other adverse effects.
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Chapter 1
Section 1.1 Introduction
Alcohol use is prevalent among community-dwelling older adults and is projected to
increase in the coming years with the aging of the baby-boomer generation. Few observational
studies have attempted to understand the extent of alcohol use taking comorbid conditions and
medication use into consideration. As older adults are the leading consumers of medications in
the U.S., it is essential to understand what proportion of older adults could be at risk of
experiencing an alcohol-medication interaction due to concurrent use of alcohol and alcoholinteractive medications. Additionally, it is also important to investigate the impact of the
potential concurrent use of alcohol and alcohol-interactive medications in older adults on health
outcomes. Based on the high rates of use and risk profile of central nervous system (CNS)-acting
medications observed in older adults, this class of medication was selected to be studied. In
addition, CNS-acting medications share similarity with alcohol, originating from comparable
pharmacological effect. The interaction between alcohol and CNS-acting medications potentiates
sedation and impairment of psychomotor functions which may lead to falls, and this hypothesis
outlines the rationale for the study.
To provide an overview of this document, this section describes the specific aims,
hypotheses and significance of this research endeavor. The Chapter 2 provides background
information and elucidates the conceptual framework supporting the study. The chapter 3
reviews of literature focusing on alcohol-medication use in older adults. Chapters 4, 6, and 5,
details the results and discussion for each of the study objectives. Finally, the chapter 7
summarizes the conclusions and includes suggestions for future research.
1

Section 1.2 Specific Aims
Specific Aim 1
I.

To determine the prevalence and pattern of at-risk drinking among non-institutionalized
older adults

II.

To identify factors associated with at-risk drinking among non-institutionalized older
adults

Specific Aim 2
I.

To determine the prevalence and pattern of potential concurrent use of alcohol and
central nervous system (CNS)-acting medications among non-institutionalized older
adults

II.

To identify factors associated with daily alcohol use among older adults taking at least
one CNS-acting medication.

Specific Aim 3
I.

To determine if alcohol use is associated with the risk of falling among older adults.

II.

To determine if alcohol use is associated with risk for injurious falls in older adults.

III.

To determine if alcohol use is associated with risk for recurrent falls in older adults.

IV.

To determine if varying levels of alcohol use along with CNS-acting medication use is
associated with risk for falls among older adults.

2

Section 1.3 Hypotheses
These hypotheses apply to Specific Aim III. Considering the likelihood that older adults
exhibit concurrent use of alcohol and CNS-acting medication, it is of interest to understand the
combined effect of alcohol and CNS-acting medication on the risk of falling in older adults. As
documented by previous studies, high alcohol consumption and CNS-acting medication use have
been separately associated with risk of falling.1 Pharmacologically, both alcohol and CNS-acting
medication (included in this study) have CNS depressant effects and may cause sedation,
dizziness, and impairment of psychomotor functions which may lead to accidental falls2. Thus,
based on evidence available in the literature and pharmacological plausibility, we hypothesize
the following.
A.

High alcohol consumption is significantly associated with higher odds of falling

B.

High alcohol consumption is significantly associated with increased odds of injurious
fall

C.

High alcohol consumption is significantly associated with increased odds of recurrent
falls

D.

Older drinkers taking CNS-acting medication and consuming alcohol are at greater
odds of falling than older adults either taking CNS-acting medication only or
consuming alcohol only

3

Section 1.4 Significance
The older population constitutes the fastest growing segment of the U.S. population.
They formed 12.9% of the U.S. population in the year 2000 and by 2030 this group is projected
to grow to be 19% of the population.3 The coming years will also witness the aging of the babyboomer generation (individuals born during 1946-1964) ushering in a sustained demand for
healthcare services catering to the needs of older adults. This generation reportedly uses more
illicit drugs than the preceding generation.4,5 Assuming that the cohort with greater lifetime rates
of drug use will exhibit current drug use, (notwithstanding the trend of decrease in use of drugs
of abuse with age) an increase in the number of older adults with substance abuse problems is
expected.5 The large size of this cohort coupled with the higher rate of substance abuse is
predicted to result in an unprecedented number of older adults requiring substance abuse
treatment in the future.
According to the projections, the nonmedical use of psychotherapeutic drugs will rise
from 1.2% (911,000) in 2001 to 2.4% (approximately 2.7 million) in 2020.5 The increase in
prescription drug abuse may result in a rise in emergency department visits and greater
healthcare costs. Another study predicted that older adults requiring treatment for substance
abuse problem will increase from approximately 1.7 million in 2000-2001 to approximately 4.4
million in 2020.4
The use of CNS-acting medications including opioid analgesics, antidepressants, and
sedatives-hypnotics by older adults is reportedly rising. A longitudinal study of communitydwelling older adults found that 13.9% (n=2737) of participants used at least one CNS-active
medication and the prevalence increased to 17.1% (n=1907) over 5 years.6 In 2011, emergency
4

department visits involving drugs and alcohol consumed together by older adults was reported to
be 9,190 visits out of total of 606,653 visits.7 The projected increase in the use of psychoactive
substances may translate into greater need for specialized treatment as well as preventive
measures catering to substance abuse patients. Historically, preventive measures have focused on
young adults. There is a dearth of research on how to address and manage drug abuse problems
in the older generation. In addition, since most of the predictions are based on the assumption
that lifetime users will continue to use illicit drugs, alcohol, and psychotropic drugs it is
important to verify these assumptions. Observational studies conducted among a nationally
representation sample of older adults assessing alcohol use, factors and adverse outcomes
associated with alcohol use, are needed.
Understanding the impact of the concurrent use of alcohol and CNS-acting medications
on the risk of falling in older adults will be helpful in planning preventive measures to lower the
incidence of falls in high risk older adults. In situations where CNS-acting medications cannot be
discontinued patient at risk for falls due to their concurrent alcohol and CNS-acting medication
use can be counselled to monitor, reduce or stop drinking. Falls significantly impact on the
health and quality-of-life of older adults.8,9 Falls are widespread among older adults and are a
common cause of hospital admissions. The total direct medical cost of fall-related injuries in
older adults in 2010 was estimated to be $30 billion, adjusting for inflation.10 It is projected that
by 2020, the annual direct and indirect cost of fall injuries will reach $54.9 billion (in 2007
dollars).11 Therefore, generating evidence to identify risk factors for falls in order to inform the
development and implementation of appropriate preventive measures to lower the risk for falls in
older adults is crucial.

5

Chapter 2
Section 2.1 Background
2.1.1 Alcohol
Alcohol is one of the oldest psychoactive agents and is widely used in our society for
many reasons including stress relief, sleep induction, recreational purposes or for its apparent
medicinal value.12 Currently, 59.6% of American adult women and 71.8% of American adult
men reported having at least one drink in the past year.13
Beer, wine, and spirits are three major types of alcoholic beverages consumed across the
world.14 In the U.S., a standard drink is defined as any drink that contains about 14 grams of pure
alcohol and is equivalent to 12 ounces (oz.) of beer, 8-9 oz. of malt liquor, 5 oz. of table wine
and 1.5 oz. of distilled spirits.15 The pattern of alcohol consumption is a factor which has
substantial impact on the health outcomes associated with alcohol use. The pattern of alcohol
consumption is often characterized in the following scheme: lifetime abstainers, former drinkers,
light drinkers, moderate drinkers, heavy drinkers, and binge or heavy episodic drinkers.14
Alcohol consumption can impart a broad range of consequences on the physical and
mental health of a drinker, depending on a variety of factors such as age and gender of drinkers,
type of alcohol, and pattern of consumption.14 It may also have adverse social, legal,
occupational consequences. Alcohol consumption is the world’s third largest risk factor for
disease and disability; in middle-income countries, it is the greatest risk factor.14 Alcohol is a
causal factor in 60 types of diseases and injuries and a component cause in 200 others.14 In the
United States, alcohol contributes to 79,000 deaths and $223.5 billion in societal costs
6

annually.16 Almost 9% of U.S. adults (approximately 13% of those who drink) meet the criteria
for an alcohol-use disorder.17
A growing body of literature has shown the beneficial effects of moderate alcohol
consumption. Epidemiological studies have found that moderate alcohol consumption (not more
than 2 drinks per day) lowers risks for cardiovascular events, mortality, cognitive decline, and
fractures.18 Current findings suggest a U or J-shaped relationship between alcohol consumption
and coronary artery disease.18 Moderate alcohol consumption has an impact on the psychosocial
functioning in older adults; by facilitating social interaction, improving mood and stimulating
appetite.18
2.1.2 Pharmacology of Alcohol
Alcohol has a complex pharmacology and is known to affect a wide variety of
neurotransmitter systems. Alcohol exerts its primary action via a number of central nervous
system neurotransmitter or neuromodulator systems, including the N-methyl-D-aspartate
(NMDA), Gamma-aminobutyric acid (GABAA), glycine, 5-hydroxytryptamine 3 (5-HT3) and
nicotinic acetylcholine receptors (nAChRs) as well as L-type Ca2+ channels and G proteincoupled inwardly-rectifying potassium channels (GIRKs).19 Basically, it acts by disrupting
distinct receptor or effector proteins via direct or indirect interactions, whereas at very high
concentrations it might even change the composition of lipids in the surrounding membrane.19
The NMDA function was inhibited by alcohol in a concentration-dependent fashion.19 Alcohol
enhances the function of GABAA and glycine receptors. In addition, alcohol potentiates
serotonin (5-HT3) and nAChR functions. By acting on the aforementioned receptors, alcohol
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increases endogenous serotonin, dopamine and opioid release.19 Ion channels also constitute a
primary target of alcohol. Alcohol inhibits dihydropyridine-sensitive L-type Ca2+ channels.19
Alcohol, a CNS depressant, can stimulate pulse, motor activity, and mood in small doses
whereas higher dose of alcohol can impair cognitive and motor function, cause respiratory
depression and in severe cases cause coma and death. Behavioral, psychomotor, and cognitive
changes begin to occur at a blood alcohol concentration (BAC) of 0.02-0.03 (grams of alcohol
per 100 grams of individual's blood).19
Alcohol ingested by mouth reaches the stomach, where a small portion is metabolized by
the enzyme alcohol dehydrogenase (ADH). The remaining alcohol enters the intestine, where
most of it is absorbed into the blood and enters the portal system that leads to liver. 20,21 A part of
that alcohol is metabolized in the liver by ADH and cytochrome P450 enzymes. The remaining
alcohol enters the systemic circulation and from there gets distributed throughout the body
water.20,21 The liver is the primary site of alcohol metabolism. ADH converts alcohol to
acetaldehyde in an oxidative reaction. Acetaldehyde is further metabolized by aldehyde
dehydrogenase (ALDH) to acetate and acetyl CoA.20,21
2.1.3 Alcohol Consumption in Older Adults
Alcohol consumption declines with age with older adults consuming less alcohol than
their younger counterparts.22 Though a plethora of studies have been conducted to understand
different facets of alcohol use, comparatively fewer studies have been performed to understand
the effect of alcohol consumption on health-related outcomes in older adults.
Alcohol has greater physiological impact on older adults than on younger adults for a
variety of reasons. First and foremost, age-related changes in physiology significantly affect the
8

response of older adults to alcohol. As lean body mass decreases with age, the total body water
also decreases while fat increases as a proportion of body weight. Since alcohol distributes in
total body water, this alteration in the volume of total body water means that for a given dose of
alcohol, the concentration of alcohol in the blood is greater in an older adult than in a younger
adult. As a result, the same amount of alcohol that previously had little effect may now cause
intoxication.22,23 Furthermore, it is postulated that this relative change in alcohol concentration in
blood accompanied with slower reaction time observed among older adults could be responsible
for the accidents or injuries that are observed in this age group.23 The reduced secretion of gastric
alcohol dehydrogenase enzyme causes alcohol to be metabolized more slowly so the blood
alcohol level remains raised for a longer time.2 The widespread use of alcohol and medication by
older adults, especially in the presence of chronic comorbid conditions, renders them vulnerable
to the adverse effects of alcohol-medication interactions as well. Older adults consume more
medication than any other age group. According to the National Council on Patient Information
and Education (NCPIE) 34% of all prescription medication and 30% of all over-the-counter
medication is used by older adults.24 In addition, one-third of Medicare beneficiaries have four or
more chronic conditions and these may be treated with medications.24
Detection of alcohol problems in older adults is often difficult. The social stigma attached
to alcohol consumption may prevent older adults from disclosing their actual amount of
consumption.22,25 Driven by biases and stereotypes, healthcare practitioners may not enquire
about older patients’ alcohol use. Healthcare professionals and older adults may avoid discussing
alcohol consumption.22,25 Symptoms associated with heavy drinking, alcohol dependence or
abuse may coincide with symptoms of other diseases such as depression, dementia, and
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psychiatric disorders.22,25 Due to the aforementioned reasons alcohol use in older adults is
described as a “hidden epidemic”.22
The prevalence of alcohol use reported by various studies may differ in proportion but the
pattern of consumption remains similar. According to the 2011 National Survey on Drug Use
and Health (NSDUH) findings, the prevalence of current alcohol use (at least one drink in the
past 30 days) is 40.3% among participants aged 65 years or older. 8.3% of older adults reported
binge drinking (five or more drinks on the same occasion on at least 1 day in the past 30 days)
while the rate of heavy drinking was 1.7% (five or more drinks on the same occasion on each of
5 or more days in the past 30 days) in this group.26 Cross-sectional analysis of multisite
screening data obtained from older patients in primary care older reported 70.0% had no
consumption of alcohol in the past year, 21.5% were moderate drinkers (1-7 drinks/week), 4.1%
were at-risk drinkers (8-14 drinks/week), and 4.5% were heavy drinkers (>14 drinks/week).27 On
the other hand, analysis of the Medicare Current Beneficiary Survey (MCBS) data showed that
65.5% of the sample reported drinking no alcohol, 25.4% reported drinking within guidelines
(not more than 30 drinks per month), 3.8% exceeded the monthly limit only (more than 30 drinks
per month), and 5.4% reported heavy episodic drinking (4 or more drinks in a single occasion),
during a typical month in the past year.28 Thus, comparing the prevalence rates of alcohol use
becomes difficult owing to the design and setting of the study, definitions and measures of
alcohol consumption used in the study, and characteristics of the study sample. However, the
prevalence rates of the aforementioned studies indicate that substantial proportion of older adults
consumes alcohol. It is noteworthy that these proportions are likely to be an underestimation of
the true proportion. Under-reporting of alcohol consumption, whether unintentional (due to recall
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bias or type of survey questions), or intentional (due to social stigma attached to drinking) is
common.22
Alcohol use imparts various benefits and detriments to the health of older adults.
Moderate alcohol consumption has been claimed to be beneficial in reducing the risk of the
cardiovascular diseases and dementia.18 In addition, it is documented to improve cognition,
psychological functioning, bone metabolism, and mortality.18 However, immoderate amount of
alcohol intake has been found to have hazardous effects on physical and mental health.18 Chronic
heavy drinking is associated with numerous health issues including but not limited to, hepatic
disease, cardiovascular disease, various forms of cancer, diabetes mellitus, alcohol dependence
or abuse, injuries, and accidents.18
2.1.4 Alcohol and Medication Interactions
A large number of medications have the potential to interact with alcohol. There are two
types

of

alcohol-medication

interactions:

pharmacokinetic

and

pharmacodynamics

interactions.2,21,29 Quantity and frequency of alcohol consumption also influences the outcome of
alcohol-medication interactions.
In a pharmacokinetic interaction, alcohol interferes with the absorption, distribution,
metabolism and elimination of the medication or vice versa. Drinks with a high alcohol
concentration will delay gastric emptying and this may affect the absorption of some drugs (for
example propranolol, metoclopramide, and cisapride).20 Some drugs may block the first pass
metabolism of the alcohol in the liver resulting in elevated blood alcohol levels. Examples of
such medications are H2 receptor antagonists: cimetidine, ranitidine, and nizatidine. Cytochrome
P450 enzymes (primarily CPY2E1) play an important role in the metabolism of alcohol. Hence
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certain medications (such as benzodiazepines, barbiturates, warfarin, phenytoin, propranolol,
tolbutamide, isoniazid, and highly active antiretroviral therapy (HAART) drugs) require the
same enzyme for metabolism as alcohol and therefore compete with alcohol for metabolism.21 It
must be noted that the effect of CYP enzyme related interaction is influenced by the pattern of
alcohol consumption. In chronic heavy drinkers, CYP2E1 activity is induced up to tenfold. When
such drinkers are sober with no alcohol in the body to compete with medications for metabolism,
those medications undergo more rapid metabolic clearance. As a result, medications will require
higher doses to achieve a therapeutic effect. However, acute heavy drinking inhibits the hepatic
drug metabolism. Thus, the drug competes with alcohol for metabolism and these drugs will be
metabolized more slowly.2,21,29,30
Several medications can inhibit the ALDH enzyme and thereby increases the aldehyde
level in blood causing flushing (dilation of blood vessels, low blood pressure, rapid heartbeat).
Some examples of such medications are longer acting hypoglycemic agents, namely
chlorpropamide, and tolbutamide, and beta-lactum cephalosporin such as cefamandole.2 Foods
and beverages with tyramine, including red wine and beer, can increase the risk if hypertensive
crisis when consumed with nonselective monoamine oxidase inhibitors.2
In pharmacodynamic interactions, alcohol alters the effect/response of the medication.
They do not involve enzyme inhibition or activation but rather refer to the additive effects of
alcohol and certain medications on the body. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
when combined with alcohol may increase the risk of gastrointestinal bleeding by injuring
gastric mucosa and increasing bleeding time.2,21,29 Antiplatelet agents including aspirin,
clopidogrel, and ticlopidine also increase the risk of bleeding.28 Alcohol, when consumed
concomitantly

with

antihypertensive

agents
12

potentiates

orthostatic

hypotension.2

Antihypertensive agents such as vasodilators, hydralazine, nitrates, central-acting hydralazine,
central-acting antihypertensives, and alpha-blockers, may cause a severe drop in blood pressure
leading to dizziness and fall-related injuries when taken with alcohol.2 Another important class
of medication that exhibits additive pharmacodynamic interaction with alcohol is CNS-acting
medications.2,21,29 Alcohol can also have an adverse impact on disease conditions such as
hypertension, diabetes mellitus, gout, hepatic diseases, depression, insomnia, and various forms
of cancer.2,21,29
2.1.5 Interaction between Alcohol and CNS-Acting Medications
Both alcohol and CNS-acting medications are widely used. Both of the agents are
psychoactive substances with similar mechanisms of action.2,21,29 There is more than one ways in
which alcohol can interact with CNS-acting medications.31 The most prevalent type of
interaction is the additive pharmacodynamics interaction between CNS depressants and alcohol.
Concomitant use of CNS depressants and alcohol synergistically enhances the side effects
(including sedation, impairment of judgment and motor functions) of these drugs. Alcohol and
some CNS depressants act on the same neurotransmitter system (GABA receptors, release of
dopamine, serotonin).2,21,29 Pharmacokinetic interactions between certain CNS depressants and
alcohol also exist. Alcohol and certain CNS depressants such as phenytoin, benzodiazepines, and
barbiturates, may compete to be metabolized by the same metabolic enzyme.21,29 Apart from
interacting with CNS-acting medications, alcohol is also associated with behavioral health
problems. The literature has documented a complex, bidirectional relationship between alcohol
and depression. Problematic alcohol consumption accompanied by depression32 significantly
increases the potential for poor mental and physical health outcomes. The overlapping signs and
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symptoms of substance abuse and depression may lead to misdiagnosis, or missed diagnosis by
clinicians. Heavy drinking also interferes with the quality of sleep.2
2.1.6 CNS-Acting Medication Use in Older Adults
Use of CNS-acting medication, including antidepressants, anxiolytics, sedativeshypnotics, anticonvulsants, antipsychotics, and opioid analgesics, is widespread among older
adults living in all types of settings, including assisted-living facilities, nursing homes, or
congregate retirement communities.33,34

A study using Medical Expenditure Panel Survey

(MEPS) data from year 2004-2009 found that there was an increase in the use of following
classes of medications; psychotropic medication (from 57.4% to 63.8%, p-value <0.01),
benzodiazepines (from 22.7% to 30.5%, p-value <0.01), atypical antipsychotics (from 2.3 to
3.9%, p<0.01) in the span of 5 years.34 These drugs are prescribed for various purposes including
treating psychiatric conditions, sleep disorders, mood disorder, and alleviating pain, stress, and
anxiety.32
Unfortunately these medications are associated with several adverse effects including
falls, fractures, accidents, cognitive impairment, and hospitalizations.32 Use of some of these
drugs, by itself or at a certain dose, is deemed as inappropriate for older adults. Psychotropic
drugs listed in the Beer’s criteria include, but not limited to, amitriptyline, clomipramine,
imipramine, doxepine, atypical antipsychotics, long-acting and short-acting benzodiazepines,
chronic use of zolpidem, and zaleplon,.35
The growing use of CNS-acting medications and alcohol warrants an investigation on the
effect of the potential concomitant use of alcohol and CNS-acting medication. A variety of
factors influence the use and potential misuse of CNS-acting medications. The aging process,
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coexisting disease conditions, increasing dependency, life-changing events such as retirement,
bereavement and other psychosocial stressors may drive older adults to use psychotropic
medications.36
2.1.7 Falls in Older Adults
The World Health Organization (WHO) defines a fall as “inadvertently coming to rest on
the ground floor or other lower level, excluding intentional change in position to rest in furniture,
wall or other objects”.37 Falls are the leading cause of injury-related deaths and are a common
cause of non-fatal injuries inn older adults. In 2010, 2.3 million nonfatal fall injuries among older
adults in the U.S. were treated in emergency departments and more than 662,000 of these
patients were hospitalized.38 Accidental falls may result in fractures, concussions, bruises,
dislocation, sprains, and open wounds. Fractures (41.0%) are the most common reason for
injurious fall-related emergency department visits, followed by superficial/contusion injuries
(22.6%) and open wounds (21.45%).39
CNS-acting medications have been implicated as a risk factor for falls in older adults.40
Acute and or heavy alcohol consumption has also been associated with the risk of falls in older
adults.1 The pharmacodynamic interaction between the alcohol and CNS-acting medications is
the basis of the biological plausibility that concomitant use of CNS-acting medication and
alcohol may increase the risk of falling.2
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Section 2.2 Conceptual Framework
2.2.1 Conceptual Framework for At-Risk Drinking
This dissertation study is based on the concept that alcohol can interact with selected
diseases, certain classes of medications, and health-related behaviors (such as falls, memory
problem, or sleeping problem) and this interaction may lead to adverse health outcomes. Older
adults are more susceptible to alcohol-medication or alcohol-disease interactions due to several
age-related changes. These age-related physiologic changes23 include, i) decline in total body
water in which alcohol distributes as a result of which older adults achieve higher blood alcohol
concentration (BAC) than younger adults after consuming same volume of alcohol, ii) functional
changes (including changes in the neurotransmitters, receptors, hormonal changes) in the aging
brain increases the brain’s sensitivity to the psychoactive effect of alcohol, and iii) decrease in
the secretion of gastric enzymes slowing down the metabolism (this may play a minor role). 2
Thus, due to the above mentioned age-related changes older adults may experience exaggerated
response to alcohol. Besides, aging may also affect the body’s ability to develop tolerance.23
Moreover, as older adults tend to suffer from comorbid conditions and take numerous
medications, the probability of encountering alcohol-disease or alcohol-medication interaction
increases.2
The first objective of the study is to understand the extent of alcohol use in context with
disease conditions, medication use, and health-related behaviors. The purpose is to measure the
extent of risk a community-dwelling older adult may exhibit owing to their disease profile,
medication use and other health related behaviors.
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Figure 2.1 Conceptual Framework of At-Risk Drinking

Depending upon the pattern, volume, duration of consumption, and type of alcoholic
beverages consumed, alcohol may interact with certain medications or disease conditions causing
adverse events.41 Alcohol may interact with diseases or medication in several ways. This study
utilized a risk assessment tool (CARET) to study at-risk drinking which is defined as “alcohol
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use that is excessive or potentially harmful in combination with select comorbidities or
medications”.41
This risk assessment tool incorporates a list of disease conditions that may be affected by
alcohol intake. Table 2.1 describes the alcohol-disease interaction, the mechanisms of action and
its repercussions on the health of older adults.2 There are other disease conditions that may
interfere with alcohol use but this study focused on disease states listed in Table 2.1.
Table 2.1 Alcohol-Disease Interactions2,21
Disease

Mechanism of action

Effect

Hypertension

Alcohol can cause a dose-dependent
increase in blood pressure

Increases the risk of
hypertension

Diabetes

Alcohol suppresses hepatic
gluconeogenesis. Drinking without
eating may increase the risk of
hypoglycemia. Consuming sweet
alcohol beverage may induce
hyperglycemia.
Alcohol worsens hepatic disease
through inflammation and accelerates
disease progression.

Affects blood glucose
levels

Alcohol induces a hyperuricemic
effect
Alcohol affects mood and depressive
symptoms. A strong bidirectional
relationship exists between alcohol
and depression

Increases the risk of gout

Hepatic disorders

Gout
Depression

Increases the risk of
cirrhosis and hepatocellular
cancer.

Exacerbation of depressive
symptoms

The CARET questionnaire also includes selected medications that have the potential to
interact with alcohol. There are other medications that may interact with alcohol to cause adverse
effects but this study included medications listed in Table 2.2 which describes the mechanism of
action as well as effects of each alcohol-medication interaction.2
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Table 2.2 Alcohol-Medication Interactions2,21
Medications

Mechanism

Effect

CNS-acting medications
including benzodiazepines,
barbiturates, sedativeshypnotics, anticonvulsants,
antidepressants, sedatingantihistamines, opioid
analgesics

Alcohol enhances the side
effects of these medications
such as sedation, drowsiness,
impairment of psychomotor
functions, postural sway,
affects gait and balance.

Drowsiness, sedation, fall,
accidents, injuries.

Warfarin

During acute intake, alcohol
may compete with liver
enzymes decreasing warfarin
metabolism resulting in
increased anticoagulation.
Chronic intake of alcohol
induces enzymes resulting in
increasing warfarin metabolism
thereby decreasing
anticoagulation
Affects gastric mucosa and
increases gastric emptying

Interferes with the
effectiveness of the drug
(may cause bleeding)

Antihypertensives including
nitrates, vasodilators, alphablockers, diuretics,
hydralazine, centrally-acting
antihypertensives

Impairs vasoconstriction
leading to severe drop in blood
pressure

Hypotension

NSAIDs

Due to increase in production
of metabolites toxic to the liver,
damaging gastric mucosa

Hepatic toxicity

Anti-ulcer medications
including proton pump
inhibitors and H2 antagonists

Interferes with alcohol
metabolism by reducing ADH
activity in gastric mucosa and
increasing gastric emptying

Increases blood alcohol
levels

Antiplatelet agents (aspirin,
clopidogrel, ticlopidine)
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Gastrointestinal bleeding

Understanding the factors associated with at-risk drinking is important in order to identify
“high-risk” individuals and direct preventive measures to maximize the reduction of alcoholrelated adverse outcomes. Previous studies have documented relationships between at-risk
drinking and other factors including demographic factors (such as age, gender, race, and marital
status), socio-economic status (education, income, employment), and health and functional
status.42,43 Few studies have explored the relationship between at-risk drinking, comorbidities,
and medication use.42
This study aims to identify the factors, including socio-demographic factors, perceived
health status, functional status, comorbidities and medications that could be related to at-risk
drinking in older adults.
Figure 2.2 graphically depicts the complex inter-relationship between at-risk drinking and
diverse factors. More research is needed to understand the directionality and magnitude of these
associations and other mediating factors.
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Figure 2.2 Inter-relationships Between Various Factors Associated with At-Risk Drinking
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2.2.1 Conceptual Framework for Alcohol and CNS-Acting Medication Interaction
As described in Table 2.2 pharmacodynamic interactions can occurs between alcohol and
CNS-acting medications that may lead to sedation, drowsiness, and impairment psychomotor
functions. The mechanism behind pharmacodynamic interaction can be explained by two ways:
i) additive interaction where the two individual agents act separately to cause an effect that is the
sum of the two effects, ii) synergistic interaction in which the observed response is greater than
the sum of the individual effect of each drug.31 Some interaction can be attributed to the
common receptor type that is associated with some of the CNS-acting medications and alcohol.
This is the GABAA receptor which is the receptor for GABA, the primary inhibitory
neurotransmitter in the CNS. Benzodiazepines, barbiturates, and other sedatives-hypnotics bind
at separate sites in the receptor to potentiate the inhibitory action of GABA. Ethanol modifies the
receptor by altering the membrane environment so that it has increased affinity for GABA.44
Opioid analgesics depress the CNS, resulting in analgesia, sedation, drowsiness, mood changes,
euphoria, lethargy, and depressed respiration.31 Alcohol enhances the sedating property of
opioids. For antipsychotic drugs extrapyramidal symptoms, tardive dyskinesia (TD), elevated
prolactin levels, and sedation contribute to falls and fractures.45
Alcohol also interacts with certain types of CNS-acting agents in a pharmacokinetic
manner. During acute heavy alcohol consumption, alcohol may compete with certain medication
such as benzodiazepines, barbiturates, phenytoin, for cytochrome P450 enzymes (CYP2E1)
causing decreased metabolism of the medication which results in higher effectiveness of the
drug.21 This potentiates the effect of alcohol and those CNS-acting medications. For example,
alcohol intake followed by tricyclic antidepressant ingestion can cause an over 200% increase in
plasma amitriptyline concentrations in humans.31 In the scenario of acute alcohol ingestion by an
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infrequent drinker, the metabolism of the drug is inhibited.21 On the other hand, regular ingestion
of alcohol can induce the normal secretion of the CYP2E1 enzyme thereby increasing the
metabolism of those drugs. Chlorpromazine (antipsychotic agent) inhibits alcohol dehydrogenase
preventing alcohol metabolism.21
Development of cross-tolerance is also a phenomenon altering the effect of the drug in
the presence of alcohol.31 Tolerance is a phenomenon in which a repeated use of a psychoactive
agent alters the response of the target tissue to the drug itself or other chemically-related
agents.31 Cross-tolerance is seen when physiologic changes induced by prolonged exposure of
the original chemical agent (such as alcohol) is carried over to another drug (such as a
barbiturate) wherein the response to the second drug is diminished.31 An animal study,
performed to assess the sedation achieved by co-administration if alcohol and antidepressants,
reported the following strength of potentiating effect of alcohol sedation: amitriptyline ≥
imipramine > maprotiline = mianserine > desipramine ≥ chlorimpramine > iprindole ≥
alaproclate ≥ norzimelidine ≥ zimelidine.46
Figure 2.3 illustrates the pharmacodynamic interactions between alcohol and CNS-acting
medications. Another important aspect of this interaction is the age related changes occurring in
older adults that causes an exaggerated response to alcohol and CNS-acting medication. This can
be explained by the functional changes in the aging brain which includes alterations in
neurotransmitters, number of receptors, hormonal changes, and impaired glucose metabolism.47
For example, age-dependent changes in GABAA benzodiazepine receptor complex leads to
increased sensitivity to benzodiazepines which may result in negative effects on cognition, gait,
and balance.47
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Figure 2.3 Conceptual Description of the Interaction Between Alcohol and CNSActing Medications
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Based on the concept of pharmacodynamic interactions, concurrent use of alcohol and
CNS-acting medications may enhance sedation, loss of balance and gait, postural sway, and
impairment of psychomotor function, all of which increases the risk of falls, accidents, and
injuries. Hence the idea was to investigate if increased risk of falls was associated concurrent
use of alcohol and CNS-acting medications.
Before investigating the effect of the combined use of these agents, it was important to
determine the prevalence of potential concurrent use if alcohol and CNS-acting medications as
there were no recent data available indicating the extent of potential concurrent use of these
agents.
Review of literature showed a dearth of studies looking at the prevalence and extent of atrisk drinking. There is lack of evidence on the effect of the combined use of alcohol and CNSacting medications on risk for falls in older adults. Based on the conceptual framework and gaps
in the literature, the study objectives of this dissertation were formed.
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Chapter 3
Section 3 Review of Literature
3.1. Introduction
Consumption of large amounts of alcohol, in an acute or chronic manner, may increase
the risk of experiencing alcohol-attributable heath disorders. The volume, pattern and quality of
alcohol and duration of exposure impact the health outcomes encountered by drinkers.48 In
addition, consumption of alcohol in the presence of certain disease conditions may have harmful
effects.2 Alcohol may interact with selected medications to cause adverse effects.2 Even
moderate drinking may place older adults at risk of experiencing adverse events owing to their
disease profile or medication use.49 A survey of 17,000 Medicare beneficiaries found that 2 out
of 5 patients reported taking five or more prescription medications.50 More than 90 percent of
non-institutionalized older adults in the United States take at least one prescription medication,
and those who are seen in physicians’ ofﬁce take six to eight medications on average.51
Considering the high use of medication in the older population, it is imperative to understand the
magnitude of potential concurrent alcohol and medication use.
A literature review was conducted to identify, select, and evaluate the available research
studies and synthesize evidence providing insight into the nature of alcohol and medication use
among older adults. This review will provide a comprehensive look at the issue of alcohol and
medications use in older adults thereby providing evidence to support decision-making by
different stakeholders including healthcare professionals, policymakers, and researchers. The
objective is to conduct a systematic review to identify and evaluate epidemiological studies
describing the use of alcohol and medication in older adults.
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3.2 Methods
Peer-reviewed literature published from January 1990 to 19th September 2013 was
searched in Pubmed/Medline. Additionally, the reference lists of relevant reviews and research
articles were also assessed. Studies were included if: i) they were conducted in older adults (aged
60 years or older), ii) the objective of the research article was to understand alcohol and
medication use, and iii) the abstract or full text was available in the English language. Systematic
reviews, case reports, and case series were not included in this study. The age limit for older
adults was considered to be 60 years since that is the cutoff accepted in many countries.
The search terms included a combination of Medical Subject Headings (MeSH) terms
and non-MeSH terms along with Boolean operators. The search terms accompanied with filters
(including publication date from 1990/01/01 to 2013/09/19, humans, English language, age: 4564 years, 65+ years, and 80+ years) were employed to retrieve relevant articles. The search terms
included “alcohol drinking AND aged AND medication AND epidemiology”, “alcohol AND
aged AND medication”, and “at-risk drinking AND (older adults OR aged) AND alcohol”.
Screening was performed by reviewing the title and abstract for potential eligibility,
followed by further examining the full-text for potential eligibility. References of retrieved
articles and review papers were screened to find possible articles. A research study with multiple
publications is discussed as a single study in this review. Frequency or percentage of combined
use of alcohol and medication is discussed in this review.
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Table 3.1 Summary of Studies

Study

Country

Setting and sample
size
A stratified random
sample of 1,395
home-dwelling adults
aged ≥65 years

Assessment

Inference

Immonen
et al, 2013

Finland

Alcohol interactive drugs
examined using Swedish,
Finnish, Interaction Xreferencing interaction database

3,308 drinkers aged 60
years or older,
recruited from nonprofit, outpatient clinic
NHANES I, 19711974 and NHANES
Epidemiologic
Follow-up Survey,
1992

Comorbidity Alcohol Risk
Evaluation Tool (CARET) was
used

Among 1,142 drug users, 62.6% consumed
alcohol. The use of alcohol-interactive drugs
was found to be 42.2%, 34.9%, and 52.7%
among at-risk users, moderate users and
minimal/non-users
Of the 1,147 at-risk drinkers, 21.2% and 21.5%
were at-risk owing to their alcohol use with
medication and co-morbidity, respectively.

Barnes et
al, 2010 42

U.S.A

Moore et
al, 2006 61

U.S.A

Some of the items from
Comorbidity Alcohol Risk
Evaluation Tool (CARET) were
used

Prevalence of at-risk drinking was 10%. 69%
of at-risk drinkers were identified as such
because of their alcohol use in the presence of
comorbidities. Pain medication and medication
for anxiety disorders were most commonly
used by drinkers.

Aira et al,
200563

Finland

523 home-dwellers
(≥ 75 years of age)

Community-based random
survey

86.9% of alcohol drinkers use medication on
regular basis.

Pringle et
al, 2005 57

U.S.A

83,321 PA-PACE
cardholders

19% of AI drug users reported concomitant
alcohol use (p<0.001). Most common
combination of alcohol and alcohol interactive
medication occurred with NSAIDs (20.2%)

Moore et
al,
2002 62

U.S.A

166 drinkers aged 60
years or older
recruited from internal
medicine clinic

Mailed survey to collect alcohol
use data. Prescription drug
claims were used. Alcohol
interactive medications
identified using First DataBank.
ARPS and shorter version of
ARPS

59
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Out of 166 drinkers, 64 were identified at-risk
because of their medication and alcohol use.

Study

Country

Setting and sample size

Assessment

Inference

Fink et
al,
2002 43

U.S.A

549 current drinkers aged
65 years or older recruited
from academic and
community primary care
clinics

Alcohol-related Problem Survey
(ARPS)

11% were harmful drinkers and 35% hazardous
drinkers. Most hazardous drinkers were identified
by their alcohol and medication use. Anti-arthritic,
pain medications, and aspirin were commonly used
by drinkers.

Johnson
et al,
1997 69

U.S.A

Volunteer sample of 155
urban women over the age
of 85 years was
interviewed

Data on health, sleep patterns, use of
alcohol and OTC medication

“Seventy-seven (85%) of the women who used
alcohol before bedtime also used OTC medication.
Of these, 33 (43%) used alcohol and OTC
medication in combination each night.”

Adams et
al,65
1995,

U.S.A

311 independently living
residents

Alcohol use questions adapted from
the Khavari questionnaire and the
CAGE questionnaire. Prescription
and non-prescription medication use
was considered

38% used both alcohol and high-risk medication.
High-risk drugs commonly used were
antihypertensives, aspirin, NSAIDs and
medications for congestive heart failure.

Forster et
al,58
1993

U.S.A

667 community dwellers
in rural setting

Prescription and OTC medications
were included. Physician Desk
Reference used for ascertaining ADI

25% of the respondents were at risk for at least one
alcohol-related ADR and 19% reported using OTC
pain medications and alcohol.

Alcohol and Psychotropic drugs
Ilomaki
et al,
2013 64

Australia

1,705 Australian men aged 70
years or older. Data collected
from 2005-2007.

Alcohol and psychotropic drugs
were studied

Of the 135 antidepressant users 27.1% were daily
drinkers, as were 42.7% of the 97 sedativeanxiolytic drug users.

Du et al,
2008 66

Germany

1,605 older adults aged
between 60-79 years. Data
from German National Health
Interview and Examination
Survey 1997-1999.

Alcohol and psychotropic drugs
were studied

Last week prevalence of combined psychotropic
and alcohol use was 7.6%.
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3.3. Results
3.3.1 Summary of Studies
The search yielded a total of 10,180 articles. After removing duplicates or irrelevant
articles and applying the inclusion and exclusion criteria, a total of 12 original research studies
were selected. All studies were cross-sectional in design and most of them included communitydwelling older adults. Most of the studies were conducted in the U.S. Some of the studies were
excluded as they did not match the age criteria52,53 or they did not study potential combined use
of alcohol and alcohol-interactive medications.54-56 Table 3.1 summarizes the studies included in
this review.
3.3.2 Review of Design of the Studies
Interview or mailed survey methods were employed to collect the “usual” alcohol
consumption in the past 12 months in the study population in these studies. Information on
medication use was collected mostly from survey and/or interview where either participant
reported medications they had been using in the past or the interviewer inspected the containers
of all the medication products used by the subject and recorded the information. Pringle et al.
collected the medication use information of their study sample from administrative claims data.57
Potential interactions between alcohol and medications were determined by various
methods in these studies. Some studies used a clinical information system such as Physician
Desk Reference, First DataBank57,58, or a country-specific interaction database59 to ascertain
interactions between alcohol and medications.
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On the other hand some studies

42,43,50,61

introduced a novel paradigm to understand the

combined use of alcohol and medication, referring to it as “at-risk drinking”. They defined the
use of specific amounts of alcohol in the presence of certain medications, comorbid conditions
and health-related behaviors as “at-risk drinking”.41 These studies have used validated
questionnaires [Comorbidity Alcohol Risk Evaluation Tool (CARET), Alcohol Related Problem
Survey (ARPS), and shorter version of ARPS (ShARPS)] to understand the potentially harmful
use of alcohol and alcohol-interactive (AI) medications.62 These instruments have a series of
questions enquiring about the quantity and frequency of alcohol use, heavy episodic alcohol
intake, use of different classes of medications, the presence of certain comorbid conditions, and
health-related behaviors. ARPS and ShARPS classify drinkers as harmful, hazardous or nonhazardous drinkers while CARET categorizes them as at-risk-drinkers and non-at-risk
drinkers.42,61
The prevalence of alcohol and medication use was also estimated and reported in more
than one manner. Some studies reported alcohol use among medication users.57,59,63,64 While
some studies reported rate and magnitude of medication use among alcohol drinkers.59,63 Some
studies estimated the potential concurrent use of alcohol and medication in the entire study
sample.58,61,65,66 A few studies estimated at-risk drinking among the current drinkers.42,43,61
Choice of the denominator is relevant in this case as extent of medication use widely differs from
alcohol use in older adults. Hence the prevalence reported in these studies should be interpreted
accordingly and comparison of these rates to each other should be made with caution.
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3.3.3 Review of Prevalence Reported in the Studies
Alcohol use is influenced by many factors including, but not limited to, gender,
nationality, cultural or religious beliefs, educational background, life-changing events, health
condition, environment, social life and history of substance abuse.67,68 Prevalence of alcohol use
varies widely across the studies summarized in this review. Current alcohol use estimated by
these studies ranged from 39% to 62% and heavy or risky alcohol consumption was estimated to
be in the range of 7%-20%. Moderate drinkers constituted the largest group among the older
drinkers.
At-risk drinking was prevalent among older adults. Fink et al. found that among 549
current drinkers, 11% were harmful drinkers, 35% were hazardous drinkers, and the remaining
were non-hazardous drinkers.43 Hypertension was the top indicator for harmful drinking and
anti-arthritic and pain medications followed by aspirin, H2–antagonists (ranitidine, cimetidine),
antihypertensives, and antidepressants were some of the most common indicators of hazardous
drinking.43 Moore et al. studied the validity and reliability of ARPS and ShARPS and found that
these instruments were “more sensitive than AUDIT and SMAST-G in identifying older drinkers
at risk of experiencing harm as a result of alcohol and comorbidities”.62
In the SHARE study, 34.7% of the 3,308 current drinkers were identified as at-risk
drinkers. Among those, 61.0%, 61.9% and 64.3% were identified as at-risk drinkers owing to
their alcohol-medication use, alcohol-comorbidity, and alcohol intake, respectively. Among the
at-risk drinkers 56.1% fell into at least two risk categories and 31.0% fell into all three risk
categories.42 Analysis of the 1971-1974 National Health and Nutrition Examination Survey I
(NHANES I) revealed that among 4,691 older adults included in this study, 39% were current
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drinkers and 10% were at-risk drinkers. 69% of the at-risk drinkers were identified as such
because of their alcohol use in context of comorbidities. Gout, gastrointestinal ulcer, and anxiety
disorder were the top three disease conditions associated with at-risk drinking. Medications for
pain, indigestion, and insomnia were the most common medications responsible for a
classification of at-risk drinking.61
A recent Finnish study found widespread use of alcohol-interactive (AI) medications
among community-dwelling older drinkers.59 It was reported that among at-risk alcohol users
(n=90), 42.2% were on AI medication whereas among moderate users (n=625) and non/minimal
users (427), 34.9% and 52.7% were on AI medication respectively. One in 10 at-risk users used
warfarin, metformin or sedative-hypnotics. Another study conducted in Finland included 523
community-dwelling older adults aged 75 or older. This study found that most alcohol drinkers
(n=231) also used medications on a regular basis (86.9%) or as needed (87.8%). Alcohol use was
common among hypertensive, diabetic and depressive patients.63
Pringle et al examined the prevalence and pattern of concomitant alcohol and AI drug use
in a total of 83,321 older adults enrolled in the Pennsylvania Pharmaceutical Assistance Contract
for the Elderly (PA-PACE) program. A total of 20.3% (n=16,886) reported consuming alcohol.
The study stated “of current drinkers with at least one concomitant AI medication claim, 44.9%
used one AI drug, 28.6% used two, 14.1% used three, 6.9% used four, and 5.5% used five or
more AI drug”. NSAIDs and prescription antihistaminics, and miscellaneous antihypertensives
were the three most frequently used AI drugs in combination with alcohol.57 Forster et al. found
that out of 667 older adults, 25% were at risk of one alcohol-related adverse drug reaction (ADR)
while 15% were at risk for multiple ADRs due to their drug use and alcohol intake. Use of overthe-counter (OTC) pain medication, antihypertensives, prescription diuretics, OTC cold
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preparations, and prescription arthritis medications was observed in combination with alcohol.58
A cross-sectional analysis of residents of three retirement communities estimated that 38% of the
study sample was using both alcohol and high-risk medications.65 High-risk drugs commonly
used by drinkers were antihypertensives (50%), aspirin (27%), non-steroidal anti-inflammatory
drugs (20%), medication for congestive heart failure (18%), antacids or H2 blockers (16%),
sedatives (11%), narcotics (5%), and warfarin (5%).65
3.3.4 Factors Associated with Concurrent Alcohol and Medication Use
Many studies consistently demonstrate that older men compared to older women were
more likely to concurrently use alcohol and AI medications.42,57,58,61 Advanced age (75-84 years,
or 85 years or older) was associated with low alcohol consumption, thus, these groups are less
likely to be at-risk drinkers.42,57 High educational level was positively associated with combined
alcohol and medication use.57,58,61 Moore et al. found that smokers and married individuals were
more likely to be at-risk drinkers.61 Caucasians are at higher odds of being exposed to alcoholmedication interactions.42,57,61 A study by Pringle et al. showed that older adults taking multiple
AI medications were less likely to consume alcohol.57
3.3.5 Alcohol and Psychotropic Medication Use
Two studies assessed the potential combined use of alcohol and psychotropic medications
in older adults based on the premise that the pharmacodynamic interactions between of alcohol
and CNS-acting medications may cause enhanced sedation and impairment of psychomotor
functions. A study conducted using the 1998 German National Health Interview and
Examination Survey determined that out of 1605 participants, 7.6% reported combined use of
alcohol and psychotropic medication.66 Higher prevalence of combined use of alcohol and
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psychotropic medication was seen among participants who were aged between 70 and 79 years,
lived alone, used more than one medication, had a history of cardiovascular disease or had poor
health status. Psychotropic medications most likely to be concurrently consumed with alcohol
were antidepressants, hypnotics/sedatives, and benzodiazepines.66 A cross-sectional populationbased study using the Concord Health and Aging in Men Project (CHAMP) was conducted
including 1705 men aged 70 year or older. Overall, 27% of the antidepressant users were daily
drinkers and 42.7% of sedative/anxiolytic users were daily drinkers. Users of sedative-hypnotic
medication were more likely to engage in daily drinking than non-users of those medications.64
A study including a convenient sample of 155 older women interviewed about their sleep
pattern, alcohol use and over-the-counter medication use. Of the 155 older women, 130
consumed alcohol before bedtime and among those, 77 older women reported consuming
medication before going to sleep.69
3.4 Discussion
This review was performed to understand and summarize the current literature in the area
of alcohol and medication use among older adults. The search yielded twelve studies out of
which two were focused on alcohol and psychotropic medication use, and the rest dealt with
alcohol and alcohol-interactive medication use. A few studies (n=2) were not included because
they did not meet the inclusion criteria, even though these studies focused on alcohol
consumption in older adults having comorbid conditions, or taking psychotropic medications.52,55
The alcohol interactive medications included, but were not limited to, antihypertensives,
psychotropic agents, NSAIDs, antihistaminics, opioid analgesics, antihistaminics, H2-antagonists,
warfarin, antiplatelet agents, and non-prescription medications. Older adults may use alcohol for
medicinal purposes for certain conditions such as cardiovascular disease, sleep disturbance,
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common cold, relaxation, and pain relief.12,63 On the other hand, some medications used in
alleviation of the aforementioned conditions may interact with alcohol to produce undesirable
effects.
All the studies included in this review were cross-sectional in design and collected
information on alcohol consumption using surveys or through interviews. Most of the studies
focused on understanding alcohol and medication use during a reference period/recall time.
However, none of the studies could definitively ascertain the concurrent use of alcohol and
medications. Methodologically, some of the ways to determine use of alcohol and AI
medications concurrently are: i) to determine the emergency department (ED) visits occurring
due to alcohol and medication interaction, ii) to use the Drug Abuse Warning Network (DAWN)
database that collects ED visits associated with substance abuse, iii) to combine administrative
claims data with survey data (for example MCBS, NHANES) to obtain both medication use and
alcohol use information, iv) to use administrative claims data coupled with interview, survey or
diary methods for data collection to ascertain both medication and alcohol use. With technical
advances and upsurge of linked databases, creative ways to collect data to perform such studies
may be discovered.
Due to significant variations in the study design and settings, comparing the results of
studies of alcohol and medication use may be difficult. However, the proportion of older adults
at risk of potential concurrent use of alcohol and medication ranges from 7-50%. Underreporting
of alcohol intake is a potential threat in these studies. Questions about “average number of
drinks”, “overall frequency” or “typical” amount of alcohol consumption over a period of time
can lead to underestimation of alcohol use.70,71 Besides, questions regarding “standard drinks” of
alcohol may not be understood uniformly or accurately among older adults adding to the
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variability in estimation.71,72 Both recent recall and long term drinking patterns should be
investigated to obtain more clear and precise data on alcohol use. Social stigma may also
discourage older adults from revealing the actual amount of alcohol use.
3.5 Conclusion
The review of recent literature suggests that alcohol consumption is prevalent among
older adults with chronic conditions or taking alcohol interactive medications. However, there is
wide variation among the prevalence rates reported by these studies. Older adults taking AI
medications and consuming alcohol could potentially be at risk of encountering adverse events
attributable to the interaction between alcohol and medication, or alcohol and disease. There is a
dearth of studies investigating alcohol consumption in the context of disease profile and
medication use among American older adults. Moreover, understanding the impact of alcohol
and medication use on the health and quality-of-life in older adults is important. There is lack of
studies investigating the impact of concurrent use of alcohol and AI medications on health
outcomes such as falls, accidents, and cognitive impairment.
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Chapter 4
Section 4 At-risk Drinking Among Community-Dwelling Older Adults
4.1 Introduction
Traditionally, alcohol use is studied in the context of quantity and frequency of alcohol
intake or through questionnaires addressing behavioral features related to alcohol consumption.41
These methods may not capture the alcohol-related problems experienced by older adults as
older adults, apart from being more sensitive to alcohol, are also likely to suffer from co-morbid
conditions and take multiple medications that may interact with alcohol.29,41 Considering these
issues, a new paradigm was introduced that defines at-risk drinking as alcohol use that is
excessive or potentially harmful in combination with select comorbidities or medications.41 Atrisk drinking may inflict adverse effects on the health of older adults. For instance, combined use
of non-steroidal anti-inflammatory agents and alcohol are associated with increased risk of
gastric bleeding.73 Combined use of alcohol and CNS-acting medications have the potential to
cause adverse events such as traffic accidents, injuries, falls, and fractures.2 Patients with hepatic
problems/liver disease are advised against consuming alcohol. Screening tools such as the
Alcohol Related Problem Survey (ARPS), shorter version of ARPS and CARET, have been
developed to detect at-risk drinking.62
It is noteworthy that there is a lack of consensus over the definition of at-risk drinking.
Often it is defined only in terms of quantity and frequency of alcohol consumption. The
American Geriatric Society’s clinical guidelines describe at-risk drinking as consuming two or
more drinks per day on average74 while the National Institute on Alcohol Abuse and Alcoholism
(NIAAA) guideline defines it as consuming 4 or more drinks on a given day or 8 or more drinks
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in a week.76 The British Medical Association (BMA) describes at-risk drinking for older adults
as the consumption of >20g of alcohol for women and >30g of alcohol for men.74-76
A study by Barnes et al., reported that of 3,308 current drinkers, 34.7% were at-risk
drinkers, of which 64.3% were at-risk drinkers due to their alcohol behaviors, 61.9% and 61.0%
of the at-risk drinkers were categorized as such due their alcohol use in presence of particular comorbidities and certain classes of medication use, respectively.42 Examination of NHANES
1971-1975 and NHANES Epidemiologic Follow-up Survey 1992 (NHEFS) showed that 10%
(n=425) of the study population consisted of at-risk drinkers. Of the 425 at-risk drinkers, 31%
were identified as at-risk drinkers solely because of their alcohol intake, and 69% were regarded
as at-risk drinkers for their alcohol use in the presence of selected comorbid conditions.61
Analysis of the 2005-2006 National Survey on Drug Use and Health (NSDUH) data found that
13% of older men and 8% of older women reported at-risk alcohol use (defined as two or more
drinks on a usual drinking day within the past 30 days).74 A Finnish study defined at-risk drinkers
as those who consume: i) more than 7 drinks per week, ii) 3 or more drinks several times in a
week, or iii) 5 or more drinks on a typical drinking day.67 This study found that 8.2% of the study
sample (n=1395) were at-risk drinkers. A German study conducted among 3,224 non-demented
subjects aged 75 years and over and attending general practitioners in an urban area of Germany,
found that 6.5% (95% CI: 5.6-7.4) reported at-risk drinking (defined as consuming more than 20
g of alcohol for women and more than 30 g for men).75 Analysis of alcohol consumption among
older adults in primary care showed 4.1% of the 24,863 older adults were at-risk drinkers (8-14
drinks/week).27
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There is a dearth of studies examining at-risk drinking among American older adults,
especially in the context of their comorbidities and medication use. It is also important to identify
the factors associated with at-risk drinking in older adults so that preventive measures can be
channeled judiciously. This study aims to determine the prevalence and the pattern of at-risk
drinking in a nationally representative sample of older Americans and factors associated with atrisk drinking in this population.
4.2 Objective
The objectives of this study were to determine the prevalence and pattern of at-risk drinking and
to identify the factors associated with at-risk drinking among non-institutionalized older adults.
4.3 Methods
4.3.1 Description of the Data Source
The 2009 Medicare Current Beneficiary Survey (MCBS) data was utilized to conduct this
study.77 The MCBS is conducted by the Centers for Medicare and Medicaid Services (CMS)
Office of Research, Development, and Information (ORDI) through its contractor, Westat, Inc, a
survey research firm located in Maryland. It is described as “a continuous, multi-purpose survey
of a representative sample of the Medicare beneficiary population, including both aged and
disabled enrollees”. The MCBS is unique in combining both survey information and Medicare
claims data obtained from the CMS administrative files. It also collects data from communitydwelling as well as institutionalized beneficiaries. The objectives of the MCBS are to estimate
the amount and sources of overall expenditures of all types of healthcare services used by
Medicare beneficiaries including copayment, deductibles, non-covered services, and Medicare
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covered services; and collect data on the overall health status of the beneficiary over a specified
period of time.
The MCBS employs a stratified multistage area probability sampling design with three
stages of selection. In the first stage of sampling, 107 geographic primary sampling units (PSUs),
consisting of groups of counties chosen to represent the nation, are selected. In the second stage,
ZIP code clusters are selected from within the PSUs. In the third stage, the beneficiaries residing
in these ZIP code areas are selected by systematic random sampling within age strata. The
sampling probability varied in the following age groups (0-44, 45-64, 65-69, 70-74, 75-79, 8085, and 85 or over) in order to over represent the disabled and oldest old by a factor of
approximately 1.5.
The MCBS is a longitudinal rotating panel survey wherein “each sample person or an
appropriate proxy respondent, are interviewed three times a year over four years and the
average interview recall period is about 4 months”. A rotating panel is followed for up to 12
interviews. At any given time, there are four panels active and each panel has approximately
3,000 to 5,000 active sample persons depending on when the panel was originally selected. Each
year in the fall round new panels are introduced that replace the oldest panel that subsequently
retires in the following summer. The 2009 MCBS file consists of selected interview data from
the ongoing Medicare Current Beneficiary Survey (MCBS), which were collected during Round
55 (September through December of 2009) or earlier rounds for some variables for individuals in
the continuing sample.
MCBS public use files are released as two modules: the “Access to Care” file and the
“Cost and Use” file. The Access to Care file is designed to provide early release of MCBS data
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related to Medicare beneficiaries’ access to care. The focus of this file is to provide information
on access to care, satisfaction with care, and usual source of care. The Cost and Use file
integrates the survey reported events, expenditure, and other health-related information, collected
from Medicare beneficiaries, to Medicare claims data, thus, providing a comprehensive picture
of healthcare utilization. The Access to Care module is comprised of those beneficiaries that are
part of four separate MCBS panels: round 46, round 49, round 52, and round 55. The Cost and
Use module comprises of those beneficiaries that are part of five separate MCBS panels: round
46, round 49, round 52, round 55, and round 58. Both the Access to Care and Cost and Use
modules were utilized in this study. Participants included in both of the modules were included
in the study, resulting in exclusion of round 58 participants. The unique identifier (BASEID)
variable was used to link beneficiary information across various files.
4.3.2 Eligibility of Study Participants
Medicare beneficiaries aged 65 years or older, non-institutionalized, surviving through
2009, and continuously enrolled in Medicare were included in this study. Beneficiaries present in
both Access to Care and Cost and Use modules were included in the study. Older adults with
complete or partial paralysis, absence or loss of one arm or leg would were excluded from the
study as the risk of falls will differ in these individuals. Hence, the study sample represents
continuously enrolled community-dwelling Medicare beneficiaries aged 65 years or older.
4.3.3 Selection of the Study Sample from 2009 MCBS Data
Figure 4.1 illustrates the process of sample selection. The data files Key Record (RIC K)
and Administrative Identification record (RIC A) consist of both community-dwelling and
institutionalized subjects. Survey Health Status and Functioning Record – Community (RIC 2
42

and 2P) contains community-dwelling older adults participating in the survey. In the Access to
Care module, the administrative file contained 14,695 Medicare beneficiaries of which 13,751
were non-institutionalized. Similarly in the Cost and Use module, the administrative file
contained 10,859 Medicare beneficiaries of which 10,700 were non-institutionalized. The
institutionalized beneficiaries in both the modules and the enrollees of round 58 were excluded.
After merging the non-institutionalized beneficiaries from both the modules, 8,978 in
beneficiaries (mutual to both modules) remained. After excluding beneficiaries younger than 65
years, those who did not survive through 2009, and those who have complete/partial paralysis or
absence of arm or leg, a total of 7,163 community-dwelling, continuously enrolled Medicare
beneficiaries aged 65 years or older were eligible to be included in this study.
4.3.4 Selection of Covariates
Socio-demographic Variables: Demographic factors including age, gender, marital status,
income, educational level, race, perceived health status, limitations to social activity, activities of
daily living, instrumental activities of daily living, number of medications used and number of
selected co-morbid conditions were studied. All of the covariates were collected from the MCBS
survey. Older adults were categorized into three age groups (in years): 65-74, 75-84, and 85 and
above. Race was categorized as white or non-white (includes all other races except white).
Marital status was characterized as: married or non-married (includes never married, divorced,
separated, and widowed). Annual income was grouped into subjects earning $25,000 or less, or
more than $25,000. Employment status records whether the beneficiary is currently working at a
job or business (yes/no). Educational status was classified as beneficiaries with no education,
less than high school education, high school education, more than high school education.
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Access to Care module

Cost and Use module

Administrative file
(RIC A and RIC K)
(n=14,695)

Administrative file
(RIC A and RIC K)
(n=10,859)

Institutionalized
subjects were
removed (n= 944)

Institutionalized
subjects were
removed (n=789)
Survey file for
community-dwelling
respondents (RIC 2P)
(n=13,751)

Survey file for
community-dwelling
respondents (RIC 2)
(n=10,070)
Deleting Round 58
participants (n=379)
Remaining subjects in
survey file
(n=9,691)

Inner join of the data files
Subjects common in both files
(n=8,978)
Age < 65 years=1507
Did not survive= 39
Community-dwelling,
surviving, older adults
(n=7,432)
Removing subjects with
Loss of arm/leg=62
Paralysis=207
Study population
(n=7,163)

Figure 4.1 Flowchart Depicting the Selection of the Study Sample
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Health and Functional Status: The “limitations to social activity” variable inquired if the
beneficiary experienced limitations in their social activities due to health conditions in the past
month (categorized as no limitations /some of the time/and most of the time). The health status
variable was obtained from the survey question asking beneficiaries to rate their current general
health condition compared to health condition in the previous year (categorized as
better/same/worse). Functional status was measured using the Activities of Daily Living (ADL)
scale (including questions addressing difficulty in bathing, dressing, eating, transferring,
toileting, and walking) and Instrumental Activities of Daily Living (IADL) scale [including
questions addressing difficulty in using the telephone, doing light housework (like washing
dishes, straightening up, or light cleaning), heavy housework (like scrubbing floors or washing
windows), preparing meals, shopping for personal items (such as toilet items or medicines), and
managing money (like keeping track of expenses or paying bills)].78,79 Variables capturing
difficulties in performing ADLs and IADLs were categorized into whether or not the subject had
difficulty in performing at least one activity (dichotomous).
To determine chronic comorbidities among the beneficiaries survey data (inquiring about
the presence selected disease conditions in the past year) was used. The number of selected
comorbid conditions included arthritis, rheumatoid arthritis, diabetes, depression, emphysema,
hypertension, osteoporosis, congestive heart disease, myocardial infraction, arrhythmia, cardiac
failure, other heart problem, stroke, urinary incontinence, Alzheimer’s disease, and Parkinson’s
disease. The number of medications, both prescription and non-prescription, consumed by
beneficiaries in the past year were also included in the analysis.
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Regrouping of the covariates: While assessing the factors associated with at-risk drinking the
categories of some variables were collapsed and regrouped. This was done to achieve adequate
size in each cell. Initially, educational status was classified as beneficiaries with: no or less than
high school education, high school education, or more than high school education. Since the
number of older adults with no education was very small, they were merged with older adults
with less than high school education. The variable, limitations in social activities, was
categorized as whether or not beneficiaries experienced limitations in social activities due to
health conditions (yes/no). Older adults whose social activity was limited, either some of the
time or most of the time, were grouped together as “yes”.
4.3.5 Missing Data
Data for most of the variables were collected from the MCBS survey. Some of the survey
questions contained response items such as “don’t know”, “refused to answer”, and “cannot be
ascertained”. As these responses could not be utilized in the study, they were deemed as “not
available” and were not included in the analysis. Since the frequencies of these “not available”
responses were less than 5%, any kind of imputation or sensitivity analyses were not performed.
The footnote below Table 4.3 shows the frequency of “not available” response for each of the
variables.
4.3.6 Determination of Alcohol Consumption
Data on alcohol use was collected from the MCBS survey. Every alternate year
participants of the MCBS are asked three questions addressing their “usual” alcohol use over the
past year. The first question is “Please think about a typical month in the past year. On how
many days did [you/(sample person (SP))] drink any type of alcoholic beverage?”. The second
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question enquires about the quantity of alcoholic drinks consumed, “On those days that
[you/(SP)] drank alcohol, how many drinks did (you/he/she) have?”. The third questions pertain
to heavy episodic drinking “On how many days did [you/(SP)] have 4 or more drinks in a single
day?”
The typical monthly alcohol consumption in the past year was measured using the
Quantity-Frequency (QF) method.80 The first two questions inquiring about i) overall frequency
of alcohol consumption in the past year and ii) the usual number of drinks consumed on days
when the respondent drank were multiplied to estimate monthly alcohol consumption. If the
monthly alcohol consumption was estimated to be 31 drinks per month or less then it was
considered as within-limit drinking assuming respondents considered 31 days in a month. The
monthly alcohol consumption was further categorized into three following groups: i) nondrinkers (respondents who did not consume a single alcoholic beverage in the past year), ii)
within-limit drinkers (respondents who consumed 31 drinks or less per month), and iii)
exceeding-limit drinkers (respondents who consumed more than 31 drinks per month). Binge
drinking or heavy episodic drinking was determined utilizing the third survey question (number
of days respondent consumed 4 or more drinks in a single day). Any respondent consuming 4 or
more drinks, in a single day, at least once in a month was regarded as a binge-drinker.
4.3.7 Estimation of At-Risk drinking
At-risk drinking was determined by two methods: using the CARET questionnaire and
NIAAA definition of at-risk drinking in older adults. According to the NIAAA definition, older
adults consuming 4 or more drinks on a given day, or 8 or more drinks in a week, are considered
at-risk drinkers.76 Primarily, at-risk drinking was identified using the CARET, a 7-item validated
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questionnaire which classifies subjects into two categories: at-risk or non-at-risk drinkers, based
on their alcohol intake, co-morbid conditions as well as medication use.41,60 It includes 1)
comorbid conditions such as high blood pressure, diabetes, depression, gout, hepatitis and other
liver conditions, 2) symptoms of feeling sad, memory problems, falling, problem sleeping, heart
burn/stomach pain/vomiting/nausea, and tripping/bumping into things, and 3) alcohol-interactive
medications including warfarin, antiplatelet medications, nitrates, ulcer medications,
antihypertensive agents, opioid analgesics, anticonvulsants, sedatives-hypnotics, sedating
antihistaminics, arthritis and pain medications, and psychotherapeutic agents (antidepressants,
and anxiolytic). Any older adult satisfying at least one of the conditions (items in the CARET
questionnaire) was deemed to be a at-risk drinker. The total number of items that any subject
satisfies was also calculated.
The presence of hypertension, diabetes, depression, and history of falls, in the past 12
months, was determined from the MCBS survey questions. ICD-9-CM codes81 from the inpatient
and outpatient records were utilized to determine the presence of acute or chronic hepatitis,
cirrhosis or any other liver condition, heart burn/stomach pain/nausea/vomiting, and acute and
chronic gout. Additionally, use of uricosuric medications (allopurinol, probenecid, colchicine,
febuxostat) was indicative of the presence of gout. A problem with memory was determined 1)
from the survey question enquiring about the presence of Alzheimer’s disease or dementia, and
2) use of any of the following medications: memantine, donezepil, rivastigmine, galantamine.
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Table 4.1 Diagnostic Codes for Selected Disease Conditions
Disease Conditions

ICD-9-CM codes

Hepatitis, cirrhosis or any
other liver condition
Heartburn/stomach
pain/nausea/vomiting
Acute or chronic gout

570, 571.0-571.9, 572.0-572.8, and 573.0-573.9
530, 531, 532, 533, 534, 525, 577.0-577.1
274.0-274.9

The information on medication was derived from the medication file that contains both
survey and administrative claims data. Selection of alcohol-interactive medications was achieved
in two steps. First, the classes of medication enlisted in the CARET questionnaire were selected
from the data file. The brand name of the medication was used to do so as that was the
medication identifying variable available in the data file. Second, the nature of potential
interaction between alcohol and that medication was appraised based on available published
literature.21,29,41 The categories of medications were mutually exclusive. Only those drugs that
have been documented to interact with alcohol were included. Medications such as
methylphenidate, modafinil-provigil, glargine, prolix, ridilin, memantine, levodopa-carbidopa,
fenofibric acid were not included.
A few of the items in the CARET questionnaire including “driving after drinking
alcohol” and “bumping or tripping into things” were not collected by the MCBS survey. These
variables were not considered while assessing at-risk drinking in the current study. Although the
survey did not include question on “problem sleeping”, information on assessment of at-risk
drinking using CARET was performed based on pre-specified decision rules that have been
validated Table 5.3. Respondents who met one or more criteria for at-risk drinking were
classified as at-risk drinkers.
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Items

Table 4.2 Description of the CARET Questionnaire
Quantity and frequency of alcohol

Comorbid conditions
High blood pressure
Diabetes
Acute or chronic gout
Depression
Acute or chronic hepatitis, cirrhosis
or other liver conditions

≥3 drinks at least 4 times per week, ≥4 drinks at least 2 times
per month, ≥5 drinks at any frequency
≥2 drinks at least 4 times per week, ≥3 drinks at least 2 times
per month, ≥4 drinks at any frequency
Any number of drinks at any frequency

Health-related behaviors
Memory problems occurring often
Heart burn/stomach ache/
nausea/vomiting occurring often
Falling once or twice

≥3 drinks at least 2 times per week,
≥4 drinks at least 2 times per month,
≥5 drinks at any frequency

Memory problems occurring sometimes
Heart burn/stomach ache/
nausea/vomiting occurring sometimes
Falling more than twice

≥2 drinks at least 2 times per week,
≥5 drinks at any frequency

Medications
(at least 3-4 times a week)
Antihypertensive medications
Blood agents: clopidogrel, aspirin,
ticlopidine, dipyridamole, warfarin
Gastric medication: proton pump
inhibitors, H2 antagonist
Nitrates: ISM, ISD, nitroglycerine
Pain medications used in arthritis
(NSAIDS)
Opioid analgesics, Sedatives-hypnotics
Anticonvulsants, Psychotherapeutics
(antidepressants, anxiolytics,
antipsychotics, except CNS stimulants)
Non-prescription
medication
for
allergies (anti-histaminics, cough and
cold preparations)
Excessive alcohol use

≥3 drinks at least 4 times per week, ≥4 drinks at least 2 times
per month, ≥5 drinks at any frequency

≥2 drinks at least 4 times per week,
≥5 drinks at any frequency

≥3 drinks at least 4 times per week, ≥4 drinks at least 4 times
per month, ≥5 drinks at any frequency

Binge drinking
≥4 drinks on one occasion at least once a week or more
*adapted from the CARET questionnaire.
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4.3.8 Statistical Analyses
Analysis of the complex survey: The complex sampling design was taken into account during
the analysis. Cross-sectional full sample weights have been developed to compensate for nonresponse, under-coverage, and overlapping coverage of constituent panels. Cross-sectional
weights provided for each beneficiary in the dataset reflect the overall selection probability of
each sample person. A total of 100 replicate cross-sectional weights developed using Fay’s
balanced repeated replication (BRR) method, with the Fay coefficient being 0.30, for variance
estimation to account for the complex features of the sampling design. The principle behind the
replication is “to select subsamples (replicates) from full sample, calculate the statistics of
interest for each replicate, and then use these replicate statistics to estimate the variance of full
sample statistic”.77,82,83 Thus, both the full-sample weight and the replicate weights are used to
compute weighted estimates and their variance.77,82,83
Analysis plan for this study: Frequencies and weighted estimates were calculated to describe
the study population representing continuously enrolled non-institutionalized Medicare
beneficiaries aged 65 years or older surviving through 2009. Chi-square tests were performed to
study the bivariate association between at-risk drinking and other covariates. Multi-nominal
logistic regression analysis (using SAS procedure PROC SURVEYLOGISITC) was performed
to identify the factors associated with at-risk drinking.84 The multinomial logistic regression
model was used to predict probabilities of being either an at-risk drinker or a non-at-risk drinker,
compared to non-drinker, given a set of regressor variables (predictors).
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Sensitivity analyses were performed to understand the impact of the methodological
decisions or assumptions made during the execution of this study. Different definitions of
alcohol use were adopted and analyzed to determine the prevalence of at-risk drinking. Weighted
analyses were performed to account for the complex sampling design of the study. All analyses
were conducted in the SAS version 9.2 and 9.3, at the significance level of α= 0.05.
4.4 Results
4.4.1 Characteristics of the Study Sample
Of the 7,163 older adults, 47.5% were aged between 65 and 74 years, 37.0% were
between 75 and 84 years of age, and the remaining 15.5% were 85 years or older. The study
sample was predominantly white (87.2%), not currently employed (87.5%) and educated (with
77% having high school or advanced level of education). Approximately 57% were female,
53.8% were married, and 53.9% earned more than $25,000 per year. The majority of the older
adults (71.8%) did not experience any restriction in their social activity due to health, 18.3%
faced it some of the time, and the remaining 9.9% faced it most of the time. A total of 65.5%
perceived their general health condition to be same as in the preceding year, however, 20.1%
said it worsened and 14.4% said it improved. Although approximately 26% reported having
difficulty in performing at least one of the activities of daily living, 74% reported having no
difficulty in performing any of the ADLs. A total of 33.5% reported having difficulty in
performing at least one of the IADLs but the remaining 66.5% reported having no difficulty in
performing any of the IADLs. Most of the study sample have either no smoking history (41.5%)
or were former-smokers (49.7%) but only 8.8% reported smoking currently. Approximately
6.7% of the older adults reported not having any disease and 5.1% did not take any medication.
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Assessment of comorbidities showed that 34.7% of older adults had 1-2 diseases, 35.4% had 3-4
diseases, and 23.2% had 5 or more diseases. Distribution of medication use reflected
polypharmacy with 35.9% older adults taking 1-5 medications, 35.3% taking 6-10 medications,
and 23.7% taking more than ten medications. Table 4.3 summarizes the demographic
characteristics of the study sample.
Table 4.3 Demographic Characteristics of the Study Population
Variables

Sample persons
interviewed

Weighted percent
(95% CI)

Age (years)
65-74
75-84
85 and older

2919
2890
1354

47.51 (46.56-48.47)
36.95 (35.95-37.94)
15.54 (14.73-16.34)

Gender
Male
Female

3094
4069

43.03 (42.06-44.01)
56.97 (55.99-57.94)

Race
White
Black
Others

6241
586
336

87.23 (86.41-88.06)
8.12 (7.54-8.69)
4.65 (3.99-5.31)

Marital status
Married
Others

3723
3436

53.80 (52.47-55.12)
46.20 (44.88-47.53)

Education
No education
Less than high school
High school
More than high school

77
1707
2189
3164

0.92 (0.70-1.15)
22.16 (21.08-23.25)
30.75 (29.67-31.82)
46.17 (44.75-47.59)

3478
3685

46.06 (44.44-47.68)
53.94 (52.32-55.56)

6381
778

87.52 (86.67-88.37)
12.48 (11.63-13.33)

Income
Less than $25,000
More than $25,000
Employment
No
Yes
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Limitations in social activity
No
Some of the time
Most of the time
Perceived health status
Better
Same
Worse
Difficulties in ADL
No
Yes
Difficulties in IADL
No
Yes
Smoking status
Never-smoker
Former-smoker
Current-smoker
Chronic comorbidities
No disease
1-2
3-4
5 or more

4965
1378
768

71.78 (70.55-73.02)
18.32 (17.30-19.35)
9.89 (9.15-10.64)

1015
4594
1506

14.38 (13.31-15.45)
65.50 (64.40-66.59)
20.12 (19.36-20.89)

5166
1997

74.06 (72.83-75.30)
25.94 (24.70-27.17)

4603
2560

66.53 (65.37-67.69)
33.47 (32.31-34.63)

3003
3543
595

41.53 (40.39-42.67)
49.66 (48.58-50.75)
8.81 (8.09-9.53)

434
2380
2584
1765

6.75 (6.17-7.33)
34.67 (33.35-35.99)
35.42 (34.41-36.42)
23.16 (22.04-24.29)

Number of medications
No medication
346
5.13 (4.52-5.74)
1-5
2482
35.89 (34.58-37.20)
6-10
2557
35.29 (34.18-36.41)
11 or more
1778
23.69 (22.49-24.89)
The following indicates covariates and its corresponding frequencies for
responses deemed as “not applicable (NA)”
Income=4
Marital status=4
Education=26
Social activity=52
Smoking status=22 Perceived health=48

4.4.2 Prevalence and Pattern of At-Risk Drinking
The prevalence of current drinkers who reported drinking at least one drink in the past 12
months was estimated to be 34.9% (95% CI: 33.2-36.7 %, n=2316, missing=73). Binge
drinking, defined as consuming 4 or more drinks in a single day, was reported to be 4.6%
(95% CI: 3.9-5.3 %, n=295). Table 4.4 compares rates of at-risk drinking measured by
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more than one method. According to NIAAA guidelines, 11.5% (95% CI: 10.3-12.6 %)
of the study population were determined to be at-risk drinkers and 23.2% (95% CI: 22.024.4 %) were non-at-risk drinkers. Older adults are advised to consume not more than
one drink per day or seven drinks in a week by NIAAA guidelines.76 As per this
recommendation, 28.4% (95% CI: 27.0-29.8 %) of the older adults consume alcohol
within the NIAAA recommended limits and 6.3% (95% CI: 5.8-7.2 %) drink alcohol
more than the NIAAA recommended limits. Ninety-six older adults provided responses,
for at least one of the first two survey questions enquiring alcohol use, which could not
be utilized in the analysis. Of the 7163 community-dwelling older adults included in this
study, 5.6% (95% CI: 4.8-6.4 %) were assessed to be at-risk drinkers and 29.1% (95%
CI: 27.6-30.5 %) were non-at-risk drinkers based on the CARET questionnaire. Nondrinkers comprised 65.3% (95% CI: 63.6-67.1 %) of the study population.
Table 4.4 Prevalence of At-Risk Drinking
Variables

Pattern of alcohol use
(NIAAA guidelines)
Non-drinker
Within-limit drinker
Exceeding-limit
drinker

Total
N

Weighted Percent
(95% CI)

Men
N

Weighted Percent
(95% CI)

Women
N

Weighted Percent
(95% CI)

4774
1890
403

65.32 (63.56-67.07)
28.39 (27.01-29.78)
6.29 (5.39-7.19 )

1800
957
290

57.21 (54.79-59.63)
32.54 (30.57-34.51)
10.25 (8.53-11.97)

2974
933
113

71.43 (69.54-73.32)
25.27 (23.59-26.95)
3.30 (2.64-3.97)

At-risk drinking
(NIAAA guidelines)
Non-drinker
Non-at-risk drinker
At-risk drinker

4774
1544
749

65.32 (63.56-67.07)
23.23 (22.02-24.44)
11.45 (10.29-12.61)

1800
760
487

57.21 (54.79-59.63)
25.92 (24.18-27.65)
16.87 (14.87-18.88)

2974
784
262

71.43 (69.54-73.32)
21.21 (19.64-22.78)
7.36 (6.36-8.37)

At-risk drinking
(based on CARET)
Non-drinker
Non-at-risk drinker
At-risk drinker

4774
1927
366

65.32 (63.56-67.07)
29.07 (27.63-30.52)
5.61 (4.82-6.40)

1800
977
270

57.21 (54.79-59. 63)
33.27 (31.27-35.28)
9.52 (8.05-10.98)

2974
950
96

71.43 (69.54-73.32)
25.91 (24.15-27.66)
2.67 (2.04-3.29)

* N= No. of sample persons interviewed
Total sample persons =7067, weighted frequency of total sample persons= 19760750, No. of missing = 96
Bivariate analysis (chi-square test) between gender and at-risk drinking was significant p-value <0.05
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Table 4.5 Pattern of At-Risk Drinking (Based on CARET Items)
Reasons for identifying atrisk drinker

At-risk drinkers
Sample Weighted percent
persons 95% CI

Non-at-risk drinker
Sample Weighted percent
persons 95% CI

Regular alcohol use

155

6.86 (5.66-8.07)

2139

93.14 (91.94-94.34)

Heavy episodic drinking

131

5.98 (4.77-7.19)

2163

94.02 (92.82-95.23)

68
26
21
31
-

3.13 (2.21-4.04)
1.24 (0.80-1.68)
1.13 (0.62-1.65)
1.32 (0.85-1.78)

2224
2267
2270
2261
2293

96.87 (95.96-97.79)
98.76 (98.32-99.20)
98.87 (98.35-99.38)
98.68 (98.22-99.15)
100.00

17
18

0.68 (0.37-0.99)
0.73 (0.34-1.12)

2275
2276

99.32 (99.01-99.63)
99.26 (98.88-99.65)
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2.32 (1.64-3.00)

2232

97.68 (96.99-98.36)

29
44
88
91
17
34
32
68
24
25
82

1.36 (0.79-1.93)
2.02 (1.39-2.65)
3.89 (2.95-4.83)
4.14 (3.13-5.15)
0.79 (0.39-1.19)
1.32 (0.82-1.82)
1.40 (0.88-1.92)
3.00 (2.30-3.70)
1.01 (0.65-1.37)
1.13 (0.74-1.52)
3.45 (2.61-4.29)

2264
2249
2205
2203
2276
2259
2261
2225
2269
2268
2211

98.64 (98.07-99.21)
97.98 (97.35-98.61)
96.11 (95.17-97.05)
95.86 (94.85-96.87)
99.21 (98.81-99.61)
98.68 (98.18-99.19)
98.60 (98.09-99.12)
97.00 (96.29-97.70)
98.99 (98.63-99.35)
98.87 (98.48-99.26)
96.55 (95.71-97.39)

Medical conditions
High blood pressure
Gout
Diabetes
Depression
Liver diseases
Health-related behavior
Memory problems
Heartburn/stomach pain/
nausea/vomiting
History of a fall
Medication use
Antiplatelets
Arthritis and pain medicines
Ulcer/stomach medicines
Antihypertensive medicines
Nitrates
Warfarin
Non-prescription medicines
Psychotherapeutics
Anticonvulsants
Sedatives/hypnotics
Opioid analgesics

*Denominator: 2293 older adults (includes drinkers only). The rows add up to 100 and are statistically
different with p-value less than 0.0001 (Rao-Scott Chi-square analyses).

Of the 2,293 drinkers, 7.6% (95% CI:6.3-8.9 %, n=167) were regarded as “at-risk
drinker” owing to their alcohol consumption in the presence of selected disease states. Similarly,
12.2% (95% CI: 10.5-13.8 %, n=276) of the drinkers were considered “at-risk” due to alcohol
and medication use, and 8.9% (95% CI: 7.5-10.3 %, n=198) for their higher than recommended
alcohol intake.
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Of the 2,293 drinkers, 7.4% (95% CI: 6.2-8.6 %) satisfied three or more items in the
CARET questionnaire, 3.7% (95%CI: 2.9-4.5 %) fulfilled two items, and 5.1% (95%CI: 4.06.2%) fulfilled one item in the CARET questionnaire. Use of antihypertensive medications, antiulcer medications, and opioid analgesics, presence of hypertension and history of falls (in the
presence of alcohol use of a specified amount) were some of the common factors rendering older
adults at-risk drinkers (Table 4.5).
4.4.3 Predictors of at-risk drinking
Bivariate analyses were conducted to study the association between each covariate and
at-risk drinking (Table 4.6). The Rao-Scott Chi-square analyses found that age, gender, race,
marital status, education, employment, income, perceived health status, difficulties in ADL,
difficulties in IADL, chronic comorbidities, polypharmacy, and limitations in social activity were
significantly associated with at-risk drinking with p-value <0.0001.

Table 4.6 Distribution of Socio-demographic Characteristics in the Drinking Groups
Variables

Non-drinker

Non-at-risk drinker

At-risk drinker

N

Weighted Percent
(95% CI)

N

Weighted Percent
(95% CI)

N

Weighted Percent
(95% CI)

Age (years)
65-74
75-84
85 and older

1775
1980
1019

59.99 (57.75-62.23)
67.65 (65.47-69.82)
75.94 (73.55-78.34)

889
757
281

32.73 (30.78-34.69)
27.70 (25.84-29.57)
21.22 (19.06-23.38)

203
125
38

7.28 (6.07-8.48)
4.65 (3.76-5.55)
2.84 (1.90-3.78)

Gender
Male
Female

1800
2974

57.21 (54.79-59.63)
71.43 (69.54-73.32)

977
950

33.27 (31.27-35.28)
25.91 (24.15-27.66)

270
96

9.52 (8.05-10.98)
2.67 (2.04-3.29)

Race
White
Others

4039
735

63.19 (61.27-65.11)
80.10 (77.10-83.10)

1783
144

30.72 (29.14-32.31)
17.59 (14.68-20.50)

345
21

6.09 (5.20-6.97)
2.31 (1.16-3.45)

57

2298
2475

60.20 (57.91-62.48)
71.30 (69.49-73.11)

1161
765

33.17 (31.22-35.12)
24.28 (22.74-25.83)

222
144

`
6.63 (5.64-7.63)
4.42 (3.52-5.32)

1475
1553
1724

82.37 (79.87-84.88)
70.25 (67.71-72.80)
53.24 (50.84-55.63)

230
525
1170

14.15 (12.03-16.27)
24.80 (22.87-26.73)
39.60 (37.46-41.74)

56
92
218

3.48 (2.26-4.71)
4.95 (3.53-6.37)
7.16 (6.05-8.28)

2729
2045

78.46 (76.50-80.42)
54.09 (52.05-56.14)

600
1327

18.46 (16.79-20.12)
38.14 (36.31-39.97)

98
268

3.08 (2.32-3.85)
7.77 (6.71-8.83)

4353
420

67.10 (65.31-68.99)
52.82 (48.72-56.92)

1635
291

27.61 (26.10-29.14)
39.35 (35.25-43.46)

314
51

5.29 (4.50-6.08)
7.83 (5.45-10.20)

3074
1692

60.32 (58.36-62.28)
77.94 (76.11-79.76)

1566
360

33.43 (31.75-35.10)
18.06 (16.39-19.72)

286
80

6.25 (5.36-7.15)
4.00 (3.13-4.89)

693
2948
1128

66.99 (62.70-71.27)
62.37 (60.46-64.28)
73.61 (71.17-76.06)

265
1356
306

27.35 (23.70-31.01)
31.63 (29.92-33.33)
22.07 (19.70-24.45)

54
253
59

5.66 (3.96-7.37)
6.00 (5.08-6.93)
4.32 (3.18-5.45)

Difficulties in ADL
No
Yes

3247
1527

61.55(59.46-63.65)
75.96 (73.95-77.97)

1547
380

32.30 (30.49-43.10)
19.95 (18.05-21.86)

292
74

6.15 (5.28-7.02)
4.09 (2.99-5.18)

Difficulties in IADL
No
Yes

2810
1964

59.79 (57.74-61.85)
76.18 (74.26-78.10)

1443
484

33.76 (31.98-35.54)
19.85 (18.21-21.50)

270
96

6.45 (5.44-7.46)
3.97 (3.16-4.77)

Smoking status
Never-smoker
Former-smoker
Current-smoker

2241
2151
381

72.96 (71.02-74.90)
59.14 (56.75-61.52)
64.25 (60.31-68.20)

660
1126
141

24.48 (22.65-26.31)
33.59 (31.62-35.56)
25.12 (21.44-28.79)

65
239
62

2.56 (1.93-3.18)
7.27 (6.12-8.43)
10.63 (7.69-13.57)

Chronic comorbidities
No disease
1-2
3-4
5 or more

240
1394
1773
1367

52.97 (47.52-58.42)
57.69 (55.29-60.09)
67.61 (65.19-70.03)
76.68 (74.42-78.95)

157
792
662
316

39.83 (34.47-45.20)
35.60 (33.31-37.89)
27.05 (25.04-29.07)
19.38 (17.35-21.40)

30
145
125
66

7.20 (4.63-9.76)
6.71 (5.44-7.98)
5.34 (4.38-6.29)
3.94 (2.78-5.10)

Number of medications
No medication
1-5
6-10
11 or more

203
1524
1728
1319

58.73 (52.30-65.15)
60.10 (57.97-62.23)
66.09 (63.50-68.68)
73.44 (71.19-75.70)

116
786
667
358

34.79 (28.31-41.27)
34.17 (32.15-36.19)
28.22 (26.11-30.34)
21.43 (19.36-23.49)

23
128
132
83

6.48 (3.86-9.11)
5.73 (4.48-6.98)
5.69 (4.56-6.81)
5.13 (4.08-6.18)

Marital Status
Married
Others
Education
No or less than high
school
High school
More than high school
Income
$25,000 or less
More than $25,000
Employment
No
Yes
Limitations of social
activity
No
Yes
Perceived health status
Better
Same
Worse
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Table 4.6 shows the distribution of at-risk drinking for each covariate. Compared to other
age groups, 65-74 years age group had higher proportions of at-risk drinkers. Similarly, greater
number of males and whites were at-risk drinkers compared to females and older adults of other
races, respectively. Relatively higher proportions of at-risk drinkers had attained more than high
school education, earned more than $ 25,000 per year, and were employed. Proportions of at-risk
drinkers with no difficulties in performing ADLs or IADLs; with either no disease or having1-2
disease; with health status not limiting to their social activity; and with perceived health status
being same as previous year, were higher than other corresponding covariate category,
suggesting that at-risk drinkers seemed to have better functional status.
Table 4.7 Factors Associated with At-Risk Drinking
Variables
Age
85 and older
75-84
65-74
Gender
Female
Male
Race
White
Others
Marital status
Married
Others
Education
More than high
school
High school
No or less than high
school
Income
More than 25,000
Less than 25,000

Non-at-risk
drinker

p-value

At-risk drinker

p-value

1 (ref)
1.18 (1.01-1.37)
1.24 (1.04-1.48)

0.0356
0.0151

(ref)
1.47 (0.99-2.18)
2.22 (1.50-3.30)

0.0568
<.0001

(ref)
1.15 (1.01-1.30)

0.0356

(ref)
3.16 (2.31-4.34)

<.0001

0.0002

(ref)
0.39 (0.22-0.67)

0.0007

(ref)
1.04 (0.91-1.18)

0.6095

(ref)
1.42 (1.09-1.87)

0.0107

(ref)
0.57 (0.49-0.66)
0.36 (0.29-0.44)

<.0001
<.0001

(ref)
0.69 (0.50-0.97)
0.50 (0.33-0.77)

0.0327
0.0018

<.0001

(ref)
0.41 (0.31-0.53)

<.0001

(ref)
0.65 (0.52-0.82)

(ref)
0.53 (0.45-0.63)
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Employment
No
Yes
Limitations in social
activity
No
Yes
Perceived health
status
Worse
Same
Better
Difficulties in ADL
No
Yes
Difficulties in IADL
No
Yes
Smoking status
Never-smoker
Former-smoker
Current-smoker
Chronic comorbidities
5 or more
3-4
1-2
No disease
Number of
medications
11 or more
6-10
1-5
No medication

(ref)
1.14 (0.92-1.40)

0.2294

(ref)
1.01 (0.69-1.49)

0.9309

<.0001

(ref)
0.75 (0.56-1.00)

0.0476

(ref)
1.07 (0.89-1.28)
0.4770
0.93 (0.72-1.20) 0.5933

(ref)
1.20 (0.84-1.71)
1.08 (0.70-1.67)

0.3144
0.7172

(ref)
0.95 (0.79-1.14)

0.5552

(ref)
0.98 (0.68-1.43)

0.9305

0.1071

(ref)
1.00 (0.71-1.40)

0.9827

<.0001
0.0308

(ref)
2.55 (1.89-3.43)
3.89 (2.56-5.90)

<.0001
<.0001

(ref)
1.20 (1.02-1.42)
1.53 (1.29-1.81)
1.71 (1.27-2.32)

0.0287
<.0001
0.0005

(ref)
1.26 (0.87-1.81)
1.72 (1.18-2.53)
1.85 (1.06-3.25)

1.5018
0.0053
0.0313

(ref)
1.15 (0.97-1.37)
1.19 (1.00-1.42)
1.17 (0.81-1.69)

0.1195
0.0536
0.4169

(ref)
0.94 (0.70-1.27)
0.77 (0.55-1.07)
0.74 (0.41-1.35)

0.6808
0.1155
0.3267

(ref)
0.65 (0.54-0.77)

(ref)
0.88 (0.75-1.03)
(ref)
1.64 (1.44-1.87)
1.29 (1.02-1.63)

A multi-nominal logistic regression model was built to identify factors associated with atrisk drinking and non-at-risk drinking (results in Table 4.7). Older adults belonging to the 65-74
year age group were at higher odds (odds ratio: 2.22, 95%CI: 1.50-3.30) of being at-risk drinkers
than older adult aged 85 years or older. Similarly, older adults aged between 65 to 74 years were
at 24% higher odds (odds ratio: 1.24, 95%CI: 1.04-1.48) of being non-at-risk drinkers than older
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adult aged 85 years or older. Older men were at higher odds of being at-risk drinkers (odds ratio:
3.16, 95%CI: 2.31-4.34) and non-at-risk drinkers (odds ratio: 1.15, 95%CI: 1.01-1.30) compared
to women. Older adults of non-white race were less likely to be at-risk drinkers (odds ratio: 1.42,
95%CI: 1.09-1.87). Compared to married older adults, non-married older adults were at higher
odds (odds ratio: 1.42, 95%CI: 1.09-1.87) of indulging in at-risk drinking. Older adults with a
high school or less than a high school education were at lower odds of being at-risk drinkers and
non-at-risk drinkers than older adults with more than a high school education (includes college
educated or graduate degree). Older adults with annual income less than $25,000 were less likely
to be at-risk drinkers (odds ratio: 0.41, 95%CI: 0.31-0.77). A similar association was observed
between non-at-risk drinking and lower income. Employment status was not significantly
associated with at-risk drinking in this population where many of the participants were no longer
in the workforce.
Perceived health status and functional status as measured by ADLs, and IADLs were not
significantly associated with at-risk drinking. Older adults experiencing limitations in social
activity owing to their health were less likely to be a non-at-risk drinker (OR: 0.65, 95%CI: 0.540.77). The number of chronic comorbidities was found to be significantly associated with at-risk
drinking. Compared to older adults suffering from five or more chronic conditions, older adults
with no or with less than five disease conditions were more likely to indulge in at-risk drinking
as well as non-at-risk drinking. A linear relationship was observed wherein as the number of
comorbidities decreases the magnitude of odds of at-risk drinking increases. Number of
medication taken by older adults was not significantly associated with at-risk drinking. Former
smokers (OR: 2.55, 95% CI: 1.89-3.43) and current smokers (OR: 3.89, 95% CI: 2.56-5.90)
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showed greater odds of being at-risk drinkers compared to those who have never smoked before
(never-smoker).
4.4.4 Sensitivity Analyses
Sensitivity analyses were performed to understand how the results are affected by changing
the methodological decisions or assumptions made during the process of data analysis. Quantity
and frequency of alcohol use is the principal component of at-risk drinking. In addition,
measuring alcohol consumption is subject to high variability. Hence, it is essential to determine
how the prevalence of at-risk drinking changes by altering the alcohol use limits.

A. Sensitivity Analysis on Prevalence of At-risk Drinking: Different definitions of at-risk
drinking were applied and the following are the conditions and the results of those
scenarios:
1) At-risk drinkers were defined as those who experience the diseases and health-related
behaviors and/or take medications mentioned in CARET, and consume alcohol
(including those who drink within-limit and exceeding limit recommended by NIAAA).
In this analysis, older adults consuming 4 or more drinks in a single day were also
regarded as at-risk drinkers. 30.98% (95% CI: 29.38-32.58, n=2061) were found to be atrisk drinkers, 3.70% (95% CI: 3.19-4.21, n=232) were non-at-risk drinkers. The RaoScott Chi-square test showed proportions were significantly different (p-value <0.0001).
2) At-risk drinkers were defined as those who experience the diseases and health-related
behaviors and/or take medications mentioned in CARET, and consume alcohol at an
exceeding limit (by NIAAA definition). 5.36% (95% CI: 4.52-6.20, n=343) were
considered as at-risk drinkers and 29.33% (95% CI: 27.92-30.73, n=1950) were non-at62

risk drinkers. Heavy episodic drinkers were not included in this analysis. The Rao-Scott
Chi-square test showed proportions were significantly different (p-value <0.0001).
3) At-risk drinkers were defined as those who experience the diseases and health-related
behaviors and/or take medications mentioned in CARET and exhibit heavy episodic
drinking only. 3.78% (95%CI: 3.20-4.37, n=242) were at-risk drinkers and 30.95% (95%
CI: 29.38-32.51, n=2053) were non-at-risk drinkers. The Rao-Scott Chi-square test
showed proportions were significantly different (p-value <0.0001).
4) At-risk drinkers were defined as those who show the presence of diseases, medications,
and/or health-related behaviors mentioned in CARET and exhibit heavy episodic
drinking as well as drinking that exceed limit. 6.77% (95% CI: 5.85-7.69, n=436) were
at-risk drinkers and 27.96% (95% CI: 26.6-29.3 %, n=1,859) were non-at-risk drinkers.
The Rao-Scott Chi-square test showed the proportions were significantly different (pvalue <0.0001).
5) At-risk drinkers were defined as those who show the presence of diseases, medications,
and/or health-related behaviors mentioned in CARET and consume alcohol ≥4 drinks/day
or ≥8 drinks/week (NIAAA guideline for at-risk drinking). 9.82% (95% CI: 8.74-10.89
%, n=645) were at-risk drinkers and 24.87 (95% CI: 23.56-26.17 %, n=1648) were nonat-risk drinkers. The Rao-Scott Chi-square test showed the proportions were significantly
different (p-value <0.05).
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B. Alcohol use among excluded subjects
Alcohol use among those excluded for having partial/complete paralysis and/or amputation
leading to loss of arm or leg was studied. A total of 371 subjects were excluded from the final
sample. After removing two subjects from analysis due to missing data on alcohol consumption,
70.2% (95% CI: 64.8-75.6 %) were non-drinkers, 26.3% (95% CI: 21.3-31.3 %) were within
limit drinkers, 3.5% (95% CI: 1.5-5.6 %) were exceeding limit drinkers, and 7.7% (95% CI: 4.710.7 %) were at-risk drinkers (NIAAA definition).
C. Alcohol use among all the subjects in Access to Care module
Alcohol use among all community-dwelling older adults, aged 65 years or older and surviving
through 2009, present in the Access to Care module was studied. A total of 11,393 communitydwelling older adults surviving through 2009, were present in Access to Care module. After
removing 119 subjects from the analysis due to missing data on alcohol consumption, 63.7%
(95% CI: 62.1-65.2 %) were non-drinkers, 29.8% (95% CI: 28.5-31.0 %) were within limit
drinkers, 6.5% (95% CI: 5.9-7.2 %) were exceeding limit drinkers, and 11.9% (95% CI: 11.112.8 %) were at-risk drinkers.
D. Proxy Respondents
Proxies were designated when participants were too ill or could not complete the community
interview for other reasons. Among the 7,163 study subjects, 7.4% were proxy respondents
(n=531). The relationship between the participants and their proxy was collected and assessed.
Of the 531 proxy respondents 46.7% were the spouse, 30.1% were a daughter, and 8.5% were a
son of the participants.
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4.4 Discussion
This population-based cross-sectional study was conducted to understand the prevalence
and pattern of at-risk drinking and factors associated with at-risk drinking among communitydwelling Medicare beneficiaries, aged 65 years or older, surviving through 2009. The prevalence
of at-risk drinking, based on the CARET questionnaire, was estimated to be 5.6% (95% CI: 4.86.4). Age, gender, race, marital status, educational level, income, smoking status, comorbidity,
and limitations to social activity were the factors associated with at-risk drinking in this
population.
In this study, at-risk drinking was assessed by more than one method. Apart from using
the CARET questionnaire, the NIAAA definition of at-risk drinking for older adults was also
utilized to determine at risk drinking.76,41,60 Based on the NIAAA definition, the prevalence of
at-risk drinking was estimated to be 11.5% (95% CI: 10.3-12.6). The substantial difference
between the two rates could be attributed to the criteria for the NIAAA guidelines and the
CARET decisions. The NIAAA guideline defines at-risk drinking in terms of quantity and
frequency of alcohol use i.e. consuming 4 or more drinks on a given day, or 8 or more drinks in a
week. The CARET describes at-risk drinking not only in terms of quantity and frequency of
alcohol use, but also addresses use of alcohol in the presence of alcohol interactive disease and
medication use. Hence, sensitivity analyses were performed to understand how the prevalence of
at-risk drinking varies under different conditions of alcohol consumption. In the sensitivity
analyses, prevalence of at-risk drinking was determined by using different definitions of “risky”
alcohol use while keeping the CARET specified disease conditions, health-related behaviors, and
medications constant. Sensitivity analyses showed that depending upon the different definitions
of alcohol use, at-risk drinking may range from 4% to 31%.
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Two studies have investigated at-risk drinking in U.S. older samples employing the
CARET tool. Analysis of 1971-1974 NHANES I data estimated 10% at-risk drinking (n=425)
among 4,691 U.S. civilian non-institutionalized older adults aged 60-74 years.60 Barnes et al
found 34.7% of the 3,308 currently drinking older adults aged 60 years or more, in Santa
Barbara, California area were at-risk drinkers.42 It must be noted that the above two studies
included adults aged between 60 to 64 years that has not been included in the current study. In
addition, a Finnish study examining at-risk drinking, using the NIAAA guideline definition of atrisk drinking among a randomly selected sample of older adults aged 65 year or older found that
8.2% of the 2,100 older adults were at-risk drinkers.67
In this study, 75.1% (95% CI: 70.0-80.2 %) of the at-risk drinkers were categorized as
such due to their alcohol interactive medication use, 46.8% (95% CI 40.6-53.0 %) due to their
disease profile and health-related behaviors, and 55.2% (95% CI: 50.1-60.4 %) due to their
pattern of alcohol use. Patterns of at-risk drinking in the NHANES I study showed that 69% of
at-risk drinkers were classified as such because of their alcohol consumption combined with
comorbidities.60 The SHARE study found that 64.3% were at-risk drinkers due to alcohol
behavior, 61.9% were deemed at-risk drinkers owing to alcohol use in the presence of select
comorbidities, and 61.0% were classified as at-risk drinkers due to medication use combined
with alcohol consumption.42 Our study found antihypertensive medications, ulcer/stomach
medications and, opioid analgesics, presence of hypertension, and history of falls, to be some
commonly identified items responsible for classification as an at-risk drinker. The NHANES I
study reported presence of gout, ulcer, and anxiety disorder as the three most common
comorbidities associated with at-risk drinking, medication for pain and indigestion, and insomnia
as the three most frequently consumed medications associated with at-risk drinking. 60 The study
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by Ryan et al. assessed the drinking pattern of older adults with chronic medical conditions.
Seven percent of the Medicare beneficiaries with one or more of the seven chronic conditions
(Alzheimer’s disease and other senile dementia, chronic obstructive pulmonary disease,
depression, diabetes, heart failure, hypertension, and stroke) reported at-risk drinking (defined as
those who exceeded monthly limits but not the single-day limit and heavy episodic drinkers who
exceeded the single day limit, with or without exceeding the monthly limit).55 6.9% of the older
adults with hypertension reported drinking in excess of current guidelines. At-risk drinking
prevalence was reported as 3.4% in persons with Alzheimer’s disease, 7.4% in persons with
COPD, and 4.5% in persons with diabetes.55
Many studies have defined unhealthy drinking based on the NIAAA recommendation of
“not more than one drink per day or seven per week” for older adults. Examination of 2003
MCBS data showed that 3.8% of 10,523 older adults (community-dwelling, fee-for-service
Medicare beneficiaries aged 65 years or older) reported consuming more than 30 drinks per
month, and 5.4% reported heavy episodic drinking.28,55,56 This pattern of heavy alcohol
consumption is very similar to that found in our study. Secondary analysis of the 2005 and 2006
National Survey on Drug Use and Health data performed among 4,236 older adults aged ≥65
years established that 13% of men and 8% of women were at-risk drinkers (defined as two or
more drinks on a usual drinking day within the past 30 days).74 A study in the noninstitutionalized Belgian elderly population (n=4,825) found 50.4% were non-or-occasional
drinkers (mean of zero glasses/week), 29.1% were moderate drinkers (1-7 glasses/week), 10.4%
were at-risk drinkers (8-14 glasses/week), 4.6% were heavy drinkers (15-21 glasses/week), and
5.5% problematic drinker (>21 glasses/week).85 A German study conducted on 3,224 nondemented subjects aged 75 years or older and attending general practitioners, identified 6.5%
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(95% CI: 5.6-7.4), of the sample as at-risk drinkers (defined as intake of >30g/day of alcohol for
men and >20g/day of alcohol for women).75
In this study we identified that older adults aged between 65-74 years were more likely to
be at-risk drinkers than those aged 85 years or older. Most studies have reported comparatively
higher intake of alcohol by younger elderly than the older ones, thus, as age increases, alcohol
consumption decreases. 42,66,85 As reflected by most of the studies, older men tend to drink more
than older women.42,66,75,85,106 Similar to the Barnes et al findings, we found that whites consume
more alcohol than individuals of other races.42 Education and income were recognized as
determinants associated with at-risk drinking. Older adults with higher education and higher
income may be inclined to consume alcohol at a level considered harmful. Such association of
at-risk drinking with education and income was also evident in other studies. 42,61,66,106 Contrary
to the findings of other studies42,61,66 , older adults who lived alone (were separated, widowed,
divorced, unmarried) were more likely to be at-risk drinkers when compared to those who were
married or were living with partner. A similar observation was made by Merrick et al (2008)
reporting higher prevalence of unhealthy drinking by divorced or single older adults.
Interestingly, the aforementioned study was conducted using MCBS data.28 In light of the
inconsistent association between marital status and at-risk drinking, a detailed analysis is
warranted.
Having one or more comorbid conditions is inversely associated with at-risk drinking and
even with non-at-risk drinking. This might suggest that healthier older adults tend to consume
more alcohol. ADL, IADL, and perceived health status did not show any significant relationship
with at-risk drinking. Not many studies have investigated ADL, IADL and alcohol consumption.
A few studies that investigated the relationship between at-risk drinking and self-reported health
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status also failed to establish any significant association.61,67,85 Several studies have established
positive association between alcohol intake and at-risk drinking with smoking status. 42,61,67 This
seems to strengthen the supposition that subjects, who are currently using a substance of abuse or
with the history of the same, may be more prone to at-risk drinking, or problematic alcohol use.
Besides, there may be a possibility that the data or this analysis has failed to capture other
important aspect of at-risk drinking.
Comparison of our findings with other epidemiological studies is difficult because the
setting of the study, the study population, definitions of at-risk drinking, and assessment tools
vary from study to study. However, the pattern of alcohol consumption estimated by our study is
comparable with the findings of other studies. This study assessed the relationship of at-risk
drinking with various socio-demographic factors as well as health-related factors (ADL, IADL,
health status, comorbidity, and medication use) providing an understanding of elements
connected with at-risk drinking among older adults. The weighted estimates from the study
represent the national population of older adults in U.S. in the year 2009. The MCBS consists of
survey as well as administrative claims data, thus, enabling the analyses to include large number
of variables in the analysis.
Like all studies, our study also has some limitations. There may be underestimation of the
prevalence of at-risk drinking determined by this study due to various reasons enlisted below:
1. It could be due to inability to obtain data for all the items mentioned in the CARET. Items
including “how many days did you drive a vehicle within 2 hours of drinking 3 or more
drinks”, and “how much of the time you have the following problems: i) feeling sad and blue,
and ii) tripping, bumping into things” were not included in this study due to lack of this
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information in the dataset. The proportion of older adults who drink alcoholic beverage and
drive exhibiting risky behavior were not captured in this study due to absence of that
information in the dataset. A study found that among older drivers involved in fatal crashes,
5% had blood alcohol concentration (BAC) of 0.08 grams per deciliter (g/dL) or higher.86
2. Besides translating and matching the MCBS data with the CARET questionnaire and
decisions may have led to loss of information or misclassification. This could be due to the
difference in the categorization of items in the CARET and the MCBS survey questions
regarding alcohol use. For example, in the CARET questionnaire, subjects were asked to
report frequency of their alcohol consumption by choosing one of the following items: never,
once a month or less, 2-4 times a month, once a week, 2-3 times a week, 4-5 times a week, 67 times a week. While in MCBS subjects are asked to provide the frequency (numerical) of
alcohol use in a typical month. No items are provided in the frequency question (to
categorize their frequency of consumption). So while matching the frequency of alcohol
consumption of a subject to the items in CARET loss of information or misclassification may
have resulted.
3. Health utilization data for HMO-covered incidents were not available in the dataset; hence,
the inpatient and outpatient hospitalization records of a proportion of individuals were not
available. This may misclassify some older adults who could be at-risk drinkers due to their
liver conditions or presence of gout, but due to lack of data were classified as non-at-risk
drinker in this study. Moreover, mostly severe cases of gout or liver conditions require
hospitalization hence the cases that did not result in hospitalization were not considered in
this study.
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4. Some studies assess at-risk drinking among the current-drinkers, and thus the denominator
comprises of current drinkers. But in our study, the denominator comprised of the entire
study population (except subjects with missing information n=96).
5.

Some studies have included adults aged 60 years or older. This study defined older adults as
aged 65 years or older. Hence, older adults aged 60-65 years were not included in the
analysis.

6. On comparing the prevalence of alcohol use reported using the NHANES data and the
MCBS data, it can be seen that the number of older adults identifying themselves as nondrinkers was 47.85% (95% CI: 44.07-51.63) in the NHANES study while it was 65.32%
(95% CI: 63.56-67.07) in the MCBS study. This may suggest that some proportion of underreporting could be attributed to the source collecting the information. It should be noted that
CMS collects MCBS data so some older adults may be hesitant revealing their alcohol intake
to the federal health insurance agency.
7. Proxy responses and inability to accurately recall may lead to underreporting of alcohol use.
8. There is likelihood that alcohol dependent or abuse patients may be under-represented in the
survey itself.
9. There is a possibility that some non-drinkers may include former drinkers who stopped
drinking due to health conditions, side effects of alcohol, or other factors.
Another important limitation is the possibility of intentional under-reporting of alcohol
consumption by older adults driven by social desirability response bias.87,88 Studies have shown
that individuals are reluctant to admit indulging in unpopular behaviors such as alcohol intake, to
avoid creating a negative impression.87,88 A study involving undergraduate students found that
students who were impression managers reported 20 to 33% less alcohol consumption, and were
71

about 50% less likely to report risky drinking.87,88 Social desirability response bias results in
underestimating the rate of heavy drinking, however, this bias does not compromise the study of
predictors of heavy drinking.87,88 And self-reporting of alcohol consumption is regarded as a
reliable and valid approach of estimating alcohol consumption.87
Another factor correlated to possible under-reporting was the quantity-frequency (QF)
approach of measuring alcohol consumption. Questions about “typical” frequency of alcohol
consumption or “on average” number of alcoholic beverage consumed, may lead to
underestimates alcohol consumption.71,89 When subjects are questioned about their average
intake over the past period they tend to report median rather than mean, apparently because they
fail to consider the occasional high drinking episodes.71,89 Studies have shown that the diary
method of data collection yields higher mean quantity of alcohol consumed than QF measure.71,89
Questions about alcohol consumption pertained to “standard drinks” of alcohol that may
be misinterpreted by older adults providing biased information.55,90 The assumption that older
adults can consider the definition of size of standard drink while reporting their alcohol
consumption may not hold leading to misclassification bias. Information on types of alcoholic
beverages consumed (i.e. wine, beer, spirits) was not collected. Different types of alcoholic
beverage have different impact on health. For example two glasses of hard liquor or wine will
have different health implications.90
There was no way to ascertain if the alcohol consumption was concurrent with
medication use in older adults. The CARET question inquires about the medication used by older
adults “at least 3-4 times a week”. Since the dose and frequency of medication use could not be
determined from the MCBS data, it was assumed that all of the medications were consumed at
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least 3-4 times a week. This may lead to an over-estimation of medication use. Nonetheless, most
of the CARET enlisted medications are used for chronic conditions and taken regularly by older
adults, such as antihypertensives, nitrates, antidepressants, anticonvulsants, arthritis and pain
medications, warfarin, aspirin, and anxiolytics/sedatives. There is a possibility of individuals
with dementia or memory problem not being able to provide accurate information. Moreover, a
reference period of 12 months could be too long resulting in recall bias or misclassification bias.
Proxy responses may not provide accurate insights on health related behaviors.91 Association
between at-risk drinking and past use of illicit drugs has been documented in the literature.92
Apart from information on smoking, the MCBS does not capture data on current or past use of
other substances of abuse such as heroin, cocaine, and marijuana. Combined use of alcohol and
illicit drugs is also considered “risky” behavior but it could not be captured in this study.
This study is generalizable to community-dwelling older adults and does not include
institutionalized older adults. The MCBS data only includes older Medicare beneficiaries (older
adults who are eligible for Social Security payments), thus, older adults not enrolled in Medicare
were not included. As the MCBS is a survey including Medicare beneficiaries voluntarily
participating in the survey, the results of this study are not applicable to non-responders.
However, it should be noted that the weighting process takes into account the non-responder’s
bias, attrition rate and post-stratification bias.
This study shows that at-risk drinking is prevalent among older adults and identifies
factors associated with at-risk drinking. Considering the proportion of at-risk drinkers, it is
imperative to understand the effect of at-risk drinking on health-related outcomes, quality of life,
or mortality of older adults. Several studies have assessed the effect of at-risk drinking on healthrelated outcomes such as fall, gastrointestinal bleeding, injuries/accidents, mortality, and
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economic cost of alcohol-related disorders. Previous research had shown that at-risk drinking is
associated with greater mortality rates in older men.60 At-risk drinkers are also more prone to
falling or injuring themselves and missing taking their medications.66 High alcohol consumption
is also associated with falling.1,73,93 Concurrent use of alcohol and NSAIDs or aspirin heightens
the risk of gastric bleeding in older adults.73 Further research needs to be conducted to confirm
the impact of at-risk drinking on health outcomes, quality of life, or mortality in American older
adults.
Harmful effects of at-risk drinking can be averted by implementing preventive measures.
Creating awareness among older adults by providing educational interventions, behavioral or
motivational counseling, educational workshops or programs with healthcare professional, may
help in reducing at-risk drinking. Previous research has shown that such interventions have been
helpful in creating awareness about potential risks associated with alcohol use among older
adults and have played a significant role in altering their alcohol consumption.94,95 A secondary
analysis of data obtained from a randomized controlled trial in older at-risk drinkers established
“older adults reduce their drinking when they recognize that their drinking habits may be causing
them harm”. Older adults have cited environment and circumstances as major factors influencing
their drinking habits.111
Table 4.9 summarizes the studies investigating at-risk drinking measured in different ways.
Some of these studies have determined at-risk drinkers from among the current drinkers. The
SHARE study conducted the study in a population that may report higher alcohol consumption
compared to a nationally representative sample.42.
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Table 4.8 Summary of Studies
Studies

Setting

Sample
size

Subjects

Assessment tool

Prevalence of atrisk drinking

Other findings

Wilson,50
2013
U.S.A

NHANES
2005-2008

1,083

Older adults aged
65 years or older
who consume
alcohol.

ARPS. 47 of the
63 items applied
in this study

Harmful drinkers
= 37.4 % of older
drinkers (95 % CI:
34.9 %, 40.0 %).
Hazardous or
harmful drinkers =
53.3 % (95 % CI:
50.1 %, 56.6 %).

14.5 % of older drinkers
(95 % CI: 12.1 %, 16.8
%) consumed alcohol
above the NIAAA’s
recommended limits.

Barnes,42
2010
U.S.A

Analysis of
survey data
collected from
subjects visiting
primary care
clinics in Santa
Barbara, CA
NHANES I
(1971-1974) and
NHANES
Epidemiologic
Follow-up
study, 1992

3,308

Current drinkers
aged ≥60 years
visiting

CARET
7-item
questionnaire

34.7% of the total
sample were atrisk-drinkers

4,691

Older adults aged
60-74 years at
baseline and who
provided alcohol
use data

CARET
(few selected
items of CARET
were employed)

39% (n=1,658) of
the sample were
drinkers. And
10% (n=425) were
at-risk drinkers.

61.9% deemed at-risk
due to alcohol and
comorbid conditions and
61.0% due to medication
and alcohol use and
64.3% only due to
alcohol use.
69% of the drinkers
were deemed as such
due to their alcohol use
and comorbidities, and
31% solely based on
their alcohol use.

Survey
conducted in
primary care
clinics

549

Older adults aged
65 years or older,
English
proficiency, and
reported drinking at
least 1 drink in the
past year

ARPS
60 item
questionnaire

Harmful
drinkers=11%
Hazardous
drinkers=35%

Moore,61
2006
U.S.A

Fink,43 2002
U.S.A
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Anti-arthritic and pain
medications were most
common followed by
antiulcer medications.
Hypertension was
common comorbidity.

Factors associated
with at-risk
drinking
Male drinkers had
higher odds of
being hazardous or
harmful drinkers.

At-risk drinking
decreased for
female gender;
adults aged over 80
years; Asians; and
individuals with
higher education.
Pain medication
use, gout, ulcer
diseases, anxiety
disorder were most
commonly
implicated
Items.
Harmful drinkers
were more common
in older men, and
older adults aged
<75 years.

Blazer,74
2009,
U.S.A

Data from
National Survey
on Drug Use
and Health
(2005 and 2006)

4,236

Noninstitutionalized
older adults aged
65 years or older

Immonen,67
2011,
Finland

Data gathered
using postal
questionnaire
sent to a random
sample

2,100

Older adults aged
65 years or older
living in the
medium sized city
of Espoo in Finland

Weyerer,75
2009
Germany

A part of multicenter
longitudinal
study

3,224

Non-demented
subjects aged 75
years or older,
attending general
practitioners in an
urban area.

At-risk drinking
defined as use
having two or
more drinks on a
usual drinking
day within the
past 30 days
Structured
questionnaire.
At-risk drinking
defined as i)
more than 7
drinks per week,
ii) five or more
drinks on a
typical day, or
iii) using 3 or
more drinks
several times a
week.
Structured
clinical
interview.
At-risk drinking
defined as >20 g
of alcohol for
women and >30
g for men.
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13% of men and
8% of women
reported at-risk
use

More than 14% of men
and 3% of women
reported binge drinking

Of the 1395
responders, 8.2%
(n=114) were atrisk drinkers

At-risk drinkers were
prone to falling and
forgetting to take
medications.

At-risk drinking
was associated with
male gender, older
adults aged
between 65-70
years, married or
living with partner,
good income, high
level of education,
current smoking,
and better
functional status.

At-risk drinking
was 6.5% (95%
CI: 5.6- 7.4 %).

At-risk drinking was
significantly higher
among men, current
smokers.

At-risk drinking
rate decreased with
age, was lower in
women, higher
among current
smokers, and was
associated with
better mobility and
fewer depressive
symptoms.

4.5 Conclusion
This study determines at-risk drinking, based on the CARET questionnaire, in a
nationally representative sample of older adults. It further identifies the socio-demographic or
health-related risk factors associated with at-risk drinking in this population. This study not only
helps fill gaps in literature, but also builds evidence that can be used to develop and target
preventive programs to mitigate alcohol-related problems. Furthermore it underscores the need
for additional research to understand the impact of at-risk drinking in this population. Adverse
events associated with at-risk drinking are largely preventable. Thus, identifying older adults
who are likely to be at-risk drinkers and providing then with an educational intervention may
help prevent alcohol-related adverse events, and avert expenditure of healthcare resources.
Screening older adults for problematic alcohol use based on the socio-demographic or healthrelated risk factors determined in this study may streamline the screening process saving time
and resources.
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Chapter 5
Section 5. Potential Concurrent Use of Alcohol and Central Nervous System-Acting
Medications
5.1 Introduction
Combined use of CNS-acting medications and alcohol, even in moderate quantities, may
enhance sedation and impairment of psychomotor functions resulting in traffic accidents,
injuries, falls, and fractures. Retrospective review of all zolpidem related cases reported, in the
span of two-years, to the Illinois Poison Center showed that co-ingestion of alcohol and
zolpidem was associated with intensive care unit admissions.96 A German study found the
weighted prevalence of combined use of psychotropic medication and alcohol to be 7.6% among
non-institutionalized older adults.66 Analysis of community-dwelling Australian men aged 70
years or older showed that among 135 men taking antidepressants, 27% were daily drinkers.
Among sedative or anxiolytic users (n=97), approximately 43% were daily drinkers. This study
also found that use of sedative or anxiolytics was associated with daily drinking.64
5.2 Objective
A descriptive, cross-sectional analysis was undertaken to determine the prevalence and
pattern of potential alcohol and CNS-acting medication use among non-institutionalized older
adults, and to understand the predictors of alcohol use among older adults taking CNS-acting
medication.

78

5.3 Methods
5.3.1 Data Source
The National Health and Nutrition Examination Survey (NHANES) is a continuing,
cross-sectional, nationally representative survey of the U.S. non-institutionalized civilian
population that employs a complex, stratified, multistage, probability sampling design. The
results of this study were obtained by combining the three data cycles (2005-2006, 2007-2008,
and 2009-2010). The NHANES data consist of in-person household interviews and standardized
health examinations administered in a mobile examination center (MEC).The details on the
methods used for data collection and coding can be obtained from the NHANES website.97 The
demographic details, information on medication use, and other covariates were obtained during
household interview. The overall response rates for the unweighted interview sample in
NHANES 2005-2006, 2007-2008, 2009-2010 were 80.45%, 78.4%, and 79.4%, respectively.
Information on alcohol use and depression were obtained during the medical examination. The
overall unweighted examination response rates of the sample in NHANES 2005-2006, 20072008, 2009-2010 were 77.36%, 75.4%, and 77.3%, respectively.
5.3.2 Study Population
The study population consisted of non-institutionalized adults, aged 65 years or older at
the time of interview, taking at least one prescription medication and with complete information
on alcohol and medication use. After merging relevant data files and applying eligibility criteria,
the final study sample consisted of 3320 individuals (Figure 4.1).
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5.3.3 CNS-Acting Medication Use
Prescription medication use information was collected during household interviews.
Participants were asked, ‘‘have you taken or used any prescription medicines in the past
month?’’ and if the response was affirmative, they were asked to present the medication
container. To classify medications, NHANES uses Lexicon Plus®, a proprietary, comprehensive
database of Cerner Multum, Inc. that consists of all prescription and some non-prescription drug
products available in the U.S. drug market.98,99 For the purpose of this study, CNS-acting
medication was defined as “those medications which, when consumed concomitantly with
alcohol, could intensify the effects of alcohol resulting in increased sedation, drowsiness, and
impairment of psychomotor function”.2 CNS medications were classified into ten mutually
exclusive

categories;

opioid

analgesics,

anticonvulsants,

anxiolytics,

antidepressants,

antipsychotics, anti-emetics, barbiturates, benzodiazepines, muscle relaxants, and respiratory
agents. NHANES does not capture any information on the disease condition for which the
medication was prescribed for. Some medications are used for more than one indication, for
example, benzodiazepines and barbiturates can be used as either an anticonvulsant agent or an
anxiolytic/sedative agent. Hence, the aforementioned categorization was adopted in this study to
form mutually exclusive medication groups. A total of 157 CNS-acting medications were
included in this study. Combination medications were counted as single medications for the
purpose of calculating total number of medications. For example, acetaminophen with codeine
was counted as one medication. Information on the dosage and frequency of use were not
collected by NHANES. Interviewers could record up to 20 prescription medications.
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Lexi-Interact, Lexicomp®, Wolters Kluwer Health (Philadelphia) and Micromedex®,
Thomson Reuters Healthcare Inc. were used to ascertain the level of interaction between alcohol
and CNS-acting medication.98,99 Based on Micromedex® any CNS-acting medication suspected
of moderate, major or contraindicated types of interactions with alcohol were included in this
study.99 Similarly, based on Lexi-Interact®, C (the use of drugs require monitoring), D (the use
of drugs require change in therapy) and X (combined use those drugs should be avoided) types of
interactions between any CNS-acting medications and alcohol were included in the study.98
5.3.4 Alcohol Use
Alcohol use was recorded by administering an alcohol use questionnaire, using the
Computer Assisted Personal Interview (CAPI) system, to participants during mobile examination
center interview. The alcohol use questionnaire enquired about lifetime and current alcohol
consumption of the participants. Questions were not specific to type of alcohol and one drink
was defined as 12 oz. of beer, 5 oz. of wine, or one and half ounces of liquor.
By using the Quantity*Frequency method, the average daily alcohol consumption was
calculated.70,80 To calculate frequency, the number of days respondent’s had alcohol (whether
recorded as weekly, monthly or yearly) was converted into drinking days per week. Average
number of drinks consumed (quantity) was multiplied with “drinking days per week” to obtain
average weekly consumption which was further divided by 7 to obtain average daily alcohol
consumption.80 Based on the average daily alcohol consumption, subjects were classified into
different drinking categories. The drinking categories were determined depending upon the level
of alcohol consumption and drinking guidelines.
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According to the NIAAA recommendations, older adults should consume no more than
one standard drink per day or seven drinks on average per week.76 Considering the questions in
the alcohol questionnaire and the drinking guidelines for older adults, drinking pattern was
described in the following categories:


Non-drinkers: This category included respondents who, (1) never had at least 12 drinks of
any type of alcoholic beverage in their entire life (never drinker), or (2) reported consuming
zero drinks in the past 12 months (former drinkers).



Light-infrequent drinkers: subjects who consumed alcohol but not on a daily basis i.e. the
average daily alcohol consumption might be zero but they have reported using alcohol in
past 12 months.



Moderate drinkers: subjects who consumed one drink per day or seven drinks per week



Heavy drinkers: subjects who consumed more than one drink per day or 7 drinks per week

5.3.5 Concurrent Users
Concurrent users were defined as subjects who consumed alcohol on a daily basis
(including moderate and heavy drinkers) and reported using at least one CNS-acting medication
from in the past month. Individuals were categorized into concurrent users or non-concurrent
user.
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5.3.6 Covariates
Demographic factors including age, sex, marital status, educational level, and
race/ethnicity were studied. As NHANES truncates the age at 80 years, older adults were
categorized into four age groups: 65-69, 70-74, 75-79, and 80 and above. Older adults who were
either married or were living with a partner were grouped under one category while those who
were divorced, widowed, separated or unmarried were grouped together. Educational level was
categorized into three groups: less than high school, high school graduate and more than high
school which included college graduates or any higher degree. Non-hispanic white, non-hispanic
black and others were the three categories for race/ethnicity. Other factors included smoking
status (never smoker, former smoker, or current smoker), perceived health status
(excellent/good/fair/poor), health insurance (yes/no), and insurance with prescription medication
coverage (yes/no/ don’t know or refused). NHANES employs the Patient Health Questionnaire
(PHQ-9), a nine-item validated screening instrument that enquires about the frequency of
symptoms of depression over the past 2 weeks, to screen for depression.100 A total score can
range from 0 to 27 and a score of 10 or higher is used to identify individuals with depression
(yes/no).100
5.3.7 Statistical Analyses
Weighted prevalence estimates of alcohol use, CNS-acting medication use and the
concurrent use of both, for the combined study period (2005-2010), were reported. The pattern of
use of alcohol and CNS-acting medication, in terms of number of sample respondents, weighted
percent and 95% confidence interval (CI) were also reported. The Cochran-Armitage trend test
of unweighted sample and logistic regression of the weighted sample were done to assess the
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change in daily alcohol use, CNS-medication use and concurrent use across the three data cycles.
Chi-square analysis was carried out to assess the association between daily alcohol use and the
covariates. Logistic regression was performed to identify the factors associated with the use of
alcohol among CNS-acting medication users. The weight variables were recalculated since the
three NHANES data cycles 2005-2006, 2007-2008, and 2009-2010 were combined. NHANES
recommends use of the weight of the smallest sample subpopulation, so for all estimations
involving alcohol variable, MEC6YR= 1/3*WTMEC2YR (2-year sample weights during
examination at MEC) was used as weight variable while for medication related estimations
INT6YR = 1/3 * (2-year sample weights during interview) was used as weight variable.97 SAS
version 9.2 (SAS Institute, Cary, NC) was used to conduct the statistical analyses.101
Ethical consideration: This study was reviewed and determined to quality as exempt from
federal regulations by Virginia Commonwealth University Institutional Review Board.
5.4 Results
5.4.1 Sample Description
A total of 31,034 persons were interviewed during 2005-2010, out of which 4,268 were
older adults. Since the goal of the study was to understand the magnitude of potential alcoholdrug interactions, non-medication users were not included in this study. A total of 3,753
(89.52%, 95%CI: 88.45-90.59) older adults took at least one prescription medication in the past
month, of which 3,577 attended the NHANES medical examination. After removing the subjects
with missing information on alcohol use, 3,220 subjects were included as the final study
population (Figure 5.1). The socio-demographic characteristics of the study population are

84

described in Table 5.1. Among the 338 sample persons having no information on alcohol use,
6.87% (95%CI: 3.11-10.64, n=20) reported taking CNS-acting medications.

Sample persons interviewed
(n=31,034)
Older adults completing household interview
(n=4,268)

Older adults taking at least one prescription
medication
(n=3,753)

Older adults completing interview at Mobile
Examination Center
(n=3,577)
Missing= 338
Don’t know=19
Older adults with complete information on
alcohol and CNS-acting medication use
(n=3,220)

Figure 5.1 Flowchart Depicting Selection of the Final Study
Population
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Table 5.1 Socio-demographic Characteristics of the Study Population
Characteristics
Age
65-69
70-74
75-79
80 and above
Sex
Male
Female
Race/ethnicity
White
Black
Others
Marital status
Married/living with partner
Divorced/separated/widowed/unmarried
Educational level&
Less than High school
High school
More than High School
Smoking status@
Never smoker
Former smoker
Current smoker
Number of medications
1-5
6-10
Greater than 10
Perceived health status*
Excellent
Very good/good
Fair
Poor
Depression#
No
Yes
Alcohol Use
Non-drinker
Light-infrequent drinker
Moderate drinker
Heavy drinker
Health insurance^
Yes
No
Prescription medication coverage®
Yes
No

Number of persons
interviewed

Weighted Percent (95% CI)α

836
844
642
898

30.91 (28.67 – 33.16)
25.44 (23.63 – 27.26)
19.65 (17.87 – 21.43)
24.00 (21.92 – 26.07)

1606
1614

44.39 (42.76 – 46.02)
55.61 (53.98 – 57.24)

2101
536
583

84.27 (81.22 – 87.33)
7.88 (6.09 – 9.67)
7.85 (5.64 – 10.06)

1822
1398

61.01 (58.43 – 63.59)
38.99 (36.41 – 41.57)

1127
1261
826

25.70 (22.74 – 28.78)
45.97 (41.90 – 50.03)
28.33 (25.90 – 30.76)

1501
1437
280

`
47.30 (45.09 – 49.51)
44.98 (42.70 – 47.27)
7.72 (6.81 – 8.63)

2097
926
197

65.55 (63.60 – 67.52)
28.04 (26.13 – 29.94)
6.41 (5.27 – 7.54)

212
2046
782
179

7.60 (6.41 – 8.80)
69.03 (67.07 – 70.98)
19.15 (17.73 – 20.58)
4.22 (3.43 – 5.00)

2989
164

95.44 (94.50 – 96.38)
4.56 (3.63 – 5.51)

1702
611
739
168

47.85 (44.07 – 51.63)
20.36 (18.13 – 22.59)
26.23 (23.65 – 28.81)
5.56 (4.20 – 6.92)

3157
62

99.02 (98.65 – 99.40)
0.98 (0.60 – 1.36)

2708
447

86.47 (83.96 – 88.97)
13.53 (11.03 – 16.04)

α Total sample person= 3220 and weighted frequency= 30236526
& Don’t know=6
@ Don’t know=1, refused=1
* Don’t know=1
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# Missing=67
^ Refused=1
® Missing=42,refused=4, don’t know=19

5.4.2 Alcohol Use
Using the Quantity-Frequency method, it was found that 20.36% (95% CI: 18.13-22.59)
were light-infrequent drinkers, 26.23% (95% CI: 23.65-23.81) were moderate drinkers, 5.56%
(95% CI: 4.20-6.92) were heavy drinkers and the remaining 47.85% (95% CI: 44.07-51.63) were
non-drinkers. On the days they drink, 33.55% (95% CI: 30.55–36.55, n=937) reported drinking
one drink, 12.44% (95% CI: 11.02–13.85, n=363) reported drinking two drinks while 6.16%
(95% CI: 5.11-7.21, n=218) reported drinking three or more drinks. 23.37% (95% CI: 19.92–
26.81, n=349) of the drinkers reported drinking more than 4 days per week. 5.76% (95% CI:
4.83-6.70, n=192) of older adults reported binge-drinking (5 or more drinks on a single occasion
at least once in the past 12 months). No significant difference in trend was observed in the

Weighted Percent

pattern of daily alcohol use between the three data cycles (Figure 5.2).

40.0
37.5
35.0
32.5
30.0
27.5
25.0
22.5
20.0
17.5
15.0
12.5
10.0
7.5
5.0
2.5
0.0

35.4%
32.5%
32.0%

35.2%

34.0%

34.7%
32.9%

Drinker
CNS

30.9%

29.2%

Concurrent users
Total sample

8.3%

8.3%

05-06

07-08
Years

10.1%

09-10

Figure 5.2 Prevalence of Alcohol, CNS-Acting Medication Use, and
Concurrent Use Across the Three Data Cycles
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5.4.3 CNS-Acting Medication Use
Approximately 33.5% (95% CI: 31.34-35.71, n=1,035) of older adults reported using at
least one CNS-acting medication with a total of 1,534 CNS-acting medications being prescribed
in the past month. Antidepressants were the most commonly used class of medication followed
by opioid analgesics, benzodiazepines, and anticonvulsants (Table 5.2). Among CNS-acting
medication users, 67.34% took one CNS-acting medication, 21.35% took two CNS-acting
medications while the rest used more than two CNS-acting medications, in the past month.
Gabapentin, combination of acetaminophen and hydrocodone, sertraline, alprazolam,
fexofenadine, tramadol, zolpidem, citalopram, escitalopram, and fluoxetine were the ten most
frequently used CNS-acting medications by the study population. CNS-acting medication use did
not differ significantly over the three data cycles (Figure 5.2).
Table 5.2 Use of CNS-Acting Medications by Therapeutic Class
CNS-medication
class

Prescription
frequency*

Sample
persons^

Weighted
percentage#

95% CI

Antidepressants
Opioid analgesics
Benzodiazepines
Anticonvulsant
Respiratory agents
Anxiolytics
Anti-emetic
Muscle relaxants
Antipsychotics

422 (27.51%)
327 (21.32%)
201 (13.10%)
173 (11.28%)
137 (8.93%)
79 (5.15%)
73 (4.76%)
69 (4.50%)
39 (2.54%)

399
297
198
168
136
77
73
68
38

40.37
26.87
18.16
14.77
12.99
7.06
6.63
6.93
3.62

37.50 – 43.25
24.04 – 29.70
15.65 – 20.68
12.71 – 16.84
10.69 – 15.29
5.25 – 8.86
5.12 – 8.13
5.05 – 8.81
2.23 – 5.01

*The total number of CNS-medications used by older adults=1534.
^Out of 3220, the total number of participants taking CNS-medication=1035
# Weighted frequency of users of the drug class/Weighted frequency of the 1035 CNS-medication users
i.e. 9665992.48*100
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5.4.4 Potential Concurrent Use of Alcohol and CNS-Acting Medication
The prevalence of older adults taking at least one CNS-acting medication and drinking
daily was found to be 8.85% (95%CI: 7.22-10.49, n=244). Approximately 81% of these 244
older adults were moderate drinkers, and the 19% rest were heavy drinkers. The proportion of
potential concurrent use of alcohol and CNS-acting medication did not differ significantly over
the three data cycles. 19.74% (95% CI: 15.87–23.70, n=183) took one CNS-acting medication,
4.26% (95% CI: 2.58 – 5.94, n=39) took two CNS-acting medications, and 2.41% (95%CI: 0.89
– 3.93, n=22) took three CNS-acting medications while reporting daily alcohol consumption.
Antidepressants, opioid analgesics and benzodiazepines have a greater possibility of being
concomitantly consumed with alcohol as they were most commonly used by daily drinkers.
Some of the CNS-acting medications most commonly used by drinkers were fexofenadine,
combination of acetaminophen and hydrocodone, escitalopram, sertraline, gabapentin,
alprazolam, and zolpidem. CNS-acting medication users were less likely to drink alcohol on a
regular basis than non-users (OR=0.68, 95% CI: 0.54 – 0.86).
The relationship between daily alcohol use and other covariates among CNS-acting
medication users is described in Tables 5.3 and 5.4. Due to the small cell size, “non-Hispanic
blacks” were combined with “other” race, and health status was grouped as “poor/fair” versus
“excellent/good/very good”. A chi-square test of association demonstrated that sex,
race/ethnicity, marital status, educational level, smoking status, and perceived health status were
significantly associated with daily alcohol use (Table 5.3), while age and prescription medication
insurance coverage were not. The association between health insurance and depression and daily
alcohol use could not be computed due to low cell sample size.
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Table 5.3 Demographic Factors among CNS-Acting Medication Users by Daily Alcohol Use
Characteristics

Daily alcohol users
Sample Weighted percent
persons (95%CI)

Non-daily alcohol users
Sample Weighted percent
persons (95%CI)

Age
65-69
70-74
75-79
80 and above

65
73
45
61

27.92 (21.35-34.50)
31.35 (24.30-38.40)
24.82 (16.97-32.67)
20.97 (16.33-25.62)

222
183
154
232

72.08 (65.50-78.65)
68.65 (61.60-75.70)
75.18 (67.33-83.03)
79.03 (74.38-83.67)

Sex
Male
Female

138
106

34.75 (28.40-41.09)
21.69 (16.63-26.75)

311
480

65.25 (58.91-71.60)
78.31 (73.26-83.37)

Race/ethnicity
White
Others

196
48

28.35 (23.00-33.70)
14.74 (10.12-19.36)

506
285

71.65 (66.30-76.99)
85.26 (80.64-89.88)

Marital status
Married/living with partner
Divorced/separated/widowed/unmarried

152
92

30.35 (25.11-35.60)
21.37 (15.55-27.19)

397
394

69.65 (64.40-74.89)
78.63 (72.81-84.45)

Educational level&
Less than High school
High school
More than High School

51
64
129

12.32 (7.99-16.66)
26.44 (20.35-32.53)
36.29 (29.47-43.11)

348
195
248

87.68 (83.34-92.01)
73.56 (67.47-79.65)
63.71 (56.89-70.53)

Smoking status*
Never smoker
Former smoker
Current smoker

79
141
24

20.33 (15.01-25.65)
33.85 (27.84-39.87)
21.26 (12.73-29.78)

387
313
90

79.67 (74.35-84.99)
66.15 (60.13-72.16)
78.74 (70.22-87.27)

Number of medications
1-5
6-10
Greater than 10

95
113
36

25.53 (19.35-31.71)
27.74 (22.90-32.59)
24.68 (15.28-34.08)

314
357
120

74.47 (68.29-80.65)
72.26 (67.41-77.10)
75.32 (65.92-84.72)

Comorbid conditions
No comorbid conditions
1-2
3 or more

45
142
57

39.09 (27.41-50.77)
25.86 (21.32-30.39)
20.76 (15.59-25.93)

99
484
208

60.91 (49.23-72.58)
74.14 (69.61-78.68)
79.24 (74.07-84.40)

Perceived health status
Good/very good/excellent
Poor/fair

183
61

31.93 (25.81-38.05)
15.15 (11.07-19.23)

441
350

68.07 (61.96-74.19)
84.85 (80.77-88.93)

Depression#
No
Yes

226
14

27.85 (23.09-32.61)
13.84 (8.75-18.94)

684
77

72.15 (67.39-76.91)
86.16 (81.06-91.25)

224
0

26.61 (21.98-31.23)

776
15

73.39 (68.77 -78.02)

215
27

27.27 (22.23-32.32)
19.88 (12.01-27.75)

674
100

72.73 (67.68-77.77)
80.12 (72.25-87.99)

Health insurance
Yes
No
Prescription medication coverage®
Yes
No
#

Depression: missing=34, ®Prescription medication coverage: missing 19, *Smoking: missing=1
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The logistic regression model was built to identify factors associated with daily alcohol
consumption. Males had 49% (OR= 1.49, 95% CI: 1.02–2.60) higher odds of consuming alcohol
daily when compared to females. Former smokers were more likely (OR=1.79, 95% CI: 1.21–
2.63) to consume alcohol daily compared to never smokers. Older adults who did not complete
high school are less likely to drink daily (OR=0.33, 95%CI: 0.21-0.54) compared to college
graduates. Older adults with comorbidities were less likely to be daily drinkers compared those
with no chronic condition. Good health status and being white were predictors of daily alcohol
use.
5.5 Discussion
This cross-sectional study found the prevalence of potential concurrent use of alcohol and
CNS-acting medications among non-institutionalized older adults to be 8.8%. Though the
majority of concurrent users were moderate drinkers, alcohol consumption juxtaposed with
prescription medication use may render them susceptible to adverse effects of interactions
between alcohol and CNS-acting medication. The comparison of alcohol use between studies is
difficult owing to the differences in measures of alcohol consumption, definition of drinking
categories, and settings of the studies. Nonetheless, the pattern of alcohol use reported in this
study is consistent with other published studies adhering to the NIAAA alcohol consumption
guidelines for older adults.27,56,57
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Table 5.4 Factors Associated with Daily Alcohol Use
Factors
Age
80 and above
75-79
70-74
65-69
Sex
Female
Male
Race
White
Others
Marital
Married or living with partner
Divorced/separated/widowed/unmarried
Perceived health status
Good/very good/excellent
Poor/fair
Education
More than high school/college
High school
Less than high school
Smoking Status
Never smoker
Former smoker
Current smoker
No. of medications
1-5
6-10
Greater than 10
Chronic comorbid conditions
No chronic conditions
1-2
3 or more

Unadjusted odds
Ratio

Adjusted odds
Ratio

Reference
1.24 (0.76-2.05)
1.72 (1.20-2.47)*
1.46 (1.01-2.11)*

Reference
1.08 (0.68-1.73)
1.43 (0.93-2.19)
0.98 (0.57-1.69)

Reference
1.92 (1.39-2.67)*

Reference
1.49 (1.02-2.6)*

Reference
0.44 (0.27-0.70)*

Reference
0.68 (0.39-1.16)

Reference
0.62 (0.43-0.90)*

Reference
0.76 (0.51-1.14)

Reference
0.38 (0.25-0.57)*

Reference
0.51 (0.31-0.83)*

Reference
0.63 (0.41-0.96)*
0.25 (0.16-0.38)*

Reference
0.67 (0.44-1.03)
0.33 (0.21-0.54)*

Reference
2.01 (1.42-2.83)*
1.06 (0.63-1.76)

Reference
1.79 (1.21-2.63)*
1.19 (0.68-2.09)

Reference
1.12 (0.81-1.55)
0.96 (0.61-1.50)

Reference
0.99 (0.72-1.40)
0.80 (0.51-1.24)

Reference
0.54 (0.34-0.88)
0.41 (0.24-0.69)

Reference
0.54 (0.31-0.95)*
0.44 (0.24-0.78)*

#Number of observations used in the multivariable logistic regression model is 1034
* p-value <0.05

92

Our findings suggest that antidepressants, opioid analgesics, and benzodiazepines are not
only widely used but are also consumed by daily drinkers. The pattern of use of CNS-acting
medications observed in this study is similar to other published studies.66,102,103 Consistent with
the findings of previous studies, selective serotonin reuptake inhibitors (SSRIs), namely
sertraline, escitalopram, citalopram, and fluoxetine, were the most frequently prescribed class of
antidepressant in our study.66,102-104 Detection of high use of acetaminophen and hydrocodone
combination medication was similar to previous findings.66 Importantly, both of these
medication components interact with alcohol, albeit through separate mechanisms of action,
increasing the risk of liver toxicity and injuries.29 As sedatives/hypnotics/anxiolytics grouped as
one category did not include benzodiazepines in this study, the proportion of users was lower
compared to other studies.66,102,103 It should be noted that certain CNS-acting medications
included in this study such as naltrexone, topiramate, and SSRIs, are also used in the treatment of
alcohol dependence. Such medication use would be considered intentional and, possibly, more
controlled; however, due to the absence of information on diagnosis, the proportion of older
adults undergoing alcohol dependence treatment could not be ascertained.105
Trend analysis revealed no significant change in the use of CNS-acting medications,
daily alcohol use, and potential concurrent use of alcohol and CNS-acting medications across the
data cycles. Using data collected over a greater number of years may be required to understand
the trend of use of these variables within the older adult population. Some researchers have
reported higher alcohol consumption in the recent cohort of older adults compared to their
predecessors.106 The absence of significant change in the prevalence of concurrent use of alcohol
and CNS-acting medications indicates that the magnitude of the problem is consistent and
warrants further investigation. Several studies have documented an increase in the use of CNS93

acting medications in the U.S. adult population over a span of 6-10 years.106,107 A cross-sectional
study conducted in Spain showed an increase in the use of prescription anxiolytics and
antidepressants among older adults.108 Considering these findings, longitudinal trend analysis of
CNS-acting medication utilization and alcohol consumption in older adults is necessary.
Some factors associated with daily alcohol use in older adults taking CNS-acting
medications identified in this study are comparable to those stated in other studies.57,66,109
Previous studies found that females are more likely to use psychotropic medications while males
report drinking more often than females.110 Even among CNS-acting medication users, males are
more likely to drink daily than females (as shown in Table 4.4). As demonstrated in the
literature, other races consume less alcohol than whites. Level of education is a factor associated
with daily alcohol use. While some studies have shown that older adults with less than a high
school education were more likely to be moderate or heavy drinkers41,109 others have
demonstrated the reverse.56,66 Unlike previous findings, living alone was not found to be a risk
factor of daily alcohol use in our study population.66 Education is an indicator of socio-economic
status, as is income and employment status. Our findings suggest that former smokers showed
higher risk of consuming alcohol on a daily basis. The association between current smoking and
daily alcohol use could be biased due to a small sample size. Current or previous history of
health risks such as smoking, major depression, and substance abuse has been associated with
alcohol use.27,66,106,111 In our study, however, the relationship between depression and daily
alcohol use could not be assessed due to small sample size. Older adults who perceive their
health status as either poor or fair are less likely to drink daily.66 Conversely, Kirchner el al.
found alcohol use to be positively associated with perceived poor health among older adults in
the primary care setting27. The absence of significant change in potential concurrent use of
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alcohol and CNS-acting medications indicates that daily alcohol use is not associated with
medication use unlike the inverse associated observed between daily alcohol use and co-morbid
conditions. It was observed that as co-morbid conditions increased the likelihood of being daily
drinker decreased but this relationship was not observed between daily alcohol use and
medication use which raises concern.
This study has several limitations. It could not be definitively ascertained whether alcohol
was consumed concomitantly with CNS-acting medications. NHANES data does not permit
studying the type and size of alcoholic drink consumed by respondents or the dose and frequency
of CNS-acting medication used. This study did not include employment status and income of
older adults. These two factors would have provided insight on the relationship between socioeconomic status and alcohol use. Previous research has shown that questions regarding typical
quantity and frequency of alcohol consumed can lead to underestimation of actual
consumption.71 Deliberate under-reporting of alcohol use and CNS-acting medication use has
also been documented in this population.22 Although questions on alcohol use focused on
average frequency and amount of alcohol consumed by respondents certain events such as loss of
spouse, retirement, and dependence, may influence the drinking pattern of older adults.22 It could
not be determined if non-drinkers in this study stopped drinking alcohol due to any health-related
issues in the past. The possibility of error in reporting or recall bias due to potential cognitive
impairment or memory loss experienced by the older adult respondent is also present. In
addition, small sample sizes in certain subgroups could have influenced the precision of our
estimates.
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Several review articles have emphasized the need to understand alcohol and psychotropic
medication use among older adults.92,110 This study makes a unique contribution to the literature
by determining the pattern, prevalence and associated factors of alcohol and CNS-acting
medication use among community-dwelling older adults. Some strengths of the study are that, 1)
it utilizes a recent, nationally representative sample of non-institutionalized older adults, 2)
NHANES data collection follows a specified protocol and quality assurance process, 3) potential
concurrent use of alcohol and CNS-acting medications is estimated in a conservative manner (by
including only moderate and heavy drinkers), and 4) employing an broader definition of “CNSacting medication” for the purpose of the study.
There are few studies assessing the adverse outcomes resulting from alcohol-medication
interactions. Understanding the consequences of the combined use of alcohol and CNS-acting
medication and determining its impact on healthcare utilization is essential. Duru et al. reported
that the probability of an alcohol-related discussion between older adults and their physician
declined with the patient’s age, and factors such as having comorbidities and using medications
were not associated with alcohol-related discussions.112 The findings of our study underscore the
need to address issues related to alcohol use among older adults. Alcohol and prescription drug
misuse among older adults is regarded as a “hidden” epidemic facing the country which needs to
be further explored.92,110
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5.6 Conclusion
In summary, a considerable proportion of older adults are susceptible to consume alcohol
and CNS-acting medications, concurrently, and are therefore at risk of experiencing enhanced
sedation and impaired psychomotor functions, leading to adverse events such as falls, fractures
and accidents. Early identification of older adults at risk for alcohol-CNS-acting medication
interactions may prevent adverse events. Initiation of prescription monitoring programs and
screening for harmful alcohol use may be useful to overcome some of the alcohol use-related
problems in the older population. Discussions or counseling about safe alcohol use are necessary
between healthcare professionals and older adults.
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Chapter 6
Section 6 Effects of Alcohol and Central Nervous System-Acting Medications on
Risk of Falling
6.1 Introduction
One out of three community-dwelling older adults falls each year.113 Falls may result
from multiple risk factors that can be broadly classified into three the following categories;
environmental (poor lighting, slippery floor, loose carpet), intrinsic (chronic disease conditions
such as arthritis, vision impairment, dementia), and extrinsic (medications, alcohol).114,115
Several studies have documented CNS-acting medications to be a risk factor for falls. A
meta-analysis of observational studies found a small but consistent association between
psychotropic medication use and falls in older adults (weighted odds ratio 1.7 and 95% CI: 1.5 to
2.0).40 Antidepressants, antipsychotics, sedatives, hypnotics and anxiolytics are some of the drug
classes implicated as risk factor for falls.40 Other classes of CNS-acting medications such as
opioid analgesics and anticonvulsants have also been associated with falls.40 A prospective
cohort study found that compared to non-users, older women taking benzodiazepines
(multivariate odds ratio: 1.51, 95% CI: 1.14-2.01), and anticonvulsants (multivariate odds ratio:
2.56, 95% CI: 1.49-4.41) were at higher risk for falls. 116
Age-related pharmacokinetic and pharmacodynamic changes render older adults more
sensitive to the pharmacological effects of CNS-acting medications.47,117,118 Consequently,
adverse effects of most of the psychotropic drugs such as dizziness, sedation, cognitive
impairment, impaired psychomotor function and postural sway are exacerbated in older adults,
contributing to risk of falling.40,116 In addition, older adults using CNS-acting medications are
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likely to have depression, sleeping problems, psychiatric disorders, or poor health status that may
augment their risk of falling.40,116 Initiation of CNS-acting medication therapy, use of multiple
CNS-acting medications and any sudden change in the psychotropic drug regimen may increases
the risk of fall in older adults.116,117, 118
Alcohol is a CNS depressant that acts via various neurochemical systems in the brain and
causes sedation, dizziness, and also altered gait and balance.2 Longitudinal analysis of the
Cardiovascular Health Study (CHS) data showed that risk of falls increases by 25% in consumers
of 14 or more alcoholic drinks per week.1 A systematic review concluded that acute alcohol use
is an important risk factor for falls among young and middle-aged adults.119 A review of the
literature showed that studies examining the association between alcohol use and falls among
older adults have documented an inconsistent relationship between the two.120 A few studies
have shown that high alcohol use is associated with increased risk of falls in older adults 1,108, 120
while other others fail to find a significant relationship.120 Inconsistent findings could be
attributed to under-reporting of alcohol use, deficiencies of study design resulting in selection
and information biases or confounding effect, or publication bias. 120
Both alcohol and CNS-acting medications act on the CNS via various neurochemical
systems causing alterations in mood, behavior, cognition and physical movement which may
result in falls, fractures, and other injuries, especially in older adults.2 In 2009, the Drug Abuse
Warning Network (DAWN) detected that 519,650 emergency department visits were associated
with use of alcohol in combination with other drugs, out of which 44.1% were CNS-acting
agents (sedatives, anxiolytics and analgesics) and 8.5% were psychotherapeutic agents
(antidepressants and antipsychotic drugs).7 This indicates that combined use of alcohol and CNSacting medications may cause adverse events requiring medical care. Thus, the central
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hypothesis of the proposed study is to determine if the combined use of alcohol and CNS-acting
medications increases the risk of falls in older adults.
6.2 Objective
The objectives of this study were to determine if alcohol use was associated with risk for falls,
injurious falls, and recurrent falls. It is also of interest to determine if varying levels of alcohol
consumption with CNS-acting medication use is associated with risk for falls among older
adults.
6.3 Methods
6.3.1 Study population
The study sample was obtained from the 2009 MCBS study.77 Community-dwelling
Medicare beneficiaries aged 65 years or older, surviving through 2009 were included in this
study. Subjects with complete or partial paralysis and/or amputation were excluded from this
study. The description of the data source, sample selection, sample characteristics, and weighting
process has been described in Chapter 4.
6.3.2 Alcohol consumption
Data on alcohol use was collected from the MCBS survey. Every alternate year
participants in the MCBS are asked three questions probing about their “usual” alcohol use over
the past year. The first question is “Please think about a typical month in the past year. On how
many days did [you/(SP)] drink any type of alcoholic beverage?”. The next question enquires
about quantity of alcoholic drinks consumed; “On those days that [you/(SP)] drank alcohol, how
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many drinks did (you/he/she) have?”. The third question pertains to heavy episodic drinking “On
how many days did [you/(SP)] have 4 or more drinks in a single day?”
Monthly alcohol consumption was assessed using the quantity-frequency method.
Beneficiaries were categorized into three groups based on alcohol consumption; i) non-drinkers
(those who did not consume alcohol in past 12 months) ii) within-limit drinkers (those who
drank not more than 30 or 31 drinks in a month) iii) exceeding-limit drinkers (those who drank
more than 30 or 31 drinks in a month).56 These categories are based on the NIAAA
recommendations for alcohol use among older adults. Binge drinkers were described as those
who consumed more than 4 drinks in a single day over the past 12 months.
6.3.3 CNS-Acting Medication Use
The five mutually exclusive categories of CNS-acting medications utilized for this study
included opioid analgesics, non-benzodiazepine anticonvulsant agents, non-benzodiazepine
sedative-hypnotics, and non-benzodiazepine psychotherapeutics (antidepressant, antipsychotic)
and benzodiazepines. The information on CNS-acting medication use was collected using survey
as well as claims data. Number of refills was not included since that information was not
available on every study subject.
Both CNS-acting medication use (users vs. non-users) and alcohol use (non-drinkers,
within-limit drinkers, and exceeding-limit drinkers) were combined to form a variable with six
subcategories. Similarly binge drinking (non-drinker, non-binge drinker, and binge-drinker) and
CNS-acting medication use (users vs. non-users) were combined to form a variable with six
subcategories. These subcategories of exposure variables are described in Table 6.1.
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Table 6.1 Subcategories of Exposure Variables
CNS-acting medication use and
drinking status

CNS-acting medication use and
binge drinking

1. Non-user and non-drinkers

1. Non-user and non-drinkers

2. Non-users and within-limit drinkers

2. Non-users and non-binge drinkers

3. Non-users and exceeding limit drinkers

3. Non-users and binge drinkers

4. Users and non-drinkers

4. Users and non-drinkers

5. Users and within-limit drinkers

5. Users and non-binge drinkers

6. Users and exceeding limit drinkers

6. Users and binge drinkers

6.3.4 Outcome Variables
During the interview, subjects were asked seven questions regarding falls including
number and severity of falls, how it affected their lives, and fear of falling. To elaborate, subjects
were asked, “Since the last interview have you fallen down?”. If subjects answered affirmatively,
they were further asked about the number of times they had fallen, if the most recent fall hurt
them badly enough to seek medical help, and the kind of injury they suffered. Fear of falling was
rated on a 6 point scale ranging from “not at all afraid” to “extremely afraid”.
The outcome variable (dichotomous) was described in two ways: i) subjects who either
fell or not (fallers and non-fallers), and ii) among fallers, whether subjects had an injurious fall or
not. Subjects who required medical help after the most recent fall were considered to have an
injurious fall. Non-fallers were considered the reference group for the logistic regression model.
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6.3.5 Covariates
Several variables have been documented as risk-factors of fall in older adults. Some of
these factors could confound the relationship between use of CNS-acting medication and
alcohol, and risks of falls. In this study, a fall risk assessment tool known as “Falls Risk for
Older People-Community setting (FROP-Com) was followed to select the variables regarded as
risk factors for falls in older adults.121 Not all variables enlisted in FROP-Com were available in
MCBS dataset. Variables such as fear of fall, eye impairment, body mass index, use of
antihypertensive medications, functional status, chronic co-morbid conditions, health status, and
other socio-demographic characteristics have been found to be associated with risk of falls in the
literature (Table 6.2).
Table 6.2 Confounders Included in the Regression Model
Categories
Socio-demographic factors

Variables
Age, gender, race, marital status, education level

Fall risk factors

Eye impairment
Use of blood pressure medication
Fear of fall
Body Mass Index (BMI)

Functional status

Activities of daily living
Instrumental activities of daily living
Limitations to social activity

Health status

Perceived health status
Polypharmacy
No. of chronic co-morbid conditions

Most of the variables were categorized as described earlier in chapter 5. Older adults
were categorized into two groups based on history of eye impairment (no impairment vs.
presence of impairment). The body mass index of the older adults was calculated using their
weights (in kilograms) and heights (in meters). The following formula was used to calculated the
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BMI weight (kg) / [height (m)]2. BMI lower than 18.5 was considered as underweight, BMI
ranging between 18.5 and 24.9 was considered normal weight, BMI ranging from between 25.0
to 29.9 was regarded as overweight, and BMI of 30.0 or above was regarded as obese.122 The
total number of chronic conditions was calculated as a sum of the number of disease conditions a
respondent suffered from in the past year. The disease conditions included arthritis, rheumatoid
arthritis, osteoporosis, diabetes, depression, emphysema, hypertension, congestive heart disease,
myocardial infraction, arrhythmia, cardiac failure, other heart problem, urinary incontinence,
Alzheimer's Disease (AD), and Parkinson’s Disease (PD).
6.3.6 Statistical Analyses
Frequency and weighted percent were used to describe the characteristics of the study
sample. Bivariate association was studied by performing Chi-square tests. Separate logistic
regression was employed to determine the association between outcome variables (falls,
injurious falls and recurrent falls) and exposures (use of alcohol and CNS-acting medications),
controlling for confounders. Confounders were identified based on available evidence in the
literature, bivariate association with exposure variables and outcome variable, and if there is a
10% change in the odds ratio of exposure variable when the potential confounder was added to
the regression model. In case the association between the confounder and the outcome variable
was not found to be significant in this study but there is sufficient evidence in the literature
indicating that the variable is a risk factor for falls, then the variable is added to the model to
control for its effect.
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Multi-nominal logistic regression was used to study the association between injurious
falls or recurrent falls with exposure variables where non-fallers were the reference group. The
effect of CNS-acting drug classes included in this study and the number of CNS-acting
medications being prescribed on the risk of falls were also investigated. Adjusted odds ratio
(with 95% CI) and the p-value described the relationship between the outcome variable and
exposure variables. Multicollinearity between explanatory variables was investigated by
assessing the correlation between continuous variables, or chi-square test between categorical
variables. Test of multicollinearity was also performed in the regression model using variance
inflation factor (VIF). If the VIF was greater than 10 then the variables were said be multicollinear. SAS statistical software versions 9.2 and 9.3 were employed to perform all of the
statistical analysis78, at significance level of α=0.05.
6.4 Results
6.4.1 Description of the Sample Characteristics
A total of 7,163 (weighted frequency=20070176 and standard deviation= 116981)
community-dwelling older adults were included in this study. A total of 21.5% (95% CI: 20.522.5 %, n=1601) of the individuals in the study sample reported falling in the past month. Fiftyfour (0.8%, 95% CI: 0.5-1.2 %) older adults did not provide a usable response to this question in
the study. Among those who fell in the past 12 months, 28.2% (95% CI: 25.57-30.88 %, n=462)
had an injurious fall requiring medical help. Approximately 53% (95% CI: 95% CI: 50.9-55.8 %,
n=818) experienced a single fall and 47% (95% CI: 44.2-49.1 %, n=755) had recurrent falls, in
the past year. Among the fallers, 28 older adults did not respond to how many times they fell in
the previous year and one older adult did not mention if he or she had needed medical help after
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the fall. Thus, these individuals are considered missing in the analyses. The distribution of
outcome variables is described in Figure 6.1.

Final study sample
N=7,163

Non-fallers
n=5,508
78.5% (95% CI: 77.3-79.3 %)

Fallers
n=1,601
21.5% (95% CI: 20.5-22.5 %)

Non-injurious fallers
n=1,138
71.8% (95% CI: 69.1-74.4 %)

Non-recurrent fallers
n=818
53.3% (95% CI: 50.9-55.8 %)

Injurious fallers
n=462
28.2% (95% CI: 25.6-30.9 %)

Recurrent fallers
n=755
46.7% (95% CI: 44.2-49.1 %)

Figure 6.1 Flowchart Depicting Outcome Variables

The socio-demographic characteristics of the fallers and non-fallers are described in
Table 6.3. The fallers were likely to be older in age (21% of the fallers were aged 85 years or
older while 14% were of the fallers were aged the same). A greater proportion of fallers were
identified as Caucasians than non-fallers though smaller proportions of African American were
fallers than non-fallers.
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Table 6.3 Socio-demographic Characteristics of Fallers and Non-fallers
Fallers
Variables

Non-fallers

Frequency

Weighted
Frequency
Percent (95% CI)

Weighted Percent
(95% CI)

85 and older
75-84
65-74
Gender

396
662
543

21.1 (19.3-22.8)
37.7 (35.3-40.2)
41.2 (38.3-43.9)

950
2210
2348

14.0 (13.1-14.9)
36.8 (35.5-38.1)
49.2 (48.0-50.3)

Female
Male
Race

938
663

58.7 (56.0-61.3)
41.3 (38.7-44.0)

3099
2409

56.4 (55.5-57.4)
43.6 (42.6-44.5)

Caucasian
African American
Others
Marital

1415
87
94

88.4 (86.5-90.3)
5.8 (4.4-7.1)
5.8 (4.4-7.2)

4662
482
350

84.8 (83.8-85.8)
8.6 (7.9-9.3)
6.6 (5.8-7.3)

Married
Non-married
Education

766
835

49.6 (46.7-52.4)
50.4 (47.6-53.3)

2931
2573

55.0 (53.6-56.5)
45.0 (43.6-46.4)

More than high
school
High school
Less than high school
No Education
Income

713
472
396
18

46.2 (43.8-48.7)
29.1 (26.9-31.2)
23.8 (21.7-25.9)
0.9 (0.5-1.3)

2423
1708
1295
59

46.0 (44.5-47.6)
31.3 (30.1-32.6)
21.7 (20.5-22.8)
1.0 (0.7-1.2)

More than 25,000
25,000 or less
Employment

781
820

48.5 (45.6-51.5)
51.5 (48.5-54.4)

2878
2630

54.6 (53.0-56.2)
45.4 (43.8-46.9)

No
Yes
Social activity

1462
139

89.9 (87.9-91.8)
10.1 (8.2-12.0)

4876
628

87.0 (86.0-88.0)
13.0 (11.9-14.0)

No
Yes
Health status

916
684

58.6 (55.7-61.4)
41.4 (38.6-44.2)

4044
1456

75.5 (74.2-76.7)
24.5 (23.3-25.8)

Worse
Same
Better
Difficulties in ADL

523
855
220

31.8 (29.2-34.4)
54.2 (51.6-56.8)
14.0 (12.2-15.9)

980
3733
793

16.9 (16.1-17.7)
68.6 (67.3-69.9)
14.5 (13.2-15.7)

888
455
258

57.8 (55.0-60.6)
27.2 (24.8-29.6)
15.0 (13.2-16.8)

4228
980
300

78.3 (77.0-79.6)
16.5 (15.5-17.6)
5.2 (4.4-5.8)

Age

No difficulty
1-2
3-6
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Difficulties in ADL
No difficulty
1-2
3-6

766
510
325

50.1 (47.2-52.9)
31.3 (28.6-34.1)
18.6 (16.4-20.7)

3790
1234
484

70.8 (69.5-72.1)
21.4 (20.3-22.6)
7.7 (7.0-8.5)

Never-smoker
Former-smoker
Current-smoker
Chronic comorbidity

694
796
111

42.4 (39.6-45.3)
50.1 (46.9-53.3)
7.5 (5.8-9.1)

2280
2743
483

41.0 (39.7-42.3)
49.8 (48.5-51.1)
9.2 (8.4-10.0)

5 or more
3-4
1-2
No disease
Number of
medications

568
606
366
61

34.2 (31.6-36.7)
37.5 (31.6-36.7)
24.1 (21.6-26.7)
4.2 (2.8-5.4)

1187
1961
1991
369

20.2 (19.0-21.4)
34.9 (33.7-36.1)
37.4 (35.9-39.0)
7.5 (6.7-8.2)

575
549
423
54

35.3 (32.7-37.8)
33.8 (31.6-36.0)
27.4 (25.1-29.6)
3.5 (2.5-4.5)

1185
1992
2040
291

20.4 (19.2-21.6)
35.8 (34.5-37.0)
38.2 (36.7-37.0)
5.6 (4.9-6.3)

1011
588

63.4 (61.1-65.7)
36.6 (34.3-38.9)

4046
1447

74.7 (73.3-76.2)
25.3 (23.8-26.7)

444
1157

28.5 (26.1-30.9)
71.5 (69.1-73.9)

1799
3709

34.3 (32.7-36.0)
65.7 (64.0-67.3)

Smoking status

11 or more
6-10
1-5
No medication
Eye impairment
No impairment
Impairment/Blind
Use of
antihypertensive
medication
No
Yes
Obesity

11
0.6 (0.2-0.9)
54
1.0 (0.7-1.3)
Underweight
213
12.7
(10.8-14.7)
753
13.1
(12.2-14.0)
Normal weight
442
27.4
(25.1-29.7)
1504
26.9
(25.8-27.9)
Over-weight
935
59.3 (56.9-61.7)
3197
59.0 (57.8-60.2)
Obese
Column percentages are significantly different
(Rao-Scott-Chi-square test showed p-value <0.05)
Bivariate analysis between the covariate and fall outcome showed significant association
(p-value<0.05)
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Fallers seem to suffer from higher numbers of chronic comorbid conditions and consume
more medications. Approximately 35% of the fallers were taking 11 or more medications
whereas 20% of the non-fallers were taking the same. Similarly, while 20% of the non-fallers
reported suffering from 5 or more co-morbid conditions, 34% of the fallers reported the same.
Functional status of fallers seemed to be worse than non-fallers. Greater proportion of fallers
reported encountering limitations in social activity due to health, difficulties in performing usual
and instrumental activities of daily living (ADL and IADL), and worsening of health in the past
year. Moreover, 36.6% of fallers reported having eye impairment compared to 25% of the nonfallers. Similarly greater proportions of fallers reported taking antihypertensive medications than
non-fallers. Bivariate analysis was performed using Chi-square test of association which showed
that variables including age, race, marital status, income, employment, perceived health status,
limitations in social activity, comorbidities, number of medications used, eye impairment, and
use of antihypertensive medications were significantly associated with the falls outcome
variable.
The relationship between the exposure variables and any fall in the past 12 months was
studied using logistic regression analysis. As risk factors foe falls are multifactorial in nature so
the confounding effect of age, sex, race, marital status, educational level, perceived health status,
difficulty in social activity due to health conditions, ADLs, IADLs, presence of eye impairment,
use of blood pressure medications, number of medications taken and comorbid conditions were
controlled.
6.4.2 Effect of CNS-Acting Medication on the Risk of Falling
Of the 7,613 older adults included in this study 41.5% (95% CI: 40.0-43.0 %, n=3,019)
took CNS-acting medications in the past year. The distribution of each class of CNS-acting
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medication (figure 6.2) in the overall study sample comprised of; 22.5% (95% CI: 21.3-23.7 %,
n=1637) taking at least one opioid analgesic; 17.9 % (95% CI: 16.8-19.0 %, n=1288) consuming
at least one psychotherapeutic medication; 8.0% (95% CI: 7.3-8.7 %, n=611) taking at least one
anticonvulsants; 6.8% (95% CI: 6.3-7.3 %, n=509) taking at least one benzodiazepines; and 5.5%
(95% CI: 4.9-6.0 %, n=404) taking at least one sedative-hypnotics in the past 4 months. Figure
6.2 shows the distribution of each class of CNS-acting medication use among CNS-acting
medication users (denominator=3,019). Approximately 50% (95% CI: 48.18-51.56%, n=1482)
of the CNS-acting medication user took one CNS-acting medication, 24.77% (95% CI: 23.0726.46 %, n=762) took two CNS-acting medications, while 25.36% (95% CI: 23.58-27.15,

Weighted Percent

n=774) took more than two CNS-acting medications.

100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0

54.3%
43.1%
16.4%

13.2%

19.3%

Categories of CNS-acting medication

Figure 6.2 Pattern of use of CNS-acting medication
The effect of individual CNS-acting medication class on risk of falling is described in
Table 6.4. It was observed that 32.8% of opioid analgesic users were fallers while 19.7% were
non-fallers. The adjusted logistic regression analysis showed that use of opioid analgesics (OR:
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1.41, 95% CI: 1.21-1.65) was associated with increased the odds of experiencing fall in older
adults.
Table 6.4 Relationship Between each Class of CNS-Acting Medication
and the Risk of Falling
Variables

Fallers

Non-fallers

Adjusted Odds
Ratio (95% CI)

Sample Weighted
Persons Percent
(95% CI)

Sample
Persons

Weighted
Percent
(95% CI)

1074
527

67.2 (65.0-69.4)
32.8 (30.6-35.0)

4409
1099

80.3 (79.1-81.5)
19.7 (18.5-20.9)

1 (ref)
1.41 (1.21-1.65)**

1192
409

74.1 (71.9-76.2)
25.9 (23.8-28.1)

4640
868

84.4 (83.2-85.6)
15.6 (14.4-16.9)

1 (ref)
1.26 (1.08-1.47)**

1439
162

90.6 (89.2- 91.9)
9.4 (8.1-10.8)

5164
344

93.9 (93.3-94.5)
6.1 (5.5-6.7)

1 (ref)
1.30 (1.06-1.60)**

1419
182

89.3 (87.8-90.7)
10.7 (9.3-12.2)

5087
421

92.8 (92.0-93.5)
7.2 (6.5-8.0)

1 (ref)
1.03 (0.84-1.25)

1476
125

92.7 (91.3-94.0)
7.3 (6.0-8.7)

5232
276

95.0 (94.4-95.6)
5.0 (4.4-5.6)

1 (ref)
1.13 (0.88-1.45)

745
338
217
301

46.9 (44.5-49.4)
21.5 (19.3-23.7)
12.7 (11.0-14.4)
18.8 (16.5-21.2)

3366
1134
545
463

61.7 (60.0-63.3)
20.5 (19.3-21.7)
9.7 (8.8-10.6)
8.1 (7.4-8.9)

1 (ref)
1.15 (0.96-1.37)
1.21 (0.98-1.51)
1.73 (1.36-2.20)**

Opioid analgesics
Non-users
Users
Psychotherapeutics
Non-users
Users
Benzodiazepines
Non-users
Users
Anticonvulsants
Non-users
Users
Sedative-hypnotics
Non-users
Users
Total CNS-acting
medication
Zero
One
Two
Three or more

**Wald’s Chi-square test significant (p-value < 0.05)
The bivariate Chi-square test of association between fall and each class of CNS-acting medication was
found to be significant with p-value <0.0001.
The Chi-square test of association between falls and total number of CNS-acting medication was found to
be significant (p-value <0.0001).
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The percentage of fallers taking psychotherapeutic agents was 25.9% compared to 15.6%
non-fallers taking the same. The users of psychotherapeutic agents including antidepressants,
anxiolytics, and antipsychotics, had 26% higher risk of falling than non-users (OR: 1.26, 95%
CI: 1.08-1.47). Use of benzodiazepine was also found to be associated with higher risk of falls.
The association between use of sedative/hypnotic and anticonvulsants was not found to be
statistically significant. Moreover, taking three or more CNS-acting medications increases the
odds of having a fall by 73% (OR: 1.73, 95% CI: 1.36-2.20).
6.4.3 Effect of Alcohol and CNS-Acting Medication on the Risk of Falling
Out of the total 7,163 study sample, 96 older adults did not provide useful response to
alcohol intake questions in the survey. Hence these 96 older adults were not included in most
analyses including the alcohol use variable. Among the 3,019 CNS-acting medication users,
23.6% (95% CI: 21.8-25.4 %, n=656) were within-limit drinkers, 5.5% (95% CI: 4.4-6.6 %,
n=148) consumed alcohol at an exceeding level, and 10.1% (95% CI: 8.7-11.5 %, n=277) were
NIAAA-defined at-risk drinkers.
Of the 7,067 study sample, the potential concurrent use of alcohol and CNS-acting
medication was found to be 12.2% (95% CI: 11.3-13.2 %, n=814). Among the 814 potential
concurrent users, 52.9% (95% CI: 49.7-56.1 %, n=425) took opioid analgesics, 36.2% (95% CI:
32.9-39.5 %, n=289) used psychotherapeutic agents, 15.7% (13.0-18.3%, n=129) were
anticonvulsant users; 15.0% (95% CI: 12.3-17.7 %, n=122) were benzodiazepine users; and
14.9% (95% CI: 12.3-17.4 %, n=123) used sedative-hypnotic agents (Figure 6.3).
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Weighted Percent

100.0
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Pattern of CNS medication use

Figure 6.3 Pattern of CNS-Acting Medication use among Concurrent Users
Among the potential concurrent users (Figure 6.4), approximately 81% (95% CI: 77.984.3 %, n=656) consumed alcohol within limit; 18.9% (95% CI: 15.7-22.1, n=148) were
exceeding-limit drinkers; and 34.5% (95% CI: 30.6-38.5 %, n=277) were at-risk drinkers
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(defined by NIAAA guidelines).

100
90
80
70
60
50
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Categories of alcohol use

Figure 6.4 Pattern of Alcohol Consumption among Concurrent Users
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The majority of exceeding-limit drinkers were older men whereas a greater proportion of
non-drinkers were older women. Interestingly, the proportion of older men and women was
similar for within-limit drinkers suggesting moderate drinking is not only more prevalent but
also common in both genders. A larger proportion of CNS-acting medication users were older
women. Among concurrent users, 54.4% were women and 45.6% were men. Figure 6.5 depicts
the proportion of older men and women across the exposure groups
Male

100.0
90.0

Female

70.1%

Weighted Percent

80.0
70.0

64.2%

62.4%
49.2% 50.8%
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35.8%

37.6%

54.4%
45.6%

29.9%

30.0
20.0
10.0
0.0
CNS-medication Non-drinkers
users

Exceed-limit
drinkers

Within-limit
drinkers

Concurrent
users

Exposure Groups

Figure 6.5 Gender Distributions in the Exposure Groups
A logistic regression model was built to understand the effect of use of alcohol and CNSacting medication on the risks of fall, after adjusting for confounders (Table 6.5). After adjusting
for confounders no significant association between alcohol consumption and fall was detected.
CNS-acting medication was found to be a risk factor for falls in older adults (OR: 1.26, 95% CI:
1.08-1.46). Older adults taking at least one CNS-acting medication may have 26% higher odds
of falling than non-users of CNS-acting medication.
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Table 6.5 Effect of Alcohol and CNS-acting Medications on Risk of the Falling
Variables

Fallers

Non-fallers

Adjusted Odds
Ratio (95% CI)

Sample
persons

Weighted
percent (95%
CI)

Sample
persons

Weighted
percent (95%
CI)

1143
364
85

69.8 (67.0-72.7)
24.3 (21.9-26.7)
5.9 (4.3-7.4)

3626
1523
318

64.1 (62.2-65.9)
29.5 (28.0-31.0)
6.4 (5.4-7.4)

1 (ref)
0.91 (0.78-1.05)
1.05 (0.76-1.45)

856
745

46.9 (44.5-49.4)
53.1 (50.6-55.5)

2142
3366

61.7 (60.0-63.3)
38.3 (36.7-40.0)

1 (ref)
1.26 (1.08-1.46)*

499

30.4 (28.0-32.8)

2098

37.5 (35.7-39.2)

1 (ref)

48

3.2 (2.1-4.2)

100

2.0 (1.6-2.5)

1.72 (1.13-2.61)*

157

10.2 (8.5-11.8)

499

9.7 (8.8-10.5)

1.05 (0.81-1.37)

644
37

39.4 (37.0-41.9)
2.7 (1.8-3.7)

1528
499

26.6 (25.1-28.1)
4.4 (3.6-5.2)

1.27 (1.07-1.51)*
0.86 (0.56-1.32)

207

14.1 (12.3-15.9)

1024

19.8 (18.5-21.2)

0.97 (0.79-1.18)

Drinking status
Non-drinkers
Within-limit drinkers
Exceeding-limit
drinkers
CNS-acting
medication use
Non-users
Users
CNS-acting
medication user +
drinking status
Non-users + nondrinkers
Users + exceedinglimit drinkers
Users + within-limit
drinkers
Users + non-drinkers
Non-users +
exceeding-limit
drinkers
Non-users + withinlimit drinkers

* Wald’s Chi-square test significant with p-value <0.05.
Number of observations included in the model= 6988 and weighted frequency of these observations =19541101
Number of observations deleted due to missing values in response or explanatory variables=175

Comparing to those who neither use CNS-acting medication nor drink, it was observed
that the odds of falling was 72% (OR: 1.72 95% CI: 1.13-2.61) higher among CNS-acting
medication users who drink at an exceeding level. However, no significant association was
observed among CNS-acting medication users who drink within limit and risk of fall. However,
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CNS-acting medication use in the presence of drinking within limit did not show significantly
greater odds of falling. Alcohol use in the absence of CNS-acting medication use did not
demonstrate significant association with risk of falling.

Table 6.6 Use of CNS-acting Medications and Binge Drinking and Risk of Falling
Variables

Fallers

Non-fallers

Adjusted Odds
Ratio (95% CI)

Sample
Persons

Weighted
Percent (95%
CI)

Sample Weighted
Persons Percent (95%
CI)

1143
395
55

69.6 (66.7-72.5) 3626
26.3 (23.8-28.7) 1606
4.1 (2.9-5.3)
240

64.0 (62.2-65.9)
31.2 (29.6-32.9)
4.7 (4.0-5.5)

1 (ref)
0.93 (0.81-1.08)
1.06 (0.72-1.54)

499
220

30.3 (27.9-32.7)
2.3 (1.4-3.2)

2098
1085

37.4 (35.6-39.2)
1.5 (1.2-1.9)

1 (ref)
0.97 (0.80-1.18)

24
644
175
31

11.3 (9.6-13.0)
39.3 (36.8-41.8)
1.9 (1.1-2.6)
14.9 (13.2-16.7)

162
1528
521
78

10.2 (9.2-11.1)
26.6 (25.1-28.1)
3.2 (2.6-3.8)
21.1 (19.6-22.5)

0.83 (0.49-1.41)
1.27 (1.07-1.51)*
1.12 (0.87-1.44)
1.77 (1.07-2.92)*

Binge drinking
Non-drinkers
Non-binge drinkers
Binge drinkers
Binge drinking +
CNS-acting medication
Non-users + non-drinkers
Non-users + non-binge
drinkers
Non-users + binge drinkers
Users + non-drinkers
Users + non binge drinkers
Users + binge drinkers

* Wald’s Chi-square test significant with p-value <0.05.
Number of observations included in the model=6994 and weighted frequency of these observations =19568317 Number of
observations deleted due to missing values in response or explanatory variables=169

The association between binge drinking and risk of falling was also investigated (Table
6.6). Binge drinking was not found to be associated with risk of falling. The exposure variables,
CNS-acting medication use and binge drinking, were combined to form six subcategories. Older
adults who do not drink or take CNS-acting medications were the reference group. So compared
to non-drinker and non-user, older adults taking CNS-acting medication and binge drinking were
77% times (OR: 1.77, 95% CI: 1.07-2.92) more likely to encounter a fall in the past year. Similar
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to the previous observation, CNS-acting medication use among non-drinkers was significantly
associated with the risk of falls. However, CNS-acting medication use in the presence of nonbinge drinking was not significantly associated with higher odds of falling.

Table 6.7 Use of Alcohol and Opioid Analgesics and Risk of Falling
Variables

Fallers
Sample
Persons

Non-fallers
Weighted
Sample
Percent (95% CI) Persons

Weighted
Percent (95% CI)

45.7 (42.8-48.6)
1.7 (0.9-2.4)
6.6 (5.2-8.0)
24.1 (21.8-26.4)
17.7 (15.8-19.5)
4.2 (3.0-5.4)

50.3 (48.4-52.0)
1.0 (0.7-1.3)
4.8 (4.3-5.4)
13.8 (12.7-14.9)
24.7 (23.3-26.1)
5.4 (4.5-6.3)

Adjusted Odds
Ratio (95% CI)

Opioid analgesics + Drinking status
Non-users + non-drinkers
Users + exceeding-limit drinkers
Users + within-limit drinkers
Users + non-drinkers
Non-users + within-limit drinkers
Non-users + exceeding-limit drinkers

748
26
100
395
264
59

2835
51
248
791
1275
267

1 (ref)
1.87 (1.08-3.24)*
1.26 (0.92-1.73)
1.39 (1.16-1.66)*
0.90 (0.76-1.07)
0.98 (0.69-1.41)

* Wald’s Chi-square test significant with p-value <0.05.
Number of observations included in the model=6994 and weighted frequency of these observations =19568317 Number of
observations deleted due to missing values in response or explanatory variables=169

Assessment of risk of falls associated with alcohol consumption and opioid analgesics
(Table 6.7) revealed that exceeding-limit drinkers taking opioid analgesics had 87% (OR: 1.87,
95% CI: 1.08-3.24) higher odds of having a fall though the sample size of this group was small
(n=26). Older adults using opioid analgesic and drinking within limit did not demonstrate
significantly greater risk of falls. However, older adults taking opioid analgesics but abstaining
from alcoholic beverage seemed to have greater odds of falling compared to non-drinkers and
non-users. Effect of combined use of alcohol and other classes of CNS medication could not be
ascertained due to small sample sizes (n < 20) in these groups.
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6.4.4 Effect of alcohol and CNS-acting medication on risk for injurious falls
The fallers were further categorized into two groups (injurious falls and non-injurious
falls) based on whether or not they experienced a fall that required medical assistance. Of the
entire study sample, 6.1% (95% CI: 5.4-6.8 %, n=462) reported seeking medical assistance after
the fall, and 15.6% (95% CI: 14.8-16.4 %, n=1,138) did not require medical assistance after the
fall. The proportion of CNS-acting medication use was greater in fallers than non-injurious
fallers and non-fallers. It can be observed in Table 6.8 that the proportions of alcohol use were
lower as the severity of fall increased. Exceeding-limit drinking was reported by 5.5% of
injurious fallers compared to 6.0% of non-injurious fallers and 6.4% of non-fallers. A similar
trend was observed for within-limit drinkers as well. However, the proportion of non-drinkers
was greater in injurious fallers followed by non-injurious fallers and further by non-fallers. It
must be noted that the confidence interval of the percentage of alcohol use in three different
groups of fallers overlapped. After joining the two exposure groups (alcohol use and CNS-acting
medication use) the distribution of the six subcategories against fallers was studied. It was seen
that many of the cell sizes were small (n <20).
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Table 6.8 Distribution of Exposure Variables against Injurious Fallers
Variables

Non-fallers

Non-injurious Fallers

Injurious Fallers

Sample
persons

Weighted
percent
(95% CI)

Sample
persons

Weighted
percent
(95% CI)

Sample Weighted
persons percent
(95% CI)

3626
1523
318

64.1 (62.2-65.9)
29.5 (27.9-31.0)
6.4 (5.4-7.4)

808
264
61

68.6 (65.3-71.9)
25.4 (22.6-28.2)
6.0 (4.3-7.7)

335
99
24

73.1 (68.4-77.8)
21.4 (17.6-25.2)
5.5 (2.9-8.1)

Drinking status
Non-drinkers
Within-limit drinkers
Exceeding-limit
drinkers
CNS-acting
medication use
Non-users
Users

3366
2142

61.7 (60.0-63.3)
38.3 (36.7-40.0)

563
575

49.7 (46.7-52.6)
50.3 (47.3-53.3)

181
281

39.9 (35.7-44.2)
60.1 (55.8-64.3)

100

2.0 (1.6-2.5)

35

3.4 (1.9-4.7)

13

2.7 (1.1-4.3)

499

9.7 (8.8-10.5)

101

9.5 (7.5-11.5)

56

11.9 (8.8-15.0)

1528
218

26.6 (25.1-28.1)
4.4 (3.6-5.2)

435
26

37.3 (34.5-40.1)
2.7 (1.7-3.7)

209
11

45.0 (40.7-49.4)
2.8 (0.6-5.1)

1024

19.8 (18.5-21.2)

163

15.8 (13.6-18.1)

43

9.5 (6.8-12.1)

2098

37.5 (35.6-39.2)

373

31.3 (28.6-34.0)

126

28.1 (23.6-3.6)

CNS-acting
medication use +
drinking status
Users + exceedinglimit drinkers
Users + within-limit
drinkers
Users + non-drinkers
Non-users + exceeding
-limit drinkers
Non-users + within
limit drinkers
Non-users +
non-drinkers

Column percentages are significantly different (Rao-Scott Chi-square test showed p-value <0.05)

Multi-nominal logistic regression (Table 6.9) was conducted to investigate the effect of
alcohol and CNS-acting medication use on the risk of falls. Non-fallers were considered the
reference group. Compared to non-users of CNS-acting medications, users were 61% (OR: 1.61,
95% CI: 1.30-2.00, p-value <0.0001) more likely to experience an injurious falls. However,
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CNS-acting medication use did not seem to affect the risk of non-injurious fall. Alcohol use was
not found to be associated with risk of injurious falls as well as non-injurious falls. Due to small
cell size the joint effect of alcohol and CNS-acting medication could not be analyzed.

Table 6.9 Association Between Exposure Variables and Injurious Fallers
Variables

Non-injurious fallers

Injurious fallers

Adjusted Odds Ratio p-value
(95% CI)

Adjusted Odds Ratio p-value
(95% CI)

1 (reference)
0.96 (0.81-1.12)
1.03 (0.74-1.44)

0.5772
0.8458

1 (reference)
0.80 (0.61-1.04)
1.13 (0.65-1.95)

0.0912
0.6627

1 (reference)
1.15 (0.95-1.39)

0.1594

1 (reference)
1.61 (1.30-2.00)

<0.0001*

Drinking status
Non-drinkers
Within-limit
Exceeding-limit
CNS-medications
Non-users
Users

Number of observations included in the model= 6987
Weighted frequency of these observations =19539027
Number of observations deleted due to missing values in response or explanatory variables=176

6.4.5 Effect of alcohol and CNS-acting medication on risk for recurrent falls
Older adults falling more than once in the past year were defined as recurrent fallers. Of the
overall study sample 10.0% (95% CI: 9.4-10.6 %, n=755) reported falling more than once in the
past year and 11.4% (95% CI: 10.6-12.2%, n=818) reported a single fall in the previous year
(Table 6.10). The proportion of CNS-acting medication use in the three groups reflected a
pattern. Older adults taking CNS-acting medication were 60% among recurrent fallers, 48%
among single fallers, and 38% among non-fallers. On the other hand, the proportion of non-users
of CNS-acting medications was 61.7% in non-fallers, 52.4% in single fallers, and 41.1% in
recurrent fallers. Recurrent fallers were demonstrated to have a higher proportion of exceeding
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limit drinkers as well as non-drinkers compared to non-fallers. After joining the subgroups of
alcohol use and CNS-acting medication use variables the resulting exposure variable had six
subcategories. However, the cell sample size of few cells was less (n < 20).

Table 6.10 Distribution of Exposure Variables against Recurrent Fallers
Variables

Non-fallers

Non-recurrent fallers

Recurrent fallers

Sample
persons

Weighted
percent (95%
CI)

Sample
persons

Weighted
percent (95%
CI)

Sample Weighted
persons percent (95%
CI)

3626
1523
318

64.1 (62.2-65.9)
29.5 (27.9-31.0)
6.4 (5.4-7.4)

577
200
39

68.9 (65.0-72.8)
26.2 (23.0-29.4)
4.9 (2.7-7.0)

546
158
45

70.9 (67.3-74.6)
21.9 (18.7-25.1)
7.2 (5.1-9.2)

41.1 (37.7-44.4)
58.9 (55.6-62.3)

Drinking status
Non-drinkers
Within-limit drinkers
Exceeding-limit
drinkers
CNS-acting
medications use
Non-users
Users

3366
2142

61.7 (60.0-63.3)
38.3 (36.7-40.0)

424
394

52.4 (48.8-56.1)
47.6 (43.9-51.2)

311
444

100

2.0 (1.6-2.5)

23

2.9 (1.6-4.1)

25

3.6 (2.1-5.1)

499

9.7 (8.8-10.5)

80

9.9 (7.6-12.2)

75

10.6 (8.0-12.9)

1528
218

26.6 (25.1-28.1)
4.4 (3.6-5.2)

289
16

34.6 (31.3-37.9)
2.0 (0.71-3.3)

340
20

44.6 (41.0-48.2)
3.5 (2.0-5.1)

1024

19.8 (18.5-21.2)

120

16.3 (13.5-19.1)

83

11.4 (8.9-13.8)

2098

37.5 (35.7-39.2)

288

34.3 (30.6-37.9)

206

26.3 (23.2-29.4)

CNS medication use
+ drinking status
Users + exceedinglimit drinkers
Users + within-limit
drinkers
Users + non-drinkers
Non-users +
exceeding limit
drinkers
Non-users + within
limit drinkers
Non-users +
non-drinkers

Column percentages are significantly different (Rao-Scott Chi-square test showed p-value <0.05)
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Multi-nominal logistic regression was conducted to investigate the effect of alcohol and
CNS-acting medications on the risk of recurrent falls (Table 6.11). Non-fallers were considered
as reference group. Compared to non-users of CNS-acting medications, users were 35% (OR:
1.35, 95% CI: 1.15-1.59, p-value= 0.0002) more likely to experience a recurrent fall. However,
CNS-acting medication use did not seem to affect the risk of non-recurrent falls. Older adults
who were exceeding-limit drinkers were found that have 48% (OR: 1.48, 95% CI: 1.06-2.07, pvalue=0.0225) greater odds of being recurrent fallers compared to non-drinkers. Within-limit
drinking did not demonstrate significant association with to the risk of recurrent falls. Due to a
small cell size the joint effect of alcohol and CNS-acting medication could not be analyzed.

Table 6.11 Association Between Exposure Variables and Recurrent Fallers
Variables

Non-Recurrent Fallers
Adjusted Odds Ratio
(95% CI)

Recurrent Fallers
p-value

Adjusted Odds
Ratio (95% CI)

p-value

Drinking status
Non-drinkers
Within-limit
Exceeding-limit

1 (reference)
0.89 (0.73-1.09)
0.79 (0.48-1.31)

0.2566
0.3670

1 (reference)
0.92 (0.75-1.13)
1.48 (1.06-2.07)

0.4130
0.0225*

1 (reference)
1.19 (0.96-1.47)

0.1181

1 (reference)
1.35 (1.15-1.59)

0.0002*

CNS-acting
medication use
Non-users
Users

Number of observations included in the model=6961
Weighted frequency of these observations =19472994
Number of observations deleted due to missing values in response or explanatory variables=202
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6.5 Discussion
This study aims at to understand the effect of the combined use of CNS-acting
medications and alcohol, at different consumption levels, on the risk of falls in community
dwelling Medicare beneficiaries aged 65 years or older. The complex, non-linear relationship
observed between risk of falls and the use of CNS-acting medication and alcohol at varying
degrees is the most interesting and novel aspect of this study.
The potential concurrent use of alcohol and CNS-acting medication in the past year was
found to be approximately 12% (n=814), with almost 80% of these potential concurrent users
being within-limit drinkers and 20% drinking at an exceeding limit. Approximately 40% of the
concurrent users took more than one CNS-acting medication in the past year. The proportion of
potential concurrent users was substantial. Hence, it was important to understand the effect of the
potential concurrent use of alcohol and CNS-acting medications on the risks of falling.
Our findings showed that the use of CNS-acting medication by older drinkers who
exceeded the NIAAA recommended drinking guidelines (no more than one drink per day)
experienced 77% higher odds of falling. In addition, binge drinking in the presence of CNSacting medication use also increases the odds of falling by 87% among older adults. Increased
fall risk was also observed among exceeding-limit drinkers who consumed opioid analgesics.
Interestingly, CNS-acting medication users drinking within NIAAA recommended limit did not
seem to significantly have higher odds of falling, though non-drinking CNS-acting medication
users demonstrated 27% greater odds of falling. This suggests a complex non-linear effect of
combined use of alcohol and CNS-acting medications on the risks of falling, driven by labyrinth
of known and unknown factors.
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Some of the possible explanations for this finding are summarized below:
1. Our findings seemed to parallel the theory of protective effect of moderate drinking on
the risk of falls in older adults.1,120 The risk estimate observed in our study might be
interpreted as the protective effect of moderate alcohol intake negating the harmful effect
of CNS-acting medication use. However, it is noteworthy that the relationship between
moderate alcohol use and risk of fall has been unclear and documented inconsistently in
the literature120
2. Older adults who take CNS-acting medication and report consuming higher amount of
alcohols may tend to have psychiatric conditions, depressive symptoms, pain, or history
of problem drinking, which may increase their risk of falls.9
3. Another potential premise is the effect of alcohol on bone mineral density (BMD);
alcoholics are reported to have lower BMD, possibly due to accompanying nutritional
deficiencies whereas moderate drinking might be associated with greater BMD.123,124
4. Moderate drinkers might be healthier than heavy drinkers. Thus, the healthier profile of
moderate drinkers could be confounding the association between moderate drinking and
risk of falling.125 Moreover, such healthier older adults may have been following a
healthier lifestyle, endorsing healthy eating habits, exercising, refraining from harmful
activities such as smoking or heavy drinking. Although, the effect of health and
functional status of older adults have been controlled in the logistic regression analysis,
other variables such as diet, and exercise could not be taken into account due to lack of
this information in the dataset.
5. Studies have shown that people with higher educational level or belonging to upper
socio-economic background tend to drink regularly but moderately. There is a possibility
124

that the link between the benefits of moderate drinking observed in our study could be
explained by premorbid intellect, and its correlation with cognitive reserve. To elaborate,
individuals with better premorbid cognition (person's intellectual functioning prior to
known or suspected onset of brain disease or dysfunction) or with higher education level
tend to have more cognitive reserve. Hence such individuals may have elevated threshold
for experiencing functional impairment and less sensitive to the effect of alcohol.126,127
Besides, several studies have advocated the beneficial effect of moderate drinking on
cognitive function in older adults.126,127
6. Another possible explanation could be development of tolerance (requirement to
consume higher amount of the drug to achieve the same response) to alcohol due to
regular, moderate drinking. Continuous, constant and moderate exposure to alcohol may
result in lesser effect of alcohol due to metabolism driven by induced enzyme secretion or
several other mechanisms involved at a cellular or molecular level.128,129 The CNS-acting
medications such as benzodiazepines, barbiturates, anticonvulsant agents, and other
sedative-hypnotics potentiate the inhibitory action of GABA by acting on a separate
binding site on the receptors and changing the conformation of the receptor Alcohol
modified the GABA receptor by “altering the membrane environment such that the
receptor has an increases affinity for GABA and other sedative-hypnotics”. Thus the
pharmacological action of these benzodiazepines, barbiturates, sedatives-hypnotics, and
alcohol on the same receptor explains the similar impact of these agents and development
of cross-tolerance. 128
7. The beneficial effect of moderate drinking observed in our study could also be an artefact
of residual confounding or the cross-sectional study design.
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Some of the above explanations such as the healthy drinker effect, high cognitive reserve,
development of tolerance, and potential benefits of moderate drinking could also explain the
absence of a significant relationship between alcohol and risk of falling, controlling for CNSmedication use. The relationship between alcohol consumption and risk of falls has been
inconsistent and unclear in the literature. Some studies have found that high alcohol consumption
is associated with risk of falling1,93,114,130,131 while other studies have failed to establish the
association.132 A systematic review summarized the relationship between falls or fall injuries and
alcohol use in older adults. The review summarized four studies that reported increased risk of
falls or fall injuries associated with alcohol use (ranging from daily use to an average weekly
consumption of greater than 21 drinks) however, twenty-one studies found no association
between alcohol consumption and risk of falls or fall injuries.119 A study involving older
participants of the Cardiovascular Health Study (CHS) reported that the cross-sectional analysis
indicated an apparent inverse association between alcohol intake and risk of frequent falls
(adjusted OR: 0.41, 95% CI: 0.14-1.17), but the longitudinal analysis found 25% (95% CI: 352%) higher risk in drinkers of 14 or more drinks per week. A possible explanation for this
observation could be that older adults at risk for falling tend to decrease their alcohol use over
time or heavy drinkers at risk of fall tend not to enroll in cohort studies.1 Stenbacka et al. found
that high levels of alcohol intake (greater than 500 grams/month) were associated with higher
risk of injurious falls (relative risk: 2.27, 95% CI: 1.45-3.57).93 Few studies have described a
protective association between moderate drinking and fall risk in older adults. A case-control
study determined a protective effect (adjusted OR: 0.49, 95% CI: 0.25-0.95) of moderate
drinking on the risk of hip fracture in mid and older aged adults.118 A study by Cawthon et al.
concluded that light alcohol intake may decrease the risk if falling, but a history of problem
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drinking increased fall risk.123 Mostly the CNS depressant effect of alcohol (causing sedation,
drowsiness, dizziness, impaired and psychomotor function) has been implicated as an underlying
rationale for the increase in fall risk.2 However, the effect of alcohol on bone mineral density
may influence the association between alcohol and risk of falling. Several studies have been
conducted to assess the relationship between bone mineral density and alcohol consumption. The
evidence generated by this study is unclear and inconsistent; however, several longitudinal
studies reported moderate alcohol intake was not predictive of the rate of bone loss.123
Consistent with the literature, our findings suggest that CNS-acting medication use is a
risk factor for fall in older adults. Furthermore, use of opioid analgesics, benzodiazepines, and
psychotherapeutic agents (including antidepressants, anxiolytics, and antipsychotics) were
associated with increased risk of falls. However, use of sedative-hypnotic medications or
anticonvulsants was not significantly associated with fall risk. The higher risk for falling has
been associated with the use of CNS-acting medications or psychotropic medication as detected
by various observational studies including studies with prospective cohort and case control
designs. A nested case-control study established that using psychotropic medications within three
months of falling was associated with a higher risk of falling accidents among older men (OR:
2.14, 95% CI: 1.87-2.44) and older women (OR: 2.21, 95% CI: 2.04-2.39).133A cross-sectional
analysis of data from a large population of community-dwelling older adults estimated that the
risk of falling increases by nearly 47% (OR: 1.47, 95% CI: 1.24-1.74) in users of psychotropic
drugs.134 Previous studies have found the use of sedative-hypnotics or anticonvulsants to be
significantly associated with fall risk.115,132 Contrary to the literature, our study did not detect
significant association between the use of sedative-hypnotic or anticonvulsant, and fall risk.
Possible explanations for this could be: i) the drug classification employed by the data source, ii)
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under-reporting of sedative-hypnotic use, iii) use of newer sedative-hypnotic or anticonvulsants
with better safety profiles such as zaleplon, in older adults prone to falling, or iv) an artefact of
study design or residual confounding.
Effects of alcohol consumption and CNS-acting medication use on the risk for injurious
falls were studied separately employing a multi-nominal logistic regression model. CNS-acting
medication use was found to be a risk factor for injurious falls but not a risk factor for noninjurious falls. CNS-acting medication users had 61% greater likelihood of having an injurious
fall compared to nonusers. Alcohol use, both within-limit drinking and exceeding-limit drinking,
was not found to be associated with the odds of falling. The absence of a relationship between
high alcohol use and risk of injurious falls observed in our study could also be due to the low
sample size in that subgroup. A Swedish study found that high alcohol consumption (≥ 1,000 g
of 100% ethanol per month) was associated with increased risk for one injurious fall in older
women aged 60 years and older.93 The effect of concurrent use of alcohol and CNS-acting
medication could not be investigated in this study due to the small sample size in some
subgroups.
The effects of alcohol consumption and CNS-acting medication use on the risks for
recurrent falls were estimated separately utilizing a multi-nominal logistic regression model.
CNS-acting medication use was found to be a risk factor for recurrent falls. Users of CNS-acting
medications were 35% more likely to be recurrent fallers than non-users but association between
CNS-acting medication use and risk for single fall was not significant. Drinking at an exceeding
limit was associated with 48% higher odds of recurrent falls. However, it should be noted that
only 24 older adults were recurrent fallers who are exceeding-limit drinkers. An analysis with a
larger sample size can help confirm this finding. Other studies have also demonstrated
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association between alcohol and risk for recurrent falls in older adults.131,135 A longitudinal study
found that igh alcohol consumption (18 or more drinks per week) was a predictor of recurrent
falls.
The prevalence of falls and injurious falls reported in our study is similar to that seen in
other studies as well. An analysis of survey reported data from MCBS 2002 Cost and Use file
found that 22.1% (2909 out of 12669 respondents) of Medicare beneficiaries aged ≥65 years fell
in the previous year and 33% of the participants who reported at least one fall required medical
attention for at least one fall.136 The prevalence and pattern of alcohol consumption reported in
this study is comparable to the prevalence estimated in using other national datasets. Analysis of
the 2003 MCBS data showed that during a typical month in the past year 65.5% of the sample
reported drinking no alcohol, 25.4% reported drinking within guidelines, 3.8% exceeded the
monthly limit only, and 5.4% reported heavy episodic drinking.137 In general, the pattern and
prevalence of alcohol or CNS-acting medication use differs depending upon the setting and
design of the study or data source, definitions, cut-off limits, types of CNS-acting drug class
used, data collection method, or country of study. Hence comparison of the magnitude of use of
alcohol or CNS-acting medications between studies is difficult. Psychotropic medications are
more prevalent among community-dwelling older adults than other age groups with research
findings suggesting that between 35% and 53% of assisted living residents receive one or more
psychotropic medications.33
There are several limitations to this study. It is a cross-sectional study hence the causeeffect relationship between the exposures and risk of fall cannot be determined. Further research
using a case-control or cohort study design is necessary to confirm the findings of this study. It is
beyond the scope of this study to definitively ascertain the concurrent use of CNS-acting
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medication and alcohol. However the alcohol consumption measured in this study depicts typical
or regular consumption in the past year. Usually older adults follow a consistent pattern of
alcohol intake, however, certain events such as bereavement, retirement, loneliness, and disease
conditions may cause them to increase or decrease their alcohol intake.22,109,125 Under-reporting
of alcohol intake or fall events could bias the risk estimate assessed in this study. The duration,
dose, and regimen of CNS-acting medications were not considered in this study. Residual
confounding could also be a possibility. Inaccurate reporting or random error in collection or
coding of data could have occurred. The findings of this study are only applicable to noninstitutionalized older adults.
This study has several strengths. The risk estimates obtained in this study are controlled
for the confounding effect of various risk factors including antihypertensive medication use138,
eye impairment, functional status of the participants (using ADL and IADL, perceived health
status), comorbidity, polypharmacy, age, gender, education, race,and social activity.9,139 The
medication use has been captured using survey as well as administrative data. This study uses a
nationally representative sample of community-dwelling older adults aged 65 years or older.
6.6 Conclusion
The major findings of this study i.e. the risk of falls is higher among older adults taking
CNS medication and either binge drinking or consuming alcohol at a level that exceeds the
recommended limit, provide evidence of harmful effects of high alcohol intake by CNS-acting
medication users. Based on the premise that alcohol consumption is a modifiable behavior and
CNS-acting medication use in this group of older adults is justified, high alcohol consumption
should be discouraged among CNS-acting medication users. Furthermore, this study confirms
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that CNS-acting medication use is a risk factor for falls in older adults. To our knowledge, no
other study has investigated the combined effect of alcohol and CNS-acting medication on risk
of falls in older adults. Thus, the findings of this study may play an important role in drawing the
attention of researchers and healthcare professionals to this area of study as well as adding to the
literature
Findings of this study highlight the potential value of screening older adults for high
alcohol use, apart from other risk factors of falls. Dissemination of this information among health
professionals will create awareness about the potentially deleterious effect of high alcohol
consumption, especially among those prescribed CNS-acting medication. Greater attention
should be given to patients on multiple CNS-acting medications or taking psychotherapeutic
agents and opioid analgesics while screening for fall risk. In the era of evidence-based practice,
the findings of our study will play a significant role in clinical practice to identify older adults at
risk of fall. To summarize, these findings underscored the harmful effect of potential concurrent
use of CNS-acting medications and excessive alcohol consumption
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Chapter 7
Section 7.1 Conclusion
This dissertation aimed to provide a comprehensive perspective on alcohol use
considering medication use and comorbid conditions. The first goal was to understand the pattern
and prevalence of alcohol use that is deemed “risky” owing to the excessive amount of alcohol
consumption, and immoderate alcohol intake in the presence of certain disease conditions and
medications. In the next step, potential concurrent use of alcohol and CNS-acting medication
was studied to determine the proportion of older adults at risk of experiencing alcohol-CNS
medication interactions. Additionally, the effect of potential concurrent use of alcohol and CNSacting medication on the risk of falls was investigated by performing a cross-sectional analysis.
The findings of this study are applicable to community-dwelling American older adults aged 65
years or older.
The MCBS 2009 data showed at-risk drinking varied between 5.6%-11% among older
adults, depending on the definition of at-risk drinking. Potential concurrent use of CNS-acting
medications and alcohol was observed to be 12.1% among non-institutionalized, Medicare
beneficiaries aged 65 years or older. On the other hand, analyses of the NHANES data showed
8.9% of non-institutionalized older adults reported drinking daily and taking at least one CNSacting medication in the past month. The prevalence rate obtained from NHANES data was a
conservative estimate. These findings strongly suggest that a substantial proportion of older
adults reported potentially harmful alcohol use and could be susceptible to alcohol-related
adverse effects. Thus, identifying these vulnerable older adults and providing appropriate
intervention is necessary. Interventions such as screening for at-risk drinking, counselling, and
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screening for potential alcohol-medication or alcohol-drug interactions could minimize the risk
among those older adults. However, to maximize the utilization of healthcare resources, older
adults more likely to be at risk of alcohol-related adverse events need to be managed at the
outset. The socio-demographic factors identified in this study can provide an insight into those
risk factors. Age between 65-74 years, male gender, being white, history of smoking, high
education, and, good health condition were some factors associated with hazardous alcohol use,
identified using MCBS and NHANES data.
The effect of potential concurrent use of alcohol and CNS-acting medication on the risk
of falls was studied employing a cross-sectional study design. Though alcohol consumption was
not found to be significantly associated with fall risk, high alcohol consumption (more than 30
drinks/month) accompanied by CNS-acting medication use was associated with an increased
odds of falling (OR: 1.72, 95% CI: 1.13-2.61). Older adults taking CNS-acting medication and
reportedly binge-drinking encounter a significant increased risk of falls. CNS-acting medication
use, in the absence of alcohol intake, was found to increase the odds of falling by 27% (OR:
1.27, 95% CI: 1.07-1.51). CNS-acting medication use was also associated with risks for recurrent
falls and injurious falls. High alcohol consumption (more than one 30 drinks/month) was found
to be associated with risk for recurrent falls. The effect of combined use of alcohol and CNSacting medication on the risks for recurrent falls and injurious falls could not be studied due to
lack of small size.
The baby-boomer generation is known to use substances of abuse at a higher rate than the
previous generations, so with the aging of this generation, the number of older adults requiring
treatment for substance abuse is likely to increase. Additionally, older adults constitute the
fastest growing segment of U.S. population. Thus, the demand for specialized health care
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services will expand in future. In this scenario, understanding the adverse effects of risky
drinking and identifying the factors associated with at-risk drinking is of utmost importance.
By measuring the prevalence of at-risk drinking or potential concomitant use of alcohol
and alcohol-interactive drugs, the proportion of older adults who could be at risk was determined
which provided an insight into the magnitude of the problem. By identifying the factors
associated with at-risk drinking or daily drinking, preventive measures or screening processes
can be directed to those “high-risk” older adults. On the other hand, understanding the effects of
concurrent use of alcohol and alcohol-interactive medications (in the case of our study, CNSacting medications) on health outcomes may play a significant role in evidence-based practice. In
this current age, evidence forms the basis for framing treatment guidelines, planning preventive
measure, and creating awareness among older adults. Hence this study not only fills a gap in
literature but also creates evidence that can influence healthcare practices to achieve better
outcomes. This study can also play a role in increasing awareness among older adults about the
potential adverse effects of alcohol use in the presence of comorbid conditions or when
concomitantly consumed with medications.
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Section 7.2 Future Directions
The findings of this study can play a significant role in encouraging further research in
this area, especially understanding the effect of the concomitant use of alcohol and alcoholinteractive medications in older adults. Based on the findings of our study, further research to
understand the effect of alcohol and CNS-acting medications on the risks for falling by
employing case-control or cohort study designs is very important to confirm the findings this
study.
In the current age of “big data”, databases obtained from different sources, such as
survey-collected data, administrative claims data, and electronic medical record, can be a useful
and efficient base for conducting an epidemiological study. By using multiple years of MCBS
data, a retrospective cohort study can be designed to evaluate the aforementioned research
questions. In addition, Health Retirement Study (HRS) data linked to CMS data, or NHANES
linked with CMS data can also be potential data sources for such studies. 97,140 Several
longitudinal studies such as The Health, Aging, and Body Composition (Health ABC) study and
Cardiovascular Health study (CHS) are also potential sources of data for conducting this
research.141,142 Moreover, assessing emergency department visits resulting from coadministration of alcohol and psychotherapeutic agents can also help us understand the
implications of concurrent use of alcohol and CNS-acting medications. DAWN is one of the data
sources to conduct such a study.26
Understanding the relationship between at-risk drinking and healthcare utilization and cost of
this utilization in older adults is an important and interesting question that needs further research.
Such a study will help assess the impact of at-risk drinking on healthcare resource utilization.
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The MCBS data combines administrative claims records and information on out-of-pocket costs,
access to care and other such variables collected from survey. Linking Part D data with other
MCBS study data can also help obtain information of medication utilization. In addition,
conducting a prospective study in congregate living facilities can be an alternative which can
provide rich qualitative information about the drinking habits of older adults which a secondary
database may not be able to provide.
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Appendix A
SAS Codes
Logistic Regression
proc surveylogistic data=newCNS_fall_medddrnk
varmethod=brr (fay=0.3);
repweight CS1YR001-CS1YR100;
class
meddrnk (ref="nomed_nodrnk")
educate (ref="more highschool")
marital (ref= "married")
race
(ref= "white")
social
(ref="no")
age
(ref=">85")
H_SEX
(ref="2")
polypharm (ref=">=11")
IADL_cat (ref= "no")
ADL_cat (ref= "no")
old_health(ref="worse")
bp
(ref= "0")
eye
(ref= "no_impair")
comorbid (ref="zero") / param=ref;
model fall (event='yes') = meddrnk age H_SEX educate marital race social
polypharm IADL_cat ADL_cat old_health bp eye comorbid ;
weight CS1YRWGT;
run;

Multi-nominal Logistic Regression
proc surveylogistic data=Newlib.atrisk_wt varmethod=brr (fay=0.3);
class educate (ref="more highschool")
marital (ref= "married")
race
(ref= "white")
earn
(ref=">25000")
social
(ref="no")
age
(ref=">85")
smoke
(ref="neversmoker")
H_SEX
(ref="2")
polypharm (ref=">=11")
old_health(ref="worse")
comorbid (ref=">=5")
jobstat
(ref="No")
IADL_cat (ref= "no")
ADL_cat (ref= "no") / param=ref;
model allrisk (ref="non-drinker") = age H_SEX race marital educate social
earn jobstat smoke polypharm comorbid IADL_cat ADL_cat old_health /
link=glogit;
weight CS1YRWGT;
repweight CS1YR001-CS1YR100;
run;
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